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Abstract
Investigation of the genetic components of maternal infanticide in Sus
scrofa
Julien Bauer
The aim of this thesis was to investigate the genetic components of maternal infanticide in the domestic
pig (Sus scrofa). The killing of piglets by sows by eating them soon after birth is a signiﬁcant issue
for the pig breeding industry because of the impact on animal welfare and the cost in lost revenues.
There is evidence that part of this behavior has a genetic basis and this work aims at ﬁnding the genes
and genome regions linked to this trait. This study focuses on animals from four diﬀerent breed lines;
two have around a 5% incidence of infanticide and two have around a 10% incidence of infanticide.
The ﬁrst half of this work used a genotyping approach using the pig 60K SNP array from Illumina.
Two diﬀerent tests were used to analyse the data: Family Based Association Test (FBAT) and Parent
of Origin (PO) test. The FBAT approach uses pedigree information to test for association in the
presence of linkage and the PO approach tests for preferential transmission of allele from one parent
(this study focused on maternal transmission).
The results from the tests, along with previous results generated by our group, were used to design
three sequence capture sets in order to study these regions in more detail. The sequencing work was
done on a selection of animals grouped in pools, for each line two pools of infanticide animals were
selected: animals with an history of infanticide in the pedigree and animals with multiple instances
of infanticide. Once sequencing was completed, variants were called on the region of interest, for each
pool and the diﬀerent capture sets, using the Genome Analysis Tool Kit. The variant allele frequencies
in the pool was compared between control pools and infanticide pools to select target variants. Some
of the variants identiﬁed are interesting targets and identify genes of interests.
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1 Introduction
1.1 Maternal infanticide in Sus scrofa
In species that care for their young, early maternal behaviour is usually characterized by a phase
of bonding with the oﬀspring shortly after birth. In some cases the bonding will not occur and the
response of the mother to its litter can result in carelessness or abandonment. For some species this
can take a more extreme form, an aggressive response to the litter resulting in harm or death of the
oﬀspring. For commercial animal breeding, oﬀspring survival is an important economical factor. It is
reported in the US that 15% of piglets are lost before weaning, which resulted in an estimated loss of
revenue ranging from 130 to 330 million dollars in the year 2000 [1]. Although the proportion of losses
linked to infanticide is not well studied, the percentage of savaging dams generally varies between 5
and 15% [2, 3, 4, 5, 6], and death caused by infanticide according to some studies represent 11.2%
of pre-weaning death [6]. Therefore, the infanticide cost to the industry could be between 14 to 36
millions dollars a year for the US alone.
Maternal infanticide (also called savaging) is a behaviour aﬀecting sows shortly after giving birth,
usually within twenty four hours after parturition (childbirth), resulting in the loss of one or more
piglets. The sow attacks the piglets by biting them to death. Infanticide is not speciﬁc to domestic
pigs and also aﬀects wild boars raised in captivity [7].The etiology of this behaviour is complex and
investigations to identify its causes have concluded that several potential factors can contribute to
savaging. The main factors are environment, maternal experience and breed, the latter suggesting a
genetic component. Studies have found that diﬀerent breeds of domestic pigs have diﬀerent incidences
of aggressive behaviour [2]. Wild boar lines are also aﬀected at diﬀerent levels as one line was shown to
be highly aggressive compared to others [7]. These diﬀerences in the levels of occurrence of infanticide
in animals with a diﬀerent genetic background support the possibility of a genetic component to this
behaviour.
The contribution of environmental factors to the aetiology of aggressiveness has been the subject of
a number of studies [6, 8, 9, 10, 11]. They show that the space and the richness of the environment
available to the pig has an impact on the occurrence of infanticide behaviour, with barren environments
tending toward more aggressive behaviour[12]. Larger pens and richer environments result in less
aggressive behaviour, which could be the result of more exploratory behaviour that could help to
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alleviate stress. However some studies have shown that open pens have a higher incidence of infanticide
[8]. This could be due to the sow having more access to the litter than in a farrowing crate and therefore
more opportunity to attack its piglets.
Another environmental factor impacting infanticide is lighting of the pen. Constant lighting resulted
in lower level of savaging [6]: however this contradicts earlier ﬁndings [3]. According to the former
study, lighting could help the gilt (ﬁrst time mothers) to be more aware of the piglets and therefore
respond more positively to them.
Behaviour toward humans in contact with the sow has been investigated as a potential early sign for
savaging behaviour [8]. This study looked at the impact of the behaviour of the sow towards its handler
as a predictor of infanticide, investigating the theory that sows that are more aggressive towards humans
might be more likely to kill their progeny. The conclusion was that aggressive behaviour toward the
human handler has little correlation on the level of aggression directed toward the piglets. However
shy behaviour of the dam toward humans can be a predictor of potential aggression. Shy gilts
are more likely to be aggressive toward their litter than bold gilts. However this type of behaviour
could also be the result of social hierarchy in pig groups, as shy guilts might be picking on weaker
individuals (the piglets) as they are bullied by the more dominant sows. There is some suggestion of
this behaviour in a study which used a resident intruder test [13], although not signiﬁcant, there were
observations that the smaller pigs were victim of aggression more often.
The posture and attitude of sows before parturition was also investigated as a potential early warning
sign for a savaging event. Infanticide sows tend also to be more restless before and after parturition
[5], which combined with the shy-bold trait suggests that infanticide is not triggered by parturition
but predetermined. Considering these observations, a lack of experience with litter and birth could be
a contributing factor as gilts are more likely to kill [14, 5]. It has also been conﬁrmed that pigs can
be conditioned in their behaviour by past experience [15, 11]. Although these factors contribute to
oﬀspring behaviour only for the few weeks after birth, they show that pigs can be conditioned to some
extent by their experience in a given environment. Not all environmental factors have an impact on
aggression, e.g. seasons and feeding have little impact [3].
Another potential cause of infanticide behaviour could be linked to endocrine levels, such as steroid
levels in the sow before and just after birth. A study in gilts [9] concluded that there is no clear
link between the infanticide behaviour and levels of hormones linked to birth, although the data
demonstrated a higher (but not signiﬁcant) level of oestradiol over progesterone a day before birth for
gilts that had to be sedated because of their behaviour after parturition. This suggests that there might
be an eﬀect of the concentration ratio of hormones such as oestradiol and progesterone on infanticide.
The inﬂuence of inheritance in this behaviour has also been studied and it has been suggested that
aggressive behaviour towards other animals is a heritable trait, with an estimated heritability for
diﬀerent breeds of between 0.4 and 0.9, with a strong genetic component. [16, 4, 3]. It is likely that
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the selection of meat traits for some markets has contributed to the selection of more aggressive traits
resulting in a higher rate of infanticide in some breeds. In some Asian breeds there are almost no
occurrences of infanticides. The desired meat traits for the Asian market is very diﬀerent from the
European ones. Furthermore, the selection of dedicated sires lines resulted in a selection for speciﬁc
meat traits while dam lines are selected for litter and maternal trait. The statistics linked to maternal
infanticide are reﬂective of this selection, in the study by Quilter et al [2], the two lines with a higher
rate of infanticide are the two sire lines (line D and H) while the other two are dam lines (line B and
C). In another study by Quilter et al [17], it was observed (unpublished) that the meat quantitative
trait loci were close to the quantitative trait loci that were found in the linkage study. This observation
suggest a strong genetic component to the infanticide trait.
Given that there is no good predictor of a sow's potential for infanticide other than some behaviours
being more prevalent in savaging sows, such as restlessness and shy behaviour observed during an
approach test. However there is evidence that the infanticide trait can be linked to heritability and
varies between diﬀerent pig breeds, therefore the genetic heritage and genomic composition has an
inﬂuence on this trait. In order to get a better prediction of predisposition to savaging, the present
study proposes to look more closely at the genome contribution to infanticide behaviour in the pig.
1.2 Method for the study of genetic markers.
1.2.1 Linkage analysis.
The study of genetic heritability started with Mendel's laws enacted from his work. These laws are
the law of segregation, the law of independent assortment and the law of dominance. The law of
segregation states that alleles will segregate during gamete formation and that each gamete will carry
only one allele for each gene. The law of independent assortment states that alleles are transmitted
independently from each other, and the law of dominance deﬁnes the nature of each allele in regards
to the phenotype, either dominant or recessive.
The law of independent assortment was proven not to hold for every locus shortly after Mendel's
work was completed. Further work on the heritability of traits by Morgan [18] and Punnet [19]
challenged the rules discovered by Mendel, especially the law of independent assortment. This led to
the discovery of genetic linkage, traits can be transferred together, as a single heritable unit, if they are
in close proximity on the same chromosome. These discoveries gave rise to genomic methods to map the
genome and eventually to the study of the genetic origins of diseases. One of the advantages of genomic
methods is that they can be applied for a range of phenotypes, they do not require a particular type
of disease to work other than having a genetic component and they can be applied to a wide variety
of species. These methods are based on the fact that during meiosis recombination events happen,
leading to cross over between homologous chromosomes. The frequency of recombination between loci
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is correlated, amongst other factors, to the distance between them; the greater the distance the more
likely a recombination will happen.
Linkage equilibrium happens when loci are transmitted independently during gamete formation
while Linkage Disequilibrium (LD) deﬁnes their joint transmission: the closer the loci the more likely
they will be transmitted together. While a formal deﬁnition of Linkage Disequilibrium was not made
until the 1960s [20], this principle lead to the discovery of genetic markers and was used to construct
genetic maps, also called linkage maps. The ﬁrst map of markers was constructed in the 1980s using
Restriction Fragment Length Polymorphisms (RFLP) [21, 22] and later with microsatellites [23]. Once
the presence of polymorphic markers was discovered on the human genome, analysing and typing those
markers enabled the study of their transmission in order to identify the presence of a link between a
given marker and a gene or genomic location.
The study of the transmission of markers to the next generation is carried out using linkage data. It
usually consists of one or more families with marker data available from several generations (at least
two). Several key parameters are needed to study the linkage of traits. These are the penetrance of the
trait, dominance of the allele and its inheritance. These parameters are discussed in more detail below.
Using this information and parameters, linkage based methods ﬁrst extract the inheritance patterns
from the pedigree and from this information determine causation between loci and the trait of interest.
1.2.1.1 Log Odds Ratio for single markers
The ﬁrst methods developed to test for linkage are parametric methods and use the recombination
fraction as the parameter for the testing procedure. The recombination fraction is deﬁned as θ, and
represents the probability of recombination between two loci. Two loci are in linkage equilibrium when
θ = 0.5 and are in linkage disequilibrium when 0 < θ < 0.5.
In 1955 Morton [24] deﬁned a method to test for deviation from θ = 0.5 called the sequential test for
the detection of linkage. Given a set of observations of recombination y1, y2, y3....yn and a recombination
fraction θ for these loci, a random variable f(yi,θ) for i = 1, 2, 3, ...n is deﬁned, which represents the
probability of obtaining the current data set given θ. The null hypothesis H0 is deﬁned when θ = 0.5,
there is no linkage between the loci, the alternate hypothesis H1 is deﬁned as θ = θ1, 0 < θ < 0.5.
Morton then deﬁnes his test parameter as:
z = log f(yi,θ1)f(yi,0.5) (1.1)
The ratio z is called the Log Odds Ratio (LOD), where f(yi, θ1) represent the odds of obtaining
the current pedigree given the recombination fraction θ1, f(yi, 0.5) represent the odds of obtaining the
current pedigree under H0.
In simpler terms, it is the ratio of the probability of having the observed birth sequence if θ = θ1over
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the probability of having the observed birth sequence if θ = 0.5 (H0). In practice the value θ1 to test
is unknown, Morton suggested trying several values for θ1 (arbitrarily chosen) and the one scoring the
highest (Maximum Likelihood) on z is the best approximation of θ1.
In practice to compute the LOD for a single marker, representing a single typed genetic marker
linked to a disease loci, the probability of the recombination event given the recombination fraction
θ is deﬁned as pr = (θ/2)
r((1 − θ)/2)nr and the probability under the null as pnr = (0.5/2)N with r
the number of recombinant individuals, nr the number of non recombinant individuals, N the total
number of descendants in the generation studied (N = r + nr). The equation from Morton 1.1 can
be written as a log(pr/pnr). Morton suggested that a test value should be above 3, corresponding
to a likelihood of a 1000 to one that the marker is linked to the disease. It is considered as enough
evidence for signiﬁcant proof of linkage. This value is justiﬁable if the size and composition of the
human genome is taken into account. To be linked, two loci need to be on the same chromosome
and relatively close together, therefore this gives a prior odd of linkage between two random loci of
around 1:50. Considering that a likelihood ratio of 1000:1 is suﬃcient evidence for linkage, given a
prior of 1:50 this gives an odd of 20:1 in favour of the linkage being signiﬁcant. To identify candidates
a log(pr/pm)of 3 can be considered as signiﬁcant and enough to reject H0 and indicate linkage between
the trait and the marker [24].
An example of how the LOD is calculated is given in Table 1.1 for the pedigree in Figure 1.1. In
this case we can consider that chromosomal phasing is known as the grand parents are genotyped.
Chromosomal phasing or phase is deﬁned as the transmission of alleles from the maternal or paternal
chromosome. Phase is known when it is possible to determine which alleles came from the father or
the mother. If the phase is unknown (grand parents not genotyped) the calculation must take into
account all the possible phases from the parental genotypes. This results in a loss of power for the test
as shown in Table 1.2. The example in Figure no. 1.1; is for a single family, in general a study will
include several families. The method for LOD calculation from multiple pedigrees is simply to sum
the individual LOD scores across all of the pedigrees. Therefore the more families present in a study,
the more likely it will result in a high LOD score if linkage is present. Adding more families therefore
increases the power of the test.
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Recombinant fraction pr pnr log(pr/pnr)
0.01 3.002E-04 9.766E-04 -0.512
0.05 1.273E-03 9.766E-04 0.115
0.1 2.050E-03 9.766E-04 0.322
0.2 2.560E-03 9.766E-04 0.419
0.25 2.472E-03 9.766E-04 0.403
0.3 2.251E-03 9.766E-04 0.363
0.4 1.620E-03 9.766E-04 0.220
0.5 9.766E-04 9.766E-04 0
Table 1.1: LOD calculations for the pedigree represented in Figure 1.1. pr and pnr are calculated with
r = 1 and nr = 4. The maximum is reached for θ = 0.2 which is close to the θ that
can be estimated from the data. One recombination over 5 individuals give us an empiric
recombination probability of 0.25. However the maximum LOD score is low for this simple
example, so H0would not be rejected in this case.
Phase 1(3:C, 2:B) Phase 2 (3:B, 2:C)
θ pr pnr log(pr/pnr) θ pr pnr log(pr/pnr)
LOD combined score
for both phase
0.01 3.002E-04 9.766E-04 -0.256 0.01 3.032E-06 9.766E-04 -1.254 -1.510
0.05 1.273E-03 9.766E-04 0.058 0.05 6.698E-05 9.766E-04 -0.582 -0.524
0.1 2.050E-03 9.766E-04 0.161 0.1 2.278E-04 9.766E-04 -0.316 -0.155
0.2 2.560E-03 9.766E-04 0.209 0.2 6.400E-04 9.766E-04 -0.092 0.118
0.25 2.472E-03 9.766E-04 0.202 0.25 8.240E-04 9.766E-04 -0.037 0.165
0.3 2.251E-03 9.766E-04 0.181 0.3 9.647E-04 9.766E-04 -0.003 0.179
0.4 1.620E-03 9.766E-04 0.110 0.4 1.080E-03 9.766E-04 0.022 0.132
0.5 9.766E-04 9.766E-04 0 0.5 9.766E-04 9.766E-04 0 0
Table 1.2: LOD calculation for the pedigree represented in Figure 1.1 when the grand parent data are
not available, therefore phase is unknown. In this case the 2 possible phases from the disease
parent need to be considered, e.g. 3:C/2:B or 3:B/2:C. Both have a probability of 1/2. In
the ﬁrst case the calculations are the same as shown in Table 1.1; the ﬁnal LOD score is
divided by 2 to take in account the probability of this phase. For the second phase, we have
2 recombinations in this case rather than one, the maximum LOD is again observed for to
be matching the estimated θ(2/5=0.4). The combined LOD score is lower, as not having
the phase further diminishes the power of the test.
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Figure 1.1: Linkage Example. Phase is known as the grand parents have been typed for all 3 markers.
Each marker, A, B and C has three diﬀerent alleles noted 1, 2 and 3. The generation a
individual belongs to is noted G1,G2 or G3 and each diﬀerent individual is denoted by a
number after the generation. Total penetrance is assumed and the allele for the disease is
dominant. In this simple model it is easy to work out that the disease is linked to allele
A3, given the one recombinant individual on the third generation.
1.2.1.2 Log Odds Ratio for multiple markers
For multiple markers analysis, the LOD is calculated for each marker locus and graphs are constructed
in order to report the LOD for each position of the marker map. Several algorithms have been developed
in order to facilitate the calculation of the LOD for large pedigrees and multiple loci.[22, 25]. The
algorithm developed by Lander and Green [22]allows the computation of LOD for a large number of
markers given small pedigrees while the Elston algorithm [25] allows the computation of LOD for large
pedigrees for a low number of markers by modelling the transmission of alleles down the generations
using transmission matrices.
The Elston algorithm calculates the probability of an individual genotype conditional on the probab-
ility of its parents, starting from the most recent generation of the pedigree and repeating the process
for each generation. The computational requirements increase linearly with the number of individuals,
however the process becomes very costly as when the number of markers increases, the computational
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requirements increase exponentially. The Lander and Green algorithm uses a Hidden Markov Model
in order to model the inheritance distribution by conditioning it on the observed genotypes, allowing
computation of the LOD for small pedigrees but a large number of markers. With this approach the
computational requirements are linear with the number of markers but augment exponentially with the
number of individuals in the pedigree. GENEHUNTER [26] is a popular implementation of the Lander
and Green algorithm, capable of multipoint linkage calculation with partial pedigree information.
The parametric methods of linkage analysis are however limited to good pedigrees and diseases with
high or complete penetrance; incomplete penetrance and missing information have a high impact on
the power of the sequential test. Penetrance is deﬁned as the genetic value used to describe the impact
of the genetic component on the phenotype of interest; a higher penetrance for an allele results in a
higher risk of displaying the phenotype. If we deﬁne genetic penetrance of a disease causing allele A as
γ (γ > 1); then for an additive model the risk of the disease is increased by a factor of γ fold with one
A allele and by a factor 2γ fold for two A alleles. For the recessive model, the risk is increased by γ fold
only for the AA genotype, but for a dominant disease the risk increases by γ fold in the presence of one
or two A alleles [27].The mode of inheritance can also have an impact on tests using the recombination
fraction. If the mode of transmission is not known or wrongly speciﬁed, it will impact on the power
and the results of the test, although it might vary depending on the data [28].
1.2.1.3 Non parametric linkage test
To avoid the type of issue highlighted before, non parametric linkage tests were developed to evaluate
linkage without estimating the recombination fraction [26, 29]. Although non parametric tests are less
powerful than parametric tests, they are better suited when the inheritance mode of the disease is
unknown. The most eﬃcient methods for this type of analysis use alleles shared between individuals
in the pedigree inherited from a common ancestor; such alleles are said to be in Identity By Descent
(IBD). Other methods will use Identity By State (IBS), alleles that are shared between individuals in
the pedigree. It is obvious that an allele in IBD is also in IBS but not vice versa. Methods using IBD
are more powerful than methods using IBS as more information can be captured in order to determine
linkage. One of the ﬁrst non parametric approaches was the Aﬀected Pedigree Member (APM)[30],
using IBS between pairs of aﬀected members of the pedigree. To compute the test statistics, a score
is deﬁned by counting the alleles shared in IBS between a pair of individuals. The score is calculated
by giving a 1 if an allele is identical between the pair (so is IBS at least) and 0 if not. The following
formula is deﬁned for a pair of two aﬀected individuals labeled i and j and with x and y representing
respectively the maternal and paternal alleles for each individual:
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Zij = 1/4δ(Gix, Gjx)f(pGix) + 1/4δ(Gix, Gjy)f(pGix)
+ 1/4δ(Giy, Gjx)f(pGiy) + 1/4δ(Giy, Gjy)f(pGiy) (1.2)
With δ(G1, G2) deﬁning the Kronecker delta such as δ(G1, G2) = 1 if G1 is in IBS with G2 and 0
otherwise. f(pG) represents a function of the allele frequency of the allele studied in the population,
usually in the form 1/p or 1/
√
p, thus allowing us to weight the score of an allele according to its
frequency, p, in the population. For a given pedigree the score for an allele using the APM will be the
sum of all the Zij . This method is usually used to combine scores from several families in order to
generate a global statistic for an allele using several pedigrees, if Zm is Z for the m
th pedigree, then
we have the test statistic:
T =
∑
m
wm[Zm − E(Zm)]√
wmV ar(Zm)
(1.3)
Where wm is a positive weight, usually derived from the number of aﬀected individuals and E(Zm)
the expected value of Zm. Given the central limit theorem, T will follow a normal distribution and it
is therefore possible to derive a p-value from it.
This method is fairly restrictive as it only uses pairs of individuals and uses IBS information instead
of the more powerful IBD information that may be inferred from pedigrees. It also ignores data that
could be used to determine the status of the alleles, IBD or IBS [26]. Other methods of non parametric
testing have been developed, more appropriately for looking at large pedigrees or combining information
from several pedigrees [26, 29]. They use a scoring method by looking at allele sharing by IBD or at
all the permutations possible that could lead to allele sharing by IBD, usually by sampling alleles and
counting the number of times a founder allele is shared with subsequent generations. For example
Whittemore and Halpern [29] deﬁne two diﬀerent metrics for scoring a conﬁguration of alleles in
IBD. First they deﬁne a IBD conﬁguration, denoted φ, representing the conﬁguration of alleles in IBD
between individuals. If G = (G1x, G1y, ..., Gnx, Gny) are 2n integers representing the inheritance vector
for all the alleles, where x and y deﬁne the maternal and paternal allele respectively, as seen before. The
sharing of IBD can then be assessed between siblings using the following method: given a locus with
alleles a, b, c, the allele conﬁguration between two individuals can be noted as (a, b, a, b), representing
the sharing of both paternal and maternal alleles, whereas (c, b, a, b) would equate sharing only the
paternal allele. If two sequences G and G′ only diﬀer by the order of their paternal and maternal alleles,
as in the example(a, b, a, b) and (a, b, b, a) we deﬁne the IDB conﬁguration as φ = [abab] with (a, b, a, b)
and (a, b, b, a) as representative of φ. Generalizing φ we have φ = [G1xG1y...GnxGny] representing all
the possible IBD conﬁgurations between the 2n alleles of a pair of individuals. The scoring functions
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for this φ, τp is deﬁned as
τp = Sp(φ) =
2
n(n− 1)
∑
1<i≤j<n
fij(φ)
fij(φ) = 1/4[δ(Gix, Gjx) + δ(Gix, Gjy) + δ(Gix, Gjy) + δ(Gix, Gjy)] (1.4)
for a pair of individuals, which is very similar to the deﬁnition of (1.2) without taking into account
the frequency of the alleles.
In order to use more than pairs of individuals to score IBD in the pedigree, deﬁne u = (u1, u2, ..., un)
where ui is either Gix or Giy, for each φ there are 2
n vectors u. Let h(u) be the number of non trivial
permutations of the ui in u that leave it unchanged. The more IBD is shared between individuals the
larger h(u) will become. The scoring function, τ is deﬁned from h(u) as its average:
τ = Sall(φ) =
1
2n
∑
u
h(u) (1.5)
For two individuals the results of the two scores will be identical. For more than 2 individuals
(n > 2) the two functions will diﬀer, τ is more powerful when the disease is dominant while τp is more
powerful when the disease is recessive as the power calculation in [29] have shown. Those two scoring
methods have more power than the APM test as they use IBD while APM relies on IBS.
The two scoring functions from Whittemore and Halpern [29] were reﬁned by Kruglyak et al. [26],
introducing a normalised score for both methods Z = [S(φ)− µ]/σ where S(φ) can be either Sp(φ) or
Sall(φ) and µ and σ are respectively the mean and standard deviation of the scoring function under a
uniform distribution Puniform, representing the uniform distribution over all the possible inheritance
conﬁgurations of the inheritance vector. The mean and standard deviation can be calculated by
enumerating all the possible inheritance vectors. Under H0, Z has a a mean of 0 and a standard
deviation of 1. To combine data from several pedigrees Kuglyak et al. deﬁnes Z for multiple pedigrees
as Z =
∑m
i δiZi with δi a weighting factor such as
∑
δ2i = 1, so that under the null hypothesis, the
mean and standard deviation for Z are still 0 and 1. Taking δi = 1/
√
m is a good compromise as it
seems to perform well for both small and large pedigrees. This method has been implemented in the
software GENEHUNTER[26].
While linkage had a lot of success initially, it was employed as a method to identify genes and
markers linked to a simple disease from a genomic perspective, such as dominant or recessive traits
linked to a few locations and with good penetrance. It had good success identifying the susceptibility
of developing breast cancer linked to the BRCA family [31, 32], the link between lipoprotein-cholesterol
and chromosome 9 and was also used to identify loci linked to early onset Alzheimer's disease [33, 34] .
The successful linkage studies focused on those diseases with a strong correlation between the genetic
component and the phenotypic data. Linkage proved to be a very powerful approach to investigate
10
1 Introduction
Mendelian disease with a single genetic component. However the method is a lot less powerful when
investigating a more complex disease [35] and for several reasons [36]. This is particularly true for
diseases caused by high frequency, low eﬀect size polymorphisms. The fact that most methods rely on
allele sharing is a problem when the penetrance is limited, since an individual might carry the allele
but if the risk associated is low, its contribution to the phenotype may not be detected. This individual
will be classiﬁed as unaﬀected while still carrying risk alleles, and will be removed from the analysis.
The removal of these individuals will results in a loss of power for the test. The high frequency of such
alleles is also an issue as it will make it more diﬃcult to eﬀectively follow its inheritance pattern if it is
common in the population; these high frequency allele can enter the pedigree via multiple founders. To
detect common markers that are linked to the disease, it is possible to mitigate the impact of the latter
problem by typing more families and increasing the size of the study but this is not always practical.
Linkage test are powerful to study high penetrance and low frequency disease, also called Mendelian
disease. However in the case of more common diseases, caused by high frequency low penetrance
alleles, the inheritance pattern of the alleles is harder to link back to the disease as the individual
makers contribute less to the phenotype. A group of several markers is more likely to signiﬁcantly
contribute to the phenotype of interest. Therefore, to study the more common genetic diseases that
are more frequent in a population, a new approach was needed.
1.2.2 Genome Wide Association Studies (GWAS)
While linkage studies identify loci using heritability and recombinations within a pedigree, an alternat-
ive is to study linkage disequilibrium at the population level, using unrelated individuals to identify loci
associated with a particular phenotype. LD is stronger for loci close together in the genome but is also
inﬂuenced by the nucleotide composition and position of the markers on the chromosome; therefore
it is heterogeneous along the genome. By mapping LD and selecting markers it is possible to study
the association between markers (and therefore of the region/genes they represent) and a particular
phenotype at the population level. This method is called Genome Wide Association Study or GWAS.
Linkage studies started to show limitations in their power to identify markers when a disease had
reduced penetrance, resulting in diﬃculty for the recruitment of a suﬃcient number of samples to
achieve good power [37]. This is especially true for complex and common diseases where several loci
in the genome can contribute to the genotype of the disease. By comparing allele frequencies between
control and case (aﬀected) populations it is possible to test for loci associated with the phenotype
of interest. However this approach can have some drawbacks depending on the disease studied. For
example A disease such aS Beta-thalassemia can be challenging to study using GWAS due to genetic
heterogeneity [38]. The phenotype of this disease can be the result of more than 200 disease causing
mutations. Individuals classiﬁed as aﬀected might have diﬀerent genetic loci involved which are all
resulting in the same phenotype. Furthermore, the diﬀerent genetic causal loci might be mixed within
11
1 Introduction
a population or segregating in diﬀerent populations. If diﬀerent loci are causing the phenotype within
the same population, it will considerably reduce the power of a GWAS on this population. If this
happens between diﬀerent populations, diﬀerent loci might be identiﬁed in each population despite
them sharing a common phenotype .
1.2.2.1 Transmission Disequilibrium Test
The ﬁrst method to study association is still very close to linkage and is the Transmission Disequilibrium
Test or TDT proposed by Spielman et al. [37]. It tests for linkage in the presence of association in
parent-aﬀected child trios by looking at which combinations of alleles are transmitted to the aﬀected
child and which are not. Previous approaches were focusing on the transmission of individual alleles
instead of the combination of alleles. Suppose that we have a disease allele D1 and normal allele D2
and a marker locus with co-dominant alleles M1 and M2. Consider the Table 1.3 of transmitted and
non transmitted alleles. It was shown in [39] that the probability associated with each value in Table
1.3 is as shown as in Table 1.4 with m the frequency of the M1 allele, p the frequency of D1, θ the
recombination fraction and δ the coeﬃcient of LD. As the TDT is testing for linkage (θ = 1/2) the
only two terms of interest from Table 1.3 are b and c as they are the only ones for which the probability
function contains θ. For this test only heterozygous parents typed in the pedigree are informative. If
H0 is true (θ = 1/2, no recombination) then it is trivial that E(b) = E(c) using the expression of
probability in Table 1.4 and this is independent of the values of m, δ and p. We can then deﬁne a
χ2 to reject H0. Any χ
2 test to be valid is in the form of χ2 = (u − v)2/V ar(u − v). As in most
statistical tests, the true variance is impossible to calculate, therefore the test for b and c can be written
χ2 = (b− c)2/estimate(V ar(b− c)). If θ = 1/2 then the contributions of the heterozygous parent are
independent. In this case, the test is the 'McNemars test' and the statistic for the TDT is
χ2 =
(b− c)2
(b+ c)
Non Transmitted allele
Transmitted allele M1 M2 Total
M1 a b a+ b
M2 c d c+ d
Total a+ c b+ d 2n
Table 1.3: Combination of Transmitted and Non Transmitted Marker Allele M1 and M2 among 2n
Parents of n Aﬀected Children [37]. a, b, c and d represent the number of parents in each
categories, e.g. b is the number of heterozygous parentsM1M2 that transmitted alleleM1and
not allele M2 .
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Non Transmitted allele
Transmitted allele M1 M2 Total
M1 m
2 + (mδ/p) m(1−m) + [(1− θ −m)δ/p] m+ [(1− θ)δ/p
M2 m(1−m) + [(θ −m)δ/p] (1−m)2 − [(1−m)δ/p] 1−m− [(1− θ)δ/p]
Total m+ (θδ/p) 1−m− (θδ/p) 1
Table 1.4: Probability of Combinations of Transmitted and Non Transmitted Marker Allele M1 and
M2among 2n Parents of Aﬀected Children
Another alternative to the deﬁnition of χ2 is to consider the test as the following. The parents
transmission of their alleles can be described as a series of 2n multinomial trials with four possible
outcomes as described in [40]. The outcomes have probability x, y, y and z with x+ 2y+ z = 1, which
correspond to our case of θ = 1/2 as E(b) = E(c) = 2ny. If a, b, c and d are the number of possible
outcomes in the four categories then we have V ar(b) = V ar(c) = 2ny(1− y) and Cov(b, c) = −2ny2.
Then V ar(b− c) = V ar(b) + V ar(c)− 2Cov(b, c) = 4ny. Therefore the best estimate of the variance
is b+ c so the TDT statistic is χ2 = (b−c)
2
(b+c) . The TDT procedure described here will work on a parent-
aﬀected child trio but can be extended easily to bigger families [37]. The TDT is more sensitive than
allele sharing methods traditionally used for linkage and can make good use of family trios and families
with multiple aﬀected siblings. The only drawback to the TDT is the need for association between the
marker at the population level in order to be able to assert linkage, it is however resilient to population
stratiﬁcation and can be used as an (secondary) independent test to conﬁrm GWAS results.
1.2.2.2 Parent of Origin test: application of the TDT test.
The TDT to test can be used for preferential transmission of alleles from the father or the mother of
the aﬀected oﬀspring. The test procedure is the same as the standard TDT but only the heterozygous
mother's or father's alleles are considered in order to test for preferential transmission of some markers.
In this study the test was used because it had been shown that a dam to daughter eﬀect is present [3].
This test was used to identify any preferential transmission from the dam to her daughter that might
be linked to infanticide.
1.2.2.3 Population admixture
Real associations studies, performed to investigate association between loci and a phenotype, are
performed on unrelated individuals and not on family data and therefore do not look for the presence
of linkage with the disease allele. The tests are performed between two populations of unrelated
individuals, one of control and one of aﬀected individuals also referred to as 'cases'. The selection of
both populations is important as the results of the analysis can be biased by spurious associations
if there is a sub-structure in the population such as common ancestry or a particular ethnic group
forming part of one of the populations [27]. This is called populations stratiﬁcation, often the result
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of groups of diﬀerent genetic origin forming the population. Another type of bias can be caused by
admixture in the population, usually due to genetic mixing with populations of diﬀerent genetic origin
in recent history, introducing new alleles and shifting the allele frequencies of the original population.
Population stratiﬁcation and admixture can be assessed using Principal Component analysis (PCA)
which decomposes the variance by maximizing it and minimizing the error using Eigenvectors. Sub
populations are usually seen as clear outliers when plotting the largest components of a PCA.
Another important test to consider when looking at association is the Hardy Weinberg Equilibrium
(HWE). If the frequency of the allele a in the population is p and the frequency of the disease allele
A is q then the frequency of the genotypes in the population should be: p2 for aa q2 for AA and
2pq for the aA genotype. Any signiﬁcant deviations from those proportions is indicative of admixture
and/or stratiﬁcation in the population. Testing for HWE can be done using a χ2 test on a contingency
table. Testing for HWE is performed on the control population generally as the case population
can have markers in disequilibrium due to the genetic component of the disease [41]. In general the
study of association focuses on common variants (markers) with a Minor Allele Frequency (MAF) in
the population greater than 5% or 10% because of the sample size and disease penetrance needed to
achieve power at lower allele frequency [42]. If an allele is associated with a causal loci, but its frequency
in the population is low, it will not be well represented in the case population. It is unlikely that the
association test will successfully identify this allele as associated with the disease, its contribution at
the population level being too low. In order to use rarer alleles in association studies, more individuals
need to be typed in order to have enough observations of this allele to ﬁnd the association with the
disease.
1.2.2.4 Association test
Testing for association can be done with a simple test on a contingency table of the genotype count.
This can be done with a χ2 test, Fisher Exact test [43] or Cochran-Armitage trend test [44, 45] to
test for statistical signiﬁcance for each marker tested. The Fisher exact test is more appropriate for
data with a low sample counts while the Cochran-Armitage test is better suited to handle data when
the dominance of the disease is not known [27]. The contingency table can be based on allele counts,
Table 1.5, or on genotype counts, Table 1.6. The Fisher exact test on the allele counts table will be
written as
χ2 =
[ (x11+x12)!x11!x12! ] ∗ [
(x21+x22)!
x21!x22!
]
(2n!/(x11 + x21)!(2n− x11 − x21)! =
(x11 + x12)!(x21 + x22)!(x12 + x22)!
(2n!x11!x21!x12!x22!)
the formula can be extended to test on the genotype count table.
The Cochran-Armitage trend test of association between disease and marker is calculated on the
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genotype counts table in the form of:
T 2 =
[
∑3
i=1wi(Sn1i −Rn2i)]2
[RS/n] ∗ [∑3i=1w2iNi(n−N1)− 2∑21=1∑3j=i+1wiwjNiNj ]
where the denominator is the decomposed variance of the numerator. This trend test can account for
the various possible models of penetrance for the disease using the term wi as a weight for the impact
of the genotype on the phenotype. Following the penetrance model (if known) it is easy to choose the
w factor for the trend test: for a recessive model the w can be set as w = (0, 0, 1), for a dominant
model it can be set as w = (0, 1, 1) and for an additive model w = (0, 1, 2).
Allele a A Total
Case x11 x12 x11 + x12
Control x21 x22 x21 + x22
Total x11 + x21 x12 + x22 2n
Table 1.5: Allele count table. Two alleles are present: 'A' and 'a', the alleles are counted for each
population, case and control. x11represents the total allele count of allele 'a' in the case
population, x21the count of that allele in the control population.x12and x22 are the same
but for the 'A' allele.
Genotypes a/a a/A A/A total
Case n11 n12 n13 n11 + n12 + n13 = S
Controls n21 n22 n23 n21 + n22 + n23 = R
Total n11 + n21 = N1 n12 + n22 = N2 n13 + n23 = N3 n
Table 1.6: Genotypes count table, the genotypes are counted for each population, given three values for
each population for a given loci, n11is the number of a/a genotypes in the case population,
n21the same in the control population, n12is the number of a/A genotypes in the case
population and n22for the controls, n13is the number of A/A genotypes in the case population
and n23in the control population. Summing each line we obtain S the number of genotypes
for the case population and R for the control population. N1, N2and N3 represent the
number of genotypes for a/a, a/A and A/A respectively for both populations.
1.2.2.5 Multiple testing correction and signiﬁcance level
Usually the tests are carried out on thousands of markers at the same time, which results in a high
probability for false positive or type I error. This is because each test is supposed to be independent but
markers can aﬀect each other so this assumption is violated. To avoid or reduce type I error, multiple
testing corrections are usually applied. The simplest method is the Bonferroni correction which takes
the chosen threshold p-values and divide them by the number n of tests carried out (the number of
markers used in the study). This method however is very stringent and often too conservative, so an
alternative was proposed by Benjamini and Hochberg [46]. The p-values are ranked from the lowest to
the highest, multiplied by the number of tests carried out and then divided by their rank. The last step
is to make sure that the rank of the p-value is conserved. This is a more moderate correction as the
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rank of the p-value is used as a weight. It is widely used; however for GWAS analysis, permutations
based methods are more popular and give better results [27]. Bootstrapping methods are the most
popular and work by randomly distributing the label of control and case across the samples in the
study. The association test is then performed and the p-value obtained. The process is repeated a
number of times (usually a few hundred to a few thousand times) and a distribution of the p-values
can be built against which the empirical p-value from the true population can be compared to assess
for true signiﬁcance. These approaches have the drawback of only working for the subset of markers
studied and are only truly valid if a set of genome wide markers is available. The choice of the level
of signiﬁcance in human studies has been subject to some debate [47], the ﬁrst consensus is to use
5 × 10−8 which is signiﬁcant if all the SNPs discovered by HapMap [48] (~106) are tested and the
level of signiﬁcance is set at 0.05. The level of signiﬁcance is subject to the population tested, the
strength of association and the marker used for the analysis. Other work [47] suggests that SNP at
10−7 are worth investigating and that the 5 × 10−8might be too stringent. While a lot of work has
been done to work out the level of genome wide signiﬁcance in humans, no guidelines are available for
livestock; however one can assume that the level of signiﬁcance should be similar as the genomes are
fairly similar in size and number of markers. Most studies in the human use a large number of markers
or markers that have been identiﬁed to speciﬁcally type a particular area of interest. A higher density
of markers will help better type the genome as it will allow the analysis of smaller LD blocks, a more
sparse spacing of the markers might results in smaller LD blocks not being typed adequately. This is
an issue for this study as the array used as it does not have a large number of markers, see section
about the microarray technology 1.5 and discussion about the array 3.1.3.
1.2.2.6 Genotypic Risk Ratio and Odds Ratio
Once association is established, it is interesting to look at the strength of the association; this can be
done by two means. The Genotypic Risk Ratio (GRR) or Odds Ratio (OR). If we take piAA, piAa, piaa
as the disease penetrance for the AA, Aa, aa genotypes respectively, then the relative risk in relation
to the AA genotype would be θAA = piAA/piaa and the relative risk for the Aa genotype would be
θAa = piAa/piaa. The GRR is rarely used as it requires a population to be selected prior to developing
the disease in order to provide an estimate of the penetrance in the general population. Using a case-
control study will negate the possibility of assessing the penetrance as the ratio of cases to controls is
controlled by the investigator. A more common way of assessing the strength of association is to look
at the allelelic or genotypic odds ratio. For the allelic odds ratio, the ratio is ORAllele =
[x12/x11]
[x22/x21]
=
x12x21
x22x11
using the value from Table 1.5. This ratio represent the odds of being aﬀected when carrying
the allele linked to the phenotype of interest. For the odds ratio in relation to the genotype it is
important to separate the homozygote from the heterozygote genotype. Using the notation in Table
1.6 ORAA =
[n13/n11]
[n23/n21]
= n13n21n11n23 while ORaA =
[n12/n11]
[n22/n21]
= n12n21n11n22 . The ﬁrst ratio ORAA represents the
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odds of being aﬀected when carrying the AA genotype compare to the aa genotype. The second ratio
ORaA represents the odds for a heterozygote carrier.
1.3 Family based association test
The methods described above for association and linkage test are usually used when a complete data
set is available, unrelated individuals for the association test and pedigree data for the linkage test.
The TDT test relies on information from heterozygotes parents and cannot be used when one of the
parents is missing. However it is often the case that not all the individuals in a pedigree can be
typed for various reasons, e.g. lack of consent, individual is deceased (late onset disease) or was not
typed during the study. In these cases in order to maximize the use of the data it is necessary to ﬁnd
information outside the traditional parent-infant trio.
Several methods have been proposed to solve this issue by using siblings in order to test for association
in the presence of linkage [49], which compares the allele frequencies between aﬀected and unaﬀected
siblings. This test uses siblings in order to complete the data set if the parents are not available for
typing. If linkage is not present then the allele frequency will be similar between non aﬀected and
aﬀected siblings, only in the presence of linkage will it be possible to detect association between the
marker and disease. By using a permutation procedure such as the Monte-Carlo permutation within
families it is possible to test for a signiﬁcant diﬀerence in allele frequencies between the two categories.
A permutation approach is needed as the assumption of independence of sampling is not respected
when siblings are tested. While this method is useful if siblings are available, it is not always possible
to have data for the non aﬀected sibling.
Another method makes it possible to infer the missing parental data from the aﬀected oﬀspring data
or from any available parent data. The approach proposed by Rabinowitz and Laird [50] can test for
association in the presence of linkage without the need to be adjusted for population admixture or the
genetic model and can be used for pedigrees with missing marker allele information. The method uses
a statistical principle called conditioning on suﬃcient statistic for the null hypothesis. It revolves
around deﬁning models that share the same conditional distributions given the statistics. This means
that the computation for the p-value for all the models given the minimum statistics are the same. For
this approach it is only required to compute the conditional distribution for the data given the minimal
suﬃcient statistics for the null hypothesis, which will reduce considerably the computational burden.
In the case of a nuclear family where the parents plus aﬀected child trio are typed and their traits
are known, the minimum statistics are deﬁned as the trait and the parental genotypes. Under Hardy
Weinberg equilibrium it is easy to calculate the conditional distribution for the markers. However the
data might not always be complete, one or both parents could be missing. To be able to calculate
the conditional distribution for the marker it is necessary for the trait status to be known for some
individuals in the pedigree and in a similar fashion that some marker data are available for some
members of the pedigree. It is not required that trait status and marker data are known for the same
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individual. In order to compute the conditional probability to test for linkage in pedigrees the following
steps are proposed in [50]:
1. Find all the possible patterns of founder alleles that are compatible with the allele in the typed
marker, this involves inferring missing genotypes in founders if needed.
2. Construct the pattern of typed marker alleles compatible with the set of founder alleles deﬁned
in step 1. Find the subset of patterns that are compatible with the observed typed marker in
the available typed markers
3. For every pattern found in the ﬁrst step and in the second steps, compute the ratio between:
a) the conditional probability of the typed marker allele given the pattern for the founders
marker allele, so in general the conditional probability for any potential pattern in the
pedigree given the possible founder pattern, not restricted by the observed data.
b) the conditional probability of the observed marker alleles given the pattern for the founder
marker alleles.
4. For some subset compatible with the observed data found at step2, the ratio found at step 3
will all be the same for all the possible founders marker allele found in step 1, this is the set of
outcome with positive conditional probability.
5. The conditional distribution is found by arbitrarily choosing any of the compatible pattern of
founder makers found in step1 and computing the conditional probability for the marker allele
typed given the founders pattern chosen and given that set is part of the positive conditional
probability set described in step 4.
It is possible using this method to test for linkage following these steps. In order to test for association
in the presence of linkage the procedure needs to be slightly altered. The presence of linkage implies
that identity by descent will not be independent from the pattern of traits present in a pedigree because
of the presence of linkage. Given that association is not assumed to be present, if founder genotypes
are observed and IBD is available, the minimum statistic in this case is conditioned by the founder
genotype and the IBD relationship within the pedigree. The patterns of founders described in the
steps for the linkage test must now also take into account IBD, in a similar fashion for step 3, and
the conditional probability needs to take into account the compatible marker and compatible IBD
relationship. Any step referring to the pattern of founder alleles needs to incorporate relationship by
IBD. Various examples of what the conditional distributions would be for linkage and association are
given in [50].
The strength of this method is that it allows a test for association in the presence of linkage in a
large number of families and for a large number of markers, therefore making it possible to use a data
set with related information to ﬁnd association.
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1.4 Previous studies on pig infanticide
The link between the genome and the savaging trait has already been the subject of several studies using
diﬀerent approaches. These works include using a linkage approach, to identify regions of interest. The
inﬂuence of gene expression was also investigated, comparing gene expression level in savaging sows
against non savaging. Finally an association study comparing populations of infanticide sows against
non infanticide was also carried out. In this part these studies will be summarised to give an overview
of the current knowledge of the link between the genome and the maternal infanticide phenotype.
1.4.1 Pig as a model for puerperal psychosis
One interesting hypothesis investigated in one of these studies by Quilter et al [17] is that pig maternal
infanticide could be a good model for human puerperal psychosis. This psychological disorder is an
extreme form of baby blues that aﬀects 1 in 1000 births. The symptoms include depression, suicidal
thoughts, loss of appetite and poor bonding with the baby. It is usually linked to feelings of guilt, self
worthlessness or hopelessness. Some extreme cases have unfortunately resulted in infanticide. Mothers
with a history of bipolar disorder are more likely to develop puerperal psychosis after birth and it has
been linked to other psychiatric disorders. Due to the similarity in the phenotype of the disease with
maternal infanticide, genes implicated in maternal infanticide in the pig could be interesting targets
to investigate the origin of puerperal psychosis in humans.
1.4.2 Linkage study
Several studies have already been done to assess the genetic origin of maternal infanticide in the pig.
The ﬁrst study by Quilter et al [17] used a microsatellite study to identify potential Quantitative Trait
Loci (QTL) that might be linked to maternal infanticide. QTL are part of the genome which are
associated with a phenotype, usually containing a gene. They deﬁned large regions of the genome
that can be further investigated. This particular study used 80 microsatellite markers and used a non
parametric linkage analysis [51] on a hundred and nineteen animals from 11 diﬀerent lines. Another
linkage study was done on the pig by Chen et al [14], using a similar approach to investigate maternal
infanticide. The animals for this study came from a White Duroc intercross with a Erhualian breed.
The study investigated F2 sows across three successive rounds of farrowing, totalling 288 sows. The
Erhualian breed is an excellent breeder with an average of 16 piglets per litter and has very good
maternal behaviour. The percentage of reported infanticide dropped from litter to litter, with 12.8%
for the ﬁrst litter, 7,5% for the second and 4.5% for the third. Similarly to Quilter et al, a non
parametric linkage analysis was used.
Both studies identiﬁed QTLs in common on chromosome X and chromosome 2. Quilter et al found
an additional QTL on chromosome 10 while Chen et al found additional QTLs on chromosome 6, 14
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and 15. Because of the lack of annotation for the pig genome at the time of these studies, both used
synteny with the human genome in order to identify potential genes of interest.
Several QTL were found by both studies on chromosome X, SSCX, both on the short arm and the long
arm of the chromosome. On the short arm, both studies identiﬁed a QTL located in a pseudo-autosomal
region which includes the gene Steroid Sulfatase (STS ) that codes for an enzyme processing sulfated
steroids hormone precursors to oestrogen during the pregnancy. In human a deﬁcit in STS is associated
with an elevated risk attention deﬁcit hyperactivity disorder, autism and social communication deﬁcits
[52]. In the mouse, aggressive behaviour has been linked to this region [53, 54]. STS concentration
in the mouse liver was also linked to aggressive behaviour and was shown to modulate the behaviour
[55, 54]. Chen et al proposed another candidate on the short arm, Glycine Receptor Alpha2 subunit
(GLRA2 ) . GLRA2 is an inhibitory neurotransmitter in the central nervous system. It is regulated
by a speciﬁc glycine receptor which has been linked to the pathogenesis of schizophrenia and other
psychiatric diseases [56].
On the long arm both studies identiﬁed a locus in the Xq2.2 region, Progesterone Receptor Membrane
Component 1 (PGRMC1 ), which can bind several steroids including progesterone [57]. Progesterone
blockade during late pregnancy leads to abhorrent maternal behaviour including infanticide [58]. Fur-
thermore, increases in levels of progesterone and oestrogen have been linked to increased levels of
aggression in the pig [9]. Another gene located in the syntenic region in human is 5HTR2C, a stimu-
lating phospholipase C and that has been linked to several abnormal behaviours. Serotonin regulates
the release of dopamine via this receptor. Decreases in its level have been shown to alleviate depres-
sion by release of dopamine [59].This receptor has been linked to suicide [60], alcoholism [61], anorexia
[62, 63] and the behavioural aberrations observed in Prader Willi patients (a genetic condition causing
behaviour disorder and mental retardation) [64]. Others members of its family are associated with
mood disorder and schizophrenia [65], making it a very interesting target.
For chromosome 2 of the pig, both studies identiﬁed QTLs at diﬀerent locations, highlighting diﬀerent
genes. The study by Quilter et al identiﬁed a gene called COX7C (cytochrome subunit VIIc), which is
located on the human syntenic region 15q14. It could be an interesting candidate as cytochrome is the
terminal component of the mitochondrial respiratory chain and mitochondrial dysfunction has been
associated with bipolar disorder and schizophrenia [66, 67]. This gene is also regulated by YY1 [68],
which has been shown to be a target for stress regulated pathway in neural degeneration [69]. The
QTL identiﬁed by Chen et al is syntenic to the region of the Glucocorticoid Receptor (GR), located
on chromosome 5q31.3 in human. This gene mediates the eﬀect of glucocorticoid release in response
to stress and the regulation of the hypothalamic-pituitary adrenocortical system using a negative
feeedback mechanism. GR expression is deregulated in schizophrenia, depression and bipolar disorder
[70, 71]. The syntenic region in human on chromosome 4 has also been linked to panic disorder and
agoraphobia [72].
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The QTLs on the other chromosomes also identify interesting genes, the QTL found on chromosome
6 by Chen et al has Albumin D-site-binding protein (DPB) as a candidate gene. Decreased expression
of this gene in the mouse leads to increase susceptibility to generalized spontaneous and audiogenic
epilepsies [73]. The QTL on chromosome 10 identiﬁed by Quilter et al has PTPRC (protein tyrosine
phospatase, receptor type, C), also known has CD45 has a candidate gene. It is a candidate for
neuroinﬂamation which may exacerbate neurodegeneration and is found in conditions such as Alzheimer
disease (AD) and Down's syndrome [74, 75]. For the QTL on chromosome 14 identiﬁed by Chen et al,
the candidate gene in the corresponding human region is Alpah-2A adrenergic receptor (ADRA2A).
It plays a criticial role in the regulation of neurotransmitter release from sympathetic nerves and
adrenergic neurones in the central nervous system and has been linked to schizophrenia [76, 77]. For
SSC15 a potential candidate close to the peak of linkage is the gene for the sodium channel voltage gated
type II alpha which is involved in pain perception [78]. Another potential candidate for this region
is glycoprotein M6A (GPM6A) which might be involved in stress induced hyppocampal alterations in
psychiatric disorders such as schizophrenia [79].
1.4.3 Gene expression study
A follow up study on the linkage study done by Quilter et al [17] was done by Quilter et al [80] looking at
the gene expression in the pig hypothalamus. The hypothalamus is an important part of the brain where
parturition and maternal behaviours are regulated by neuroendocrine systems that originate from, and
are coordinated by, the hypothalamic nuclei. The areas involved in this are the medial preoptic area,
paraventricular nucleus and the supraoptic nucleus. These brain areas are responsive to stimuli such
as sex steroids, oxytocin, prostaglandin F2α and prolactin (PRL) which have been characterised in pig
and implicated in maternal behaviour. The study compared samples from infanticide individuals and
samples from non aggressive individuals to test for diﬀerentially expressed genes, using two methods
to test for over and under expression in the infanticide samples.
Several interesting candidates genes were identiﬁed as signiﬁcantly regulated between the two groups.
One of these genes was prolactin (PRL), which was found to be up-regulated in infanticide animals.
PRL plays a central role for several behaviours such as feeding, stress, fertility and aggression. High
level of PRL have been linked to aggressive and hostile behaviour [81]. PRL stimulates the release
of dopamine which in return inhibits its release via negative feedback [82]. It is also linked to other
important genes related to maternal aggression such as oxytocin and POU1F1 (POU domain class 1,
transcription factor 1). Low level of oxytocin have been linked to aggressive behaviour [83]. POU1F1
regulates PRL expression and was found regulated in this study. Another interesting gene linked to
PRL found to be regulated in this study is PRLR (prolactin receptor). It regulates the oestrogen re-
ceptor Esr1 and Esr2 via the Jak2-Stat5 pathway [84] and was found to be down regulated in infanticide
samples. Another gene directly related to PRL is DRD2 (dopamine receptor 2) which negatively regu-
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lates the expression of PRL which in turn decreases dopamine levels. It was found to be down-regulated
in this study and has been linked to a number of neuropsychiatric disorders such as schizophrenia, post-
traumatic stress disorders and migraine [85]. It is also involved in the protection of oligodendrocytes
against oxidative glutamate toxicity and oxygen-glucose depravation injury. Such injuries can trigger
abnormalities in oligodendrocytes and have been linked to schizophrenia and mood disorder [86, 87].
Other genes have been linked to dopamine levels, such as POMC (pro-opiomelanocortin) and OPRM1
(micro-opioid receptor 1). The ﬁrst one is down-regulated for the infanticide group and the second one
is up regulated. Interestingly both genes are closely linked, endorphin hormones are produced from the
precursor POMC and bind to OPRM1, up-regulation of OPRM1 could be in response to the lack of
endorphins but if the expression of OPRM1 is reduced it would result in a reduction in the secretion
of dopamine [88]. Another gene found to be up-regulated in the infanticide group is 5HTR2C and was
found in to be in a QTL region in the study by Quilter et al [17]. As discussed in a previous section
1.4.2, it is linked to the regulation of dopamine levels, serotine regulates dopamine via this receptor and
decreases in its expression have been linked to a reduction of the symptoms of depression [89]. There-
fore the up-regulation of this gene could lead to a decrease in dopamine levels and the development
of depression. Furthermore it is also linked to the activation of POMC and variation in the 5HTR2C
has been linked to bipolar aﬀective puerperal psychosis [90]. The expression of 5HTR2C has also been
linked to other psychological disease [60, 61, 62, 63, 64, 65]. Another gene found to be regulated is
POU3F3, interestingly, it is also located near a SNP that has been linked to bipolar disorder [91]. A
lot of genes are linked to dopamine expression, and dopamine receptors are known to modulate NMDA
(N-methyl-D-aspartate) glutamate receptor mediated function. GRIN1, the receptor for glutamate is
the major excitatory neurotransmitter and showed diﬀerential expression in the porcine arrays. It is
involved in learning, memory and some aspect of behaviour and schizophrenia and psychiatric disorder
[92, 93]. The study also investigated G proteins and MAP Kinase signalling pathway. The central
serotonergic, noradrenergic and dopaminergic system are all acting via protein G (Gi, Gs and Gg)
and dysfunction in this system has been linked to depression in human [94]. The Adenylase cyclase
inhibiting G alpha protein (GNAI1 or Gi) gene was found to be diﬀerentially expressed in this study.
It is involved in the MAPK signalling pathway which has been shown to be involved in Alzheimer's
Disease [95].
Another pathway that could be involved in maternal infanticide is the Oestrogen pathway. Trans-
thyretin (TTR) was found to be diﬀerentially expressed, it is a transporter of thyroid hormones and
Vitamin A. Its levels are altered in cerebral spinal ﬂuid of psychiatric patients and KO mice have shown
reduced depression [96]. Therefore the increase in expression seen in three of the individuals suggests
an increase risk of depression. Overexpression of TTR correlates with increased levels of oestrogen,
which has been linked to increased aggression towards oﬀspring [9].
Several other interesting genes linked to the mitochondrial pathway are diﬀerentially regulated in
22
1 Introduction
this study. ATP6, ATP8 COX1, ND2, 16S, ND4 and ATP5A1 are found to be diﬀerentially expressed
in this study on at least one of the various analysis. As the brain has a high aerobic activity and
therefore requires a high mitochondrial content and activity, it is therefore more likely to suﬀer from
mitochodrial defect and diseases. Such issues have been shown to play a role in a wide range of brain
disorders such as schizophrenia, bipolar disorder, Alzheimer's Disease, epilepsy and Parkinson's disease
[97].
1.4.4 Association Study
More recently, porcine infanticide was investigated using association testing in [2]. The study was
performed on four diﬀerent lines of pig: B,C,D and H, consisting of pure breed Landrace LR (B), pure
Large White LW (C) and crosses with Duroc (Duroc x LR for D, Duroc x LW for H).
The study used the pig SNP60k array from Illumina [98]. In total 225 animals were investigated
in this study and after QC, 210 animals were left with around 50 animals for each line. Diﬀerent
approaches were used to investigate the data, a test of association was performed, a haplotype test
using sliding windows was also performed and a haplotype based analysis. Two lines (D and H) had also
enough related samples to perform a sib pair analysis. Using various criteria for ﬁltering the results,
see [2], several regions of the genome were identiﬁed by the diﬀerent type of tests performed. Using the
synteny with the human genome, Quilter et al were able to select regions that have interesting genes,
with function related to maternal infanticide or brain function. Some of the regions also contain some
of the genes identiﬁed in the gene expression study discussed in section 1.4.3 and described in [80],
notably POU1F1 and GRIN1. Furthermore some regions identiﬁed match regions of the QTL found
on chromosome 2, 10a and 10b by [17, 14] and discussed in section 1.4.2.
The most interesting region identiﬁed by this study is a large region on SSC3 which is consistent
across all the analyses. Two diﬀerent peaks are presents in this region, one at 23.4MB and one at
31.9MB. The ﬁrst peak is the top SNP for the single SNP analysis and mapped to a region between
GPR139 and IQCK. Interestingly within 1MB of this peak, the corresponding region in human has
been found to be involved in bipolar disorder, with half of the female patients in these studies exhibiting
post-partum symptoms [99, 100]. There are several potential candidate genes in this region, such as
the regions from XYLT2 to ABCC1, SYT17 to XYLT1, PARN to MLK2, ERCC4 to SHISA9, which
have all have be connected to some psychological pathology such as attention deﬁcit hyperactivity
disorder (ADHD), alcoholism, Autism, Alzheimer's Disease, conduct disorder and schizophrenia [101,
102, 103, 104, 105]. GPR139 is an interesting gene, it is a G-protein coupled receptor, important in
signal transduction. In the mouse it is expressed in the putamen, medulla and caudate nucleus and also
in the thalamus, amygdala and spinal cord but at lower levels [106]. Those areas of the central nervous
system are involved in mood, behaviour and locomotion activities. On an evolutionary perspective,
GPR139 has been placed in the same group as somatostatin receptors [107]. Somatostatin plays an
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important role in the regulation of hormone release, as parturition is an event leading to an important
change in the hormonal balance of the mother, meaning this gene could contribute to post-natal
behaviour changes.
The second peak at 31.9MB is in a region between RBFOX1 and UBN1. This region is syntenic with
a region on the human chromosome 16p13 which has been linked to puerperal psychosis [108] and it is
within 2MB of a region linked to bipolar disorder [109]. RFBOX1 binds to the C-terminus of ataxin-2
and may contribute to the restricted pathology of spinocerebellar ataxia type 2 (SCA2 ). Ataxin-2 is
the product of the SCA2 gene and causes familial neurodegenerative disease [110]. RFBOX1 is also
involved in movement related adverse psychotic eﬀect for conduct disorder [111] and autism [112] and
was a potential candidate for ADHD [113]. The syntenic region in human to RFBOX1 has SNPs that
are associated with bipolar disorder, autism, Alzheimer's disease, ADHD and hyperactivity conduct
disorder [114, 115]. It is also linked to GRIN1 as it is a modulator of neurally expressed genes.
As discussed before, see section 1.4.3, GRIN1 was found to be diﬀerentially regulated in [80] and is
implicated in a number of psychiatric disorders and diseases [93, 92]. The second gene in this region,
UBN1, is in a region that has been investigated for its potential involvement in autism in human [116].
Those two regions are not in LD and therefore form two diﬀerent blocks.
Another interesting region identiﬁed is on SSC4 which is syntenic for a human region on chromosome
16 which has been linked to puerperal psychosis [108]. Some segments on SSC4 reached genome wide
signiﬁcance, the region extends from FAM135B to KHDRBS3 and SNPs in the intergenic region have
been associated with Parkinson's disease, neurotic disorders and cognition in human [117, 118, 119].
PTK2 is in this region and is associated with autism in human [120]. KCNK9 is also in this region
and a member of the superfamily of potassium channel proteins containing pore forming P domains.
It is highly expressed in the cerebellum and is imprinted in human and mouse fetal brain. It has
preferential expression from the maternal allele. It is mutated in a maternally transmitted genomic
imprinting syndrome of mental retardation [121], which makes it an interesting candidate as it has
been show that the heritability of maternal infanticide is higher from dam to daughter than sire to
daughter [4, 3].
A region on SSC9 was identiﬁed as being of potential interest after the permutation analysis. It
matches by synteny a region on human chromosome 1 containing METTL13. This gene has been
found to be linked to increased susceptibility to postpartum mood symptoms [122]. HMCN1 has also
been involved with those symptoms and is just outside the region identiﬁed.
A region identiﬁed on SSC15 reached genome wide signiﬁcance and has a few interesting candidates.
PAX3 is found in this region and is a critical gene in fetal development, more speciﬁcally in neural
development as mutations in this gene lead to spina biﬁda and exencephaly [123]. Mutation of PAX3
in human are also linked to the central nervous system, they have been associated with the craniofacial-
deafness-hand syndrome [124]. Another interesting gene is EPH4, a member of the epharin receptor
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family which is involved in mediating developmental events in the nervous system [125]. It seems also
to contribute to Alzeihmer's Disease, it has been associated with density, volume and cortical thickness
of the hippocampus [126].
1.4.5 Table summary
Table 1.7 summarises the various genes and the pathology or functions in relation to maternal aggres-
sion found in the studies discussed in section 1.4.2, 1.4.3 and 1.4.4.
1.5 Microarray technology
In general for an association study to be successful it must have a large number of markers and
participants compared to linkage studies. The discovery of frequent Single Nucleotide Polymorphisms
(SNP) during the sequencing of the human genome in the early 2000s unlocked the possibility of
performing this type of analysis on cohorts of individuals [127]. This was combined with the advance
in technology for typing DNA and the invention of the DNA microarray [128] which allows GWAS
data to be collected at a reasonable cost. The DNA microarray technology is a signiﬁcant advance in
increasing the throughput of genomic studies and can be used for a wide range of applications: gene
expression, methylation, copy number variation (array Comparative Genomic Hybridisation or array
CGH), chromatin modiﬁcation (Chromatin Immuno Precipitation or ChIP) and genotyping proﬁling
being the major ones. The principle of microarrays is simple, a probe ﬁxed on the array (a solid
support) hybridises in solution with a target with usually one dye (ﬂuorochrome) attached to it. The
dimer formed between the target and the probe will emit a signal that is used to quantify or perform a
present/absent call on the dimer. In order to type a sample, the DNA (or RNA) has to be fragmented,
ampliﬁed by Polymerase Chain Reaction (PCR), which converts the sample to cDNA in the case of
RNA, and then is hybridised to the probe attached to the surface of the array. Those probe sequences
can be tailored to the speciﬁc application, using sequences complementary to a given gene for gene
expression, having two or more probes to type speciﬁc SNPs or the methylation status of a base.
Once hybridised the array is washed to remove any non bound DNA and then the array is treated to
add or enhance the ﬂuorescent signal. The array is then scanned using confocal lasers to excite the
ﬂuorochrome and a high resolution camera to image them.
Microarrays can use a single ﬂuorochrome (single channel microarrays) or two diﬀerent ﬂuorochromes
(dual channel microarrays). The latter uses ﬂuorochromes that when excited will emit light at well
separated wave length. These arrays are used for competitive hybridisation in order to investigate
diﬀerential expression analysis or perform array CGH. Dual channel microarrays were the preferred
choice when the technology was progressing as it helps to reduce the potential bias coming from the
use of multiple arrays to process many samples. Usually the design had to include dye swapping in
25
1 Introduction
C
h
ro
m
os
om
e
G
en
es
in
vo
lv
ed
P
at
h
ol
og
y
/G
en
e
fu
n
ct
io
n
S
tu
d
y
ty
p
e
S
tu
d
y
1
O
P
R
M
1
,
G
R
IN
1
D
op
am
in
e
re
gu
la
ti
on
,
d
ep
re
ss
io
n
,
sc
h
iz
op
h
re
n
ia
G
X
,A
S
[8
0,
2]
2
C
O
X
7
C
,
Y
Y
1
,
G
R
B
ip
ol
ar
d
is
or
d
er
,
sc
h
iz
op
h
re
n
ia
,
n
eu
ra
l
d
eg
en
er
at
io
n
,
d
ep
re
ss
io
n
,
p
an
ic
d
is
or
d
er
ag
or
ap
h
ob
ia
L
in
ka
ge
,A
S
[1
7,
2,
14
]
3
P
O
M
C
,
P
O
U
3
F
3
,
D
op
am
in
e
re
gu
la
ti
on
,
d
ep
re
ss
io
n
,
b
ip
ol
ar
d
is
or
d
er
,
A
D
H
D
,
al
co
h
ol
is
m
,
au
ti
sm
,
G
X
,
A
S
[8
0,
2]
G
P
R
1
3
9
to
IQ
C
K
,
R
B
F
O
X
1
to
U
B
N
1
A
lz
h
ei
m
er
d
is
ea
se
,
sc
h
iz
op
h
re
n
ia
,
p
u
er
p
er
al
p
sy
ch
os
is
,
n
eu
ro
d
eg
en
er
at
iv
e
d
is
ea
se
,
co
n
d
u
ct
d
is
or
d
er
4
F
A
M
1
3
5
B
to
K
H
D
R
B
S
3
P
u
er
p
er
al
p
sy
ch
os
is
,
P
ar
k
in
so
n
's
d
is
ea
se
,
n
eu
ro
ti
c
d
is
or
d
er
s,
co
gn
it
io
n
,
m
en
ta
l
re
ta
rd
at
io
n
A
S
[2
]
6
D
P
B
,T
T
R
A
u
d
io
ge
n
ic
ep
il
ep
si
es
,
ag
gr
es
si
on
L
in
ka
ge
,
G
X
[8
0,
14
]
7
P
R
L
A
gg
re
ss
io
n
an
d
h
os
ti
le
b
eh
av
io
u
r
G
X
[8
0]
9
D
R
D
2
,
G
N
A
I1
,
M
E
T
T
L
1
3
,
H
M
C
N
1
sc
h
iz
op
h
re
n
ia
,
p
os
t-
tr
au
m
at
ic
,
m
ov
em
en
t
an
d
st
re
ss
d
is
or
d
er
,
m
ig
ra
in
e,
G
X
,
A
S
[8
0,
2]
A
lz
h
ei
m
er
D
is
ea
se
,
p
os
t-
p
ar
tu
m
m
o
o
d
sy
m
p
to
m
s
10
P
T
P
R
C
(C
D
4
5
)
A
lz
h
ei
m
er
d
is
ea
se
,
D
ow
n
's
sy
n
d
ro
m
e
L
in
ka
ge
,A
S
[1
7,
2]
13
P
O
U
1
F
1
R
eg
u
la
te
P
R
L
G
X
,
A
S
[8
0,
2]
14
A
D
R
A
2
A
S
ch
iz
op
h
re
n
ia
L
in
ka
ge
[1
4]
15
G
P
M
6
A
,
P
A
X
3
S
ch
iz
op
h
re
n
ia
,
sp
in
a
b
iﬁ
d
a,
ex
en
ce
p
h
al
y,
cr
an
io
fa
ci
al
-d
ea
fn
es
s-
h
an
d
sy
n
d
ro
m
e,
L
in
ka
ge
,
A
S
[1
4,
2]
A
lz
h
ei
m
er
's
D
is
ea
se
16
P
R
L
R
O
es
tr
og
en
re
gu
la
ti
on
G
X
[8
0]
X
S
T
S
,
G
L
R
A
2
,P
G
R
M
C
1
,
5
H
T
R
2
C
ri
sk
d
eﬁ
ci
t
h
y
p
er
ac
ti
v
it
y
d
is
or
d
er
,
au
ti
sm
,
so
ci
al
co
m
m
u
n
ic
at
io
n
d
eﬁ
ci
ts
,
L
in
ka
ge
,
G
X
[1
7,
80
,
14
]
ag
gr
es
si
ve
b
eh
av
io
u
r,
sc
h
iz
op
h
re
n
ia
,
in
fa
n
ti
ci
d
e,
d
ep
re
ss
io
n
,
su
ic
id
e,
al
co
h
ol
is
m
,
an
or
ex
ia
.
T
ab
le
1.
7:
T
ab
le
su
m
m
ar
y
of
al
l
th
e
lo
ci
an
d
ge
n
e
fo
u
n
d
in
th
e
d
iﬀ
er
en
t
st
u
d
ie
s.
A
S
st
an
d
s
fo
r
as
so
ci
at
io
n
st
u
d
y
an
d
G
X
fo
r
ge
n
e
ex
p
re
ss
io
n
st
u
d
y
26
1 Introduction
order to counter the bias due to the diﬀerence of signal strength coming from a speciﬁc dye [129]. The
technology is prone to a number of technical biases coming from the production of the array (print tip
variations for example), the extraction of the RNA/DNA and the preparation of the arrays. In order
to correct these biases, normalisation methods were developed [130]. These methods were designed
to remove technical biases from the data generated by microarrays. Technical biases are deﬁned as
systematic variation in signal, the origin of which comes from the technology used. The data obtained
from the scanner is called raw data and needs to be processed in order to produce normalised
data, which should be free of technical biases. Various normalisation methods were used at ﬁrst, as
the technical biases were important, nowadays the data are transformed on a log2scale (to compress
its scale) and normalised using a quantile normalisation. The resulting data will all share the same
distribution of signal which will allow better statistical analysis. The evolution of the normalisations
methods followed the improvement of the methods used to produce arrays.
At ﬁrst, most groups were producing their own microarrays or had access to a dedicated facility to
do so. There were a substantial number of methods used to produce the microarrays[129]. One of
the most widely produced microarrays in laboratories were spotted arrays, where the probes were laid
onto a slide using inkjet or contact printing technology[131]. Other more sophisticated methods use
in-situ synthesis of oligomucleotide probes. As the technology improved, the production moved from
laboratory to commercial companies, which developed more robust methods, thus improving reliability
[132, 133]. While the ﬁrst microarrays had a few hundred to a few thousands of probes on them,
this quickly increased with the advance in technology triggered by the involvement of biotechnology
companies. These improvements resulted in more robust, reproducible and cheaper arrays while also
leading to an increase in the number of probes present on the arrays and in parallel with an increase
in the number of samples being processed. This represented a major breakthrough for GWAS as the
sample sizes and number of markers needed for successful studies are large. The sample size needed to
achieve good power for GWAS is linked to the number of markers studied. The larger the sets of SNPs,
the more samples are needed in order to achieve good power [42]. The markers are chosen in order to
represent LD blocks as deﬁned below and thanks to the advances in technology, typing thousands of
SNPs on large cohorts became more viable, transforming GWAS into the major approach in the study
of genetically linked diseases [134].
In order to design good genotyping microarrays for GWAS, the selection of appropriate markers is
crucial. Ideally the markers should be selected to represent the genome as ﬁnely as possible in order to
identify any association between genotype and phenotype. The selection of markers is done using LD
to select 'tag' SNPs. As discussed before LD is characterised by the joint transmission of alleles, and
can be measured in various ways [135]. One measure is DAB = pAB − pApB which is the frequency
of the heterozygote allele minus the product of the frequency of both individual alleles. If the loci are
in linkage equilibrium then pAB = pApB and D = 0. This measure is not the most useful measure
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to compare between pairs of markers as it is tied to their allele frequencies. D can be normalised by
deﬁning Dmax as the smaller value between pA(1 − pB) and pB(1 − pA) when DAB > 0, and the less
negative value between pApB and (1−pA)(1−pB) if DAB < 0 be then we can deﬁne D′AB = DAB/Dmax
as suggested in [20]. The normalised DAB can be used to compare pairs of markers. Another measure
for LD is r2 = D
2
pA(1−pA)pB(1−pB) which is the Pearson correlation coeﬃcient between the markers. The
various ways of measuring the LD can be used to deﬁne LD for regions of the genome using known
markers. It can be used to deﬁne blocks of LD or haplotype blocks of markers (markers transmitted
together). Deﬁning those blocks allows the selection of 'tag' SNPs for the construction of microarrays
to test for association of markers to disease contributing loci using case/control studies [136]. Tag SNPs
are choosen to represent regions of the genome, they allow us to indirectly type other markers in the LD
block they belong to as those markers are transmitted together because of the linkage disequilibrium.
It is therefore possible to infer the allele of other SNPs in this region using the tag SNPs.
The array used for this study is the porcine SNP 60k array by Illumina, the design process is
described in details in [98]. Brieﬂy, libraries of pool of animal from ﬁve diﬀerent pig breeds (Duroc,
Pietrain, Landrace, Large White and Wild boar) were sequenced using short read (36bp) and longer
read on the Roche 454 platform. The reads obtained were aligned against the pre-release version 7 of
the pig genome for SNP discovery. After pruning and selection, the ﬁnal number of SNPs selected for
the array was 64,232.
1.6 Deep Sequencing technology
Once regions of interest have been identiﬁed by using tag SNPs or microsatellites, they can be studied in
more detail using deep sequencing. This methodology is used to sequence the full or part of the genome
in order to get more information about the surrounding region of the signiﬁcant SNPs. Following up
on a GWAS to study the regions discovered with a deep sequencing approach has proven useful to
identify causal variants for several diseases [137, 138, 139, 140]. Deep sequencing allows a detailed
investigation of the sequence of the genome and therefore reﬁne any leads given by the GWAS.
1.6.1 Deep sequencing methodology
Over the last 50 years the methods used to sequence DNA have greatly advanced, especially since the
completion of the ﬁrst draft of the human genome. Several methods have been developed in order to
perform deep sequencing of the DNA [141, 142]. One method was originally developed by a company
called Solexa and then bought by Illumina and became the most widely used sequencing technology
[142]. This technology performs sequencing by reversible terminator chemistry [143]. The principle
starts by ﬁrst shearing the DNA in small fragments. The fragments are ligated with adaptor sequences
speciﬁc to the Illumina platform. Each end of the fragment has a speciﬁc adaptor which also contains
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the sequencing primer. The fragment can also be labelled with speciﬁc indices sequences (also called
barcode), which can be used to track the samples they originated from. Fragments from diﬀerent
samples can then be pooled together, usually to save on the cost of sequencing . The fragments once
ready to be sequenced (pooled or not) are called a sequencing library. The library is then loaded on the
instrument. The DNA fragments will hybridise at one of their ends with the adaptors present on the
ﬂow cell used for the sequencing. The ﬂow cell consists of a glass slide with one or more channel (also
called lanes) that have complementary sequences to the adaptors used during the library preparation.
Once hybridized the fragments will undergo an ampliﬁcation step also called bridge PCR, see ﬁgures
1.2, 1.3, 1.4. The free end of the fragment will bind to a nearby free adaptor sequence ﬁxed on the
surface of the ﬂow cell and form a bridge. This bridge is then used to perform an ampliﬁcation step
resulting in the clonal copy of the original fragment: the complementary sequence is removed after
the ampliﬁcation step. The ampliﬁcation step is repeated several time to generate a cluster of clonal
copies of the same fragment. The number of clusters being sequenced will depend on the sequencer
used. Once the ampliﬁcation step completed, the clusters will be sequenced by reversible terminator
technology, ﬁgure 1.5. The technology works by using the primer sequence present on the adaptor
sequence to start a polymerase reaction. Primers are ﬂushed on the ﬂow cell to start the reaction.
Then the sequencing is started and consists of several cycles. A cycle starts with the four nucleotides
being ﬂushed onto the ﬂow cell. The nucleotides are labelled with ﬂuorochromes and have a blocking
group (3'-OH) that will result in the addition of only one base during each cycle. Once the reaction
is completed for that cycle, the remaining nucleotides in solution are washed away and the instrument
will image the ﬂow cell surface, taking a picture of the cluster colour for each cycle. As all the fragment
forming a cluster are of the same composition, the ﬂuorescent signal emitted will be the same for all
the fragments forming a cluster. After the scanning step the blocking group is removed so that a new
cycle can start. Once the sequencing is completed, the sequence generated for a cluster of the ﬂow cell
is called a read. The length of the read will be based on the number of cycles performed, which will
be determined by the user prior to sequencing. At the present the maximum sequencing length (also
called read length) for one end of the fragment is 250 nucleotide for the MiSeq platform. Sequencing
can be done from one end of the fragment, called single end sequencing, or from both end, called paired
end sequencing, which is done by paired end turn around chemistry. The strands are ﬂipped on the
ﬂow cell by performing several cycles of bridge ampliﬁcation, therefore allowing sequencing of the other
end of the fragment.
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Figure 1.2: Bridge PCR ampliﬁcation ﬁrst phase, reverse strand synthesis
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Figure 1.3: Bridge PCR ampliﬁcation second phase, bridge PCR
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Figure 1.4: Brige PCR ampliﬁcation third phase, mon-clonal ampliﬁcation
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Figure 1.5: Sequencing by synthesis, strand sequencing using reverse terminator.
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1.6.2 Targeted sequencing
While a full genome sequencing approach will give the largest amount of information, it is not always
the most cost eﬀective way to identify variants in a region of interest as a large portion of the sequencing
data will not hold any useful information. New approaches have been developed in order to sequence
only part of the genome, called targeted sequencing, sequence enrichment or sequence capture. Man-
ufacturers have designed pre made panels for various applications but most of those are available for
human genomes only. For non model organisms, once the regions of interest have been identiﬁed it is
possible to design a custom capture kit to target the regions of interest that have been identiﬁed using
an association or linkage approach. Several companies are oﬀering the design of custom capture pan-
els, Roche Nimblegen (SeqCap), Agilent (SureSelect) and Illumina (Nextera Rapid Capture). Agilent
SureSelect uses long, 120-mer, biotinylated cRNA baits to capture regions of interest in order to enrich
them from a genomic fragment library. The processe is described in ﬁgure 1.6: it starts by the shearing
of the genomic DNA (gDNA) and standard library preparation. Then the sample library is hybridised
with the baits and the hybridisation product is pulled down using magnetic streptavidin coated beads.
The selected library is then ampliﬁed and put on the sequencer. Nimblegen SeqCap uses the same
principle as the SureSelect method, as seen in ﬁgure 1.7. Illumina Nextera Rapid capture also follow
a similar protocol but instead of using traditional library preparation methods, it uses the Nextera
library preparation protocol which take less time than traditional methods as it uses transposons to
cut and add the sequencing adaptors to the gDNA which make the process a lot faster. Once this
step is completed the sequence capture is carried out in the same fashion as the other method, using
biotinylated probes and streptavidin coated beads.
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Figure 1.6: Agilent SureSelect sequence capture. Source: Agilent website (www.genomics.agilent.com)
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Figure 1.7: Nimblegen SeqCap sequence capture. Source: SeqCap Brochure 2015
1.6.3 Sequencing mapping
Once the library has been sequenced, the data generated are mapped to the reference genome and
analysed using an algorithm designed to call the variant. The variant identiﬁed can be evaluated
for potential impact on the gene expression or product of critical genes. Because the DNA consists
of only four letters, it is easy to index the reference and query sequence in order to perform fast
alignments and ﬁnd a match between the read sequence and the reference. The software used to align
the reads sequenced is called Burrows Wheeler Aligner (BWA) [144] which uses Burrows Wheeler
Transform (BWT). BWT is useful to speed up the search for a match between the reads and the
reference sequence. The reference is transformed using the Burrow Wheeler transform as illustrated
in ﬁgure 1.8. This step is also called: the indexing of the genome. The reference will be broken up
into thousands of BWT words during the indexing. The transformed reference, called the indexed
reference, is used to speed up the search of patterns (queries) in it, in this case the reads.
The BWT has two important properties. First, by sorting the BWT of the word by lexicographical
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order we can retrieve the ﬁrst column of the BWT matrix as explain in ﬁgure 1.9. This creates an
incomplete Burrows Wheeler matrix that can be used instead of the full matrix for pattern searching.
Second, another property of the BWT is that the ﬁrst occurrence of character 'X' in the last column
is the same character as the ﬁrst occurrence of 'X' in the ﬁrst column. This is easy to see this when
looking at the Burrows Wheeler matrix in ﬁgure 1.8. With those two properties it is possible to search
a pattern without the full matrix, using only the ﬁrst and last columns1.9, it is possible to search
for patterns. Take the pattern 'ANA' which occurs twice in the world BANANA. The search can be
performed with the following simple manual steps:
1. Look for the occurrence of the ﬁrst letter 'A' in the last column, there are 3 such occurrences, in
position 1, 6 and 7
2. Because of the cyclical permutation used to generate the BWT, the letter after 'A' in the original
word will be in the ﬁrst column of the BWT matrix
3. Thanks to the property of the BWT we can ﬁnd the ﬁrst column from the BWT word by sorting
it by lexicographical order.
4. In order to identify the correct occurrence of 'A' in the ﬁrst column, we use the property previously
described, the ith occurrence of a letter in the last column is the same as the ith occurrence of
the same letter in the ﬁrst column. Therefore we know that the ﬁrst occurrence of it will be
followed by '$' which does not match 'N', the next two occurrences do match our pattern. The
pattern 'N' in the ﬁrst columna and 'A' in the last matches row 6 and 7 of the BWT matrix.
5. The second letter for our search is N, which corresponds to 2 of the 3 occurrences of 'A' identiﬁed
in the previous steps.
6. By checking the 'N' in the last column and looking at the ﬁrst column we know that both
are followed by 'A' so our search is over, but if we were to continue we would apply the same
principles.
7. The matching rows of the BWT matrix are the second and third occurrences of A in the ﬁrst
column, so line 3 and 4.
However in order to use this method more eﬃciently, a few mathematical transformations allow the
automation of the search for large scale pattern mapping.
The method using a Last to Front (LF) mapping table can be used to perform a search for matching
characters:
1. Calculate the C array for the BWT of the word to reconstitute, C(i) corresponding to the number
of characters lexicographically smaller in the BWT word, for example for B there are '$' and 3
times 'A', so C(B)=4. See table 1.8
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2. Perform the LF mapping, using the following formula LF (ij) = C(i) + ni with ij being the j
th
occurrence of the character i and ni being the number of occurrence of the characteri up to and
including ij . See table 1.9.
3. Then get the ﬁrst column of the BWT matrix by sorting the BWT by lexicographical order :
$AAABNN
4. Seaching for 'ANA' we start again by the last character 'A'
5. The As have as LF value 2, 3 and 4 in the table 1.10 when checking the top row (BWT).
6. Checking the column 2, 3 and 4 of the ﬁrst row for the next letter 'N', there are two matches for
column 2 and 3 with LF numbers of 6 and 7.
7. Checking column 6 and 7 for the next letter 'A', both match, therefore the word 'ANA' is found
twice.
8. The LF to front value is 3 and 4, which indicate that the pattern start on the ﬁrst column of the
BWT matrix at row 3 and 4.
This method is also useful to exclude mismatch or partial match data, looking for ABA in BANANA:
1. Starting by the last letter 'A', the LF value are 2, 3 and 4.
2. The next letter is 'B', checking column 2, 3 and 4, B is present in column 4 with a LF value of 5.
3. The next letter is 'A', however the letter in column 5 is '$' which does not match therefore the
pattern 'ABA' is not present in our word.
The next question when one or several matches are found is to know where the match is located in
the original word. Going back to the pattern 'ANA' which had 2 occurrences in our our word, using
a walk back approach and counting the number of steps (or oﬀsets) we can get the position of the
match in the original word:
1. As determined before the 2 rows which start with the 'ANA' pattern are rows 3 and 4.
2. Starting with row 3, the letter for the last column is N with a LF of 7.
3. The 'N' at row 7 has a 'A' in the last column with a LF value of 4, the oﬀset is set to 1.
4. The 'A' on the 4th row of the matrix as a 'B ' in the last column with a LF value of 5, oﬀset is
set to 2.
5. The 'B' on the 5th column of the matrix has an LF value of 1 with the character '$' in the last
column, oﬀsets is set to 3.
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6. As '$' is the top of the matrix we have completed or walk back to get the position of the pattern
in our original word
7. Therefore the ﬁrst 'ANA' pattern start 3 character after the ﬁrst in BANANA (so the 'A' which
is the 4th letter in the word is the starting position)
8. For the second pattern we start at row 4, which as a 'B' in the last column with a value of 5.
9. The 'B' on the 5th column of the matrix has an LF value of 1 with the character '$' in the last
column, oﬀsets is set to 1.
10. As '$' is the top of the matrix we have completed or walk back to get the position of the pattern
in our original word
11. Therefore the second 'ANA' found starts 1 character after the ﬁrst in BANANA.
When working with millions of reads and longer words and patterns, this method is too slow. One
alternative is to store the oﬀset value for each line into a suﬃx array of the BWT matrix along with
the BWT, but this is also ineﬀective as the size of the oﬀset matrix will be very big, 12G for the
human genome [144], however new methods allow the size of the suﬃx array to be reduced to more
manageable and eﬃcient sizes [145].
The BWT word can also be reversed to the original word using the following method:
1. We start by the last letter of the word. Because we added '$' to the end word of the word, and
that the BWT is sorted, we know that the last letter is ﬁrst one in the BWT (ﬁrst column to
last column of the BW matrix). In this case the last letter is A and has a LF of 2.
2. Using the LF value as a reference for the column to get the next letter: the second column of
our table 1.10 and has the BWT value, 'N'. The second to last letter is N, so the word ﬁnished
by 'NA'.
3. Again using the LF value as reference, in the second column the value is 6, the 6th column in the
table has a BWT value of A and a LF value of 3. Our word ﬁnishes with 'ANA'.
4. The third column has a BWT of N and a LF value of 7. Our word ﬁnishes by 'NANA'.
5. The seventh column has a BWT of A and a LF value of 4, our word is now 'ANANA'
6. The fourth column has a BWT value of B and a LF value of 5, our word is now 'BANANA'
7. The ﬁfth column matches the special character '$', therefore the word from our previous step is
the original word.
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The examples above are simple and real data might only have partial matches to the reference genome,
sequencing technology is not a hundred percent accurate at the moment, therefore it is likely that
some reads will have erroneous bases. In case of inexact matching, the algorithm can introduce a
random letter and try to continue the matching protocol in order to ﬁnd the closest match possible.
The advantage of the BWT is that the C array and the LF mapping table can be calculated on the ﬂy,
only the BWT of the original reference needs to be stored. Therefore prior to mapping the reads, the
reference genome needs to be converted using the Burrows Wheeler Transformation. A suﬃx array is
also generated and will be used to get the position of the matches in the reference. The generation of
both ﬁles will only be performed once and can be used anytime new data needs to be mapped to the
reference.
This is the basis for Burrows Wheeler Aligners, more recent implementation of the aligners added
some improvement and heuristics enhancements in order to speed the search of patterns but the base
principle use for the mapping stays the same. For this study, deep sequencing technology were used
on intervals of interest identiﬁed using the family based association test and parent of origin test. In
addition the interval already identiﬁed from a previous study [2] were used to design a capture panel.
In total three capture panels were used in order to study the allele frequency of pools of control and
aggressive animals to look for markers that could be used to identify susceptibility to infanticide in
animals.
Character i $ A B N
C(i) 0 1 4 5
Table 1.8: C array for the BWT transform ANNB$AA . C(i) corresponds to the number of character
lexicographically smaller in the BWT word, for example for B there are '$' and 3 times 'A',
C(B)=4.
Character i A N N B $ A A
C(i) 1 5 5 4 0 1 1
index nj 1 1 2 1 1 2 3
LF (i) 2 6 7 5 1 3 4
Table 1.9: LF mapping for ANNB$AA
BWT A N N B $ A A
First column of BWT matrix $ A A A B N N
LF (i) 2 6 7 5 1 3 4
Table 1.10: Table of the BWT, LF values, used to reconstruct the original word
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Figure 1.8: Burrow Wheeler transform
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Figure 1.9: Partial reconstruction of the BWT matrix for pattern searching
1.6.4 Sequence variant calling: uniﬁed genotype caller
Once the data have been mapped the next step is to ﬁnd which bases are diﬀerent between the reference
genome and our capture set in order to identify variants that might be linked to our phenotype of
interest. Due to the nature of the sequencing data, looking for base variation is not a simple task,
diﬀerences can come from a biological source but might also be caused by technical issues arising from
the sequencing technology. The error rate for sequencing is not constant and will depend on several
technical aspects of the sequencing technology. For Illumina technology the main contributor is the
density of cluster on the ﬂow cell. The typical sequencing quality of Illumina generated sequences is
expected to have at least 75% of bases above a Phred score of 30 (Q30), which means less than 1 in 1000
error, resulting in a base call accuracy of 99.9%. While this is a very reasonable error rate, it has to be
put in perspective with the high amount of data generated by the sequencer. The NextSeq can output
between 25 to 120 Gigabases in one run. Furthermore the quality of the sequencing is not even across
the length of the read, in general the bases at the beginning of the reads are of high quality and the
quality will degrade as the sequencing progress, with the end of the read being of lower quality [146].
This is caused by the degradation of the chemistry as the sequencing progress. The Illumina reported
error rate is also not always accurate and the real error rate is often higher [146, 147]. Inaccurate error
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rate leading to higher than reported rate are problematic as they will result in a higher number of false
positives, erroneous bases called as true variants because of misleading error rate. Other factors are
also important such as sequencing depth or coverage to ensure that a high enough number of reads are
used in order to call a variant. This can also be inﬂuenced by sequencing technology: GC content has
an eﬀect on read coverage [146], higher GC content resulting in higher coverage.
In light of these issues with sequencing technology, a simple alignment and mismatch approach is not
appropriate to call variants as there is a possibility that we might mistakenly take a sequencing error
as a true variant. Therefore a more elaborate approach is required. Several approaches are available,
one of the most widely used is the Genome Analysis Toolkit (GATK) developed by the Broad Institute
[148]. It is a complex pipeline which has several steps to process the data before calling variants and
ﬁltering them once they have been called. A set of clear guidelines [149] is given to the user to make
sure that the data are processed correctly and produce a robust set of variants. Notably it recalibrates
the base mapping score in order to give a better variant call, resulting in a more robust set of variants.
The various steps involved in the GATK pipeline are explained in more detail in the material and
methods section 2.10.
The crucial step of this algorithm is calling the variants. This is done using the uniﬁed genotype
caller, a Bayesian algorithm. The algorithm can call variants on several samples at the same time or
sample with multi ploidy (ploidy is the number of chromosome present). The likelihood of the genotype
AA, AB and BB are calculated using the following equations [149]:
 P{D|GTi} =
∏
P{Di,j |GTi}
 P{Di|GTi = AB} = (P{Di,j |A}+ P{Di,j |B})/2
 P{Di,j |B} = εi,j ∗ P{B is true|Di,j, ismiscalled}, Di,,j = B, otherwise.
where P{Di,j |GTi} is the probability of observingDi,,junder the hypothesized genotypeGTi. P{Di,j |A}
and P{Di,j |B} are the probabilities of observing base Di,jgiven that the true genotype is either A or
B. εi,j is the probability of miscalling the base of interest and depends on the quality score of the base.
Finally P{B is true|Di,j, ismiscalled} is the probability of B being the true chromosomal base given
that Di,j is a miscall.
If qi is deﬁned as qi = {0, 1, 2}and is the number of alternative B alleles carried by the single
individual i and that q =
∑N
i qi is the number of chromosomes carrying the B allele among all the
individuals studied or all the members of a pool. Then P (q = X) can be estimated by:
 P{q = X|D} = P{q=X}P{D|q=X}∑
Y P{D|q=Y }
 P{q = X} = 1− θ∑2Ni=1 1/i X > 0 otherwise.
 P{D|q = X} =∑GTΓ∏Ni P{Di|GT}i
43
1 Introduction
 Γ = {GT where ∑i qi = X}
With Γis the set of all genotype assignments for the N individuals that contain exactly q = X B alleles.
P{q = X}is the inﬁnite-site neutral expectation to observe X alternative alleles in 2N chromosomes
with an heterozygosity rate of θand GTiand Di are the ith individuals' genotype and sequencing read
respectively.
Once the variants have been called the next step is to identify diﬀerences between our two phenotypes
and to look at them in their genomic context in order to identify the potential eﬀect they can have
on the data. Several annotation resources and data handling pipelines are used in order to accurately
annotate the variants.
1.7 Pig genome release 10.2
The version of the genome used for this project is Sus scrofa release 10.2, by Swine Genome Sequencing
Consortium (SGSC) [150]. It was released in August 2011 and used a Duroc as the reference pig. A
Bacterial Artiﬁcial Chromosome (BAC) library was used for the sequencing of the genome. BAC
libraries [151] are a collection of bacteria each with an insert of foreign DNA of up to 200,000bp than
can be sequenced. BAC are used to construct a physical map of the genome by ﬁngerprinting each
clone with an enzyme, allowing the identiﬁcation of overlapping features and order the BACs. The next
step is to sequence the BACs using short reads which will help the assembly as the order of the BACs
is already known. The genome was produced from the BAC libraries using short read sequences from
the Illumina Genome Analyser II and produced 9906 scaﬀolds, resulting in 20 assembled chromosomes
and 4,562 unplaced scaﬀolds.
Scaﬀolds are made of contigs and gaps. Contigs are continuous sequences assembled from short reads
and the gaps are usually of know length as they are deﬁned by pair of reads or mate pairs, as shown
on ﬁgure 1.10. The sequence of the gaps is unknown.
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Figure 1.10: Scaﬀold and contigs. The reads (known sequence in red) form the 2 contigs for this region,
the gap is covered by a pair of reads and as the insert size is known a scaﬀold can be built
including the 2 contigs and 1 gap.
The total number of base pairs in the genome is 3,024,658,544 with a golden path size of 2,808,525,991
base pairs. The golden path represents the size of the assembled scaﬀolds in a continuous sequence,
ignoring redundant regions such as pseudo autosomal region and repeat regions (for example in immune
genes). Unplaced scaﬀolds are not counted in the golden path. The scaﬀolds N50 is 576,008 base pairs
and the L50 is 1,303 scaﬀolds. N50 is the smallest size scaﬀold producing 50% of the genome in the
assembly. In other word 50% of the assembly is comprised of scaﬀolds at least as big as the N50
value or larger. The L50 is the smallest number of scaﬀold that can produce the N50 value. The
N50 value is small for this assembly, it represents less than 1% (0.2%) of the golden path and the
L50 is relatively large, meaning that the assembly is composed of a large number of relatively small
scaﬀolds. If compared to the human genome release at the same time (HG38), the N50 for scaﬀolds
was 59,364,414bp with a L50 of 17 scaﬀolds. The N50 for the human genome is 1.8% of its total size
(3.2 GB).
In terms of the contigs, for the pig a total of 243,021 contigs form the scaﬀold, the N50 of the contigs
is 69,503bp and the L50 is 8,632 contigs. Again the number for the N50 is small and the L50 is large,
therefore the scaﬀolds are formed by a large number of small contigs. In comparisons for the human,
the contigs N50 is close to the scaﬀold N50 at 56,413,054bp and the contigs L50 is 19 contigs.
In light of these numbers, compared to human genome, the pig genome assembly is still very patchy
and not to the same standard. The main issue is the size of number of pieces (scaﬀolds and contigs)
making the genome, which is a consequence of the technology used for the sequencing: short reads
are more diﬃcult to use for accurate assembly. It is likely that the assembly is not highly accurate,
therefore the positioning and annotation of features based on it is not going to be truly representative of
the real genome. Furthermore the breed chosen is a Duroc and our data includes Landrace and Large
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White which will have a diﬀerent genetic make up compared to Duroc. Despite these drawbacks,
having a reference genome, even if inaccurate, is highly preferable to having to use de novo approaches
which take a large amount of time and are more costly to analyse.
The annotation of the genome was performed using the Ensembl automatic gene annotation system
[152], which incorporates some of the RNAseq data generated by the SGSC and data from other
sources, mainly public databases. The process is divided into three diﬀerent stages, a raw compute
stage, a targeted stage and a similarity stage. The raw compute stage starts with masking repeats
using RepeatMasker [153]and Dust [154], in total 48.2% of the genome was masked. After masking
several tools are used to identify transcription start sites and then Genescan [155] is used to identify
genes structures. To check the accuracy of the prediction, the results of Genescan are aligned against
several databases: UniProt [156], Unigene and Vertebrate RNA. For the targeted stage, sequences of
known pig proteins are obtained from several sources (UniProt, SwissProt and Genbank [157]) and
used to predict coding models using Genewise. Exonerate [158] is used on cDNA, EST and ENSSSCP
models to reﬁne the results. The similarity stage uses the protein data from UniProt Protein Existence
classiﬁcation of level 1 and 2, corresponding to protein with experimental evidence at the protein
level (1) and at the transcript level (2). Taxonomy is also used to divided the protein models found
into diﬀerent groups: mammalian, non-mammalian vertebrate and invertebrates. Only protein models
corresponding to mammalian and non-mammalian vertebrates proteins are kept. Models matching
invertebrate proteins are discarded. All of those three steps and some additional evidence generated
using pig cDNA, EST (Expressed Sequence Tag) and RNA sequencing data produced by the SGSC
were used to ﬁnalise the annotation of the genomes. The combined result of this approach deﬁnes
21,630 coding genes, 3,124 non coding genes, 568 pseudogenes and a total of 30,585 gene transcripts.
1.8 Objectives and aim
The aim of this study is to get an understanding and identify the genetic factors that contribute to
maternal infanticide in pigs. Previous work done on this trait has established that there is a genetic
and heritable component to it. The work done by Quilter et al ,[17, 80, 2] and Chen et al [14]
have highlighted genes and regions of the genome that might inﬂuence maternal infanticide in pigs.
These studies used a range of methods: linkage using microsatellite, gene expression and genome wide
association study using microarrays. The evolution in the technology available allows us to further
complete some of the work done by using more advanced methods and increase the resolution at which
we look at the regions they identiﬁed as shown in ﬁgure 1.11. Using some of the previous work as
a starting point, notably Quilter et al [2], this study will use new data and combine it with existing
data from Quilter et al [2] to identify regions of interest using more powerful methods to investigate
families. Once regions of interest are deﬁned, sequence capture will be used to sequence and call
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sequence variants in these regions. For the sequencing, animals will need to be selected in order to
constitute pool of infanticide and control animals. The variant allele frequency between the two groups
will be compared in order to identify variants of interest. Once identiﬁed the variants will be annotated
and their potential impact on the region or genes assessed. An overview of the study is shown on ﬁgure
1.12.
The following objectives can be deﬁned from the works and methods covered in the introduction:
 Add new animals to the previous data generated by Quilter et al [2] in order to generate pedigree
to use parent of origin and family base association test
 Identify new regions of interest from the family based association and parent of origin test
 Design capture sets to target the regions of interest
 Select infanticide and control animals for sequencing
 Sequence the regions of interest
 Process the sequenced data to call variants
 Compare allele frequencies between infanticide and control animals to identify variants of interest
 Use resources from pig and human databases to get the most accurate annotation for the variants
of interest
 Analyse the variant to identify speciﬁc genes or precise locations of the genome linked to maternal
infanticide
 Assess the potential impact of variants in genes of interest
Combining diﬀerent approaches of genotyping and sequencing will help narrow down the regions and
genes involved in the genetic make up of maternal infanticide. Methods used in the previous study
such as microsatellite markers have helped identify regions of the genome but with the advances in
methodology such as microarray and sequencing, it is possible to investigate in greater details the
genome and identiﬁed regions a few kilobases large instead of larger scale in centimorgan. The access
to better methods to analyse the data set available will also help increase the power of the analysis to
pick good candidate regions for variant analysis. If successful this study will identify key genes and
causal variants that are signiﬁcantly contributing to maternal infanticide in pigs.
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Figure 1.11: Overview of the diﬀerent methods to identify causal loci on the genome. The resolution
of the methods improve greatly from microsatellite (scale in centimorgans), to association
study (scale in mega bases) to variant analysis (scale in kilobases or less).
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Figure 1.12: Overview of the study. The number of * highlight the various contributions: * Julien
Bauer, ** Claire Quilter, *** Kerry Harvey, **** Multiple contributions, see [2].
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2.1 Animals for the family based association and parent of origin tests
All DNA samples used in this study were extracted from animals selected from herds maintained and
catalogued by Genus PLC. Detailed pedigree information was provided by Genus where available. The
diﬀerent lines are as follow: line B is a Landrace line, C is a Large White line, D is a cross between
Landrace and Duroc and H is a cross between Large White and Duroc. Line A and B are dam lines,
selected for their good maternal instincts and litter sizes. Line D and H are both sire lines, selected
for their meat quality traits. The incidence of infanticide events for these lines is 4.8% for line B, 5.9%
for line C, 10.8% for line D and 10.3% for line H. In total 1429 animals were typed in Cambridge,
309 for line B, 219 for line C, 423 for line D and 478 for line H, more information is available in table
3.1. Genus provided data for a further 208 animals for line B, 189 for line C and 150 for line H, more
details about the animals are available in table 3.2. The number of families available for the family
based association is 76 for line B, 50 for line C, 56 for line D, 96 for line H. Details about the animals
in those families is given in table 3.5.
2.2 Summary of bioinformatics tools used for the analysis
2.2.1 Genotyping
 PLINK [159] was used for the quality control of the genotyping data and running the parent of
origin analysis (see below)
 FBAT [50] was used to perform the family based association test
 GenomeStudio (Illumina proprietary software) was used to load the data generated from the
array and generate PLINK formatted output for the analysis
 Python scripts were used to merge the data provided by Genus to the data generated and already
available in Cambridge.
2.2.2 Sequencing data processing
 FastQC [160] was used to generate quality metrics from the sequencing run.
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 The R [161] software and more speciﬁcally the TEQC [162] and ggplot2 [163] packages were used
to generate graphs and quality metrics for the sequencing data and assess the eﬃciency of the
capture sets.
 BWA [144] was used to align the data to the reference genome obtained from Ensembl [152], the
version of the pig genome used was version 10.2 at the time of the work. BWA mem was used,
it is the most recent implementation of the BWA algorithm.
 Samtools [164] was used to manipulate the alignment ﬁles (bam) after the alignment in order
to sort the ﬁle by chromosomal order, generate index ﬁle for further processing or for general
investigation of any issues or queries related to them.
 PicardTools [165]was used for the speciﬁc preparation of the data for processing in the Genome
Analysis Tool Kit (GATK), this includes generating a dictionary for the reference ﬁle, marking
duplicates reads, adding annotation to the alignment ﬁles. It was also used to extract some
quality metrics from the aligned ﬁles.
 GATK [148] was used to perform the variant calling. Several steps are involved in the process
and are described in more detail in section 2.10. This tool is often used in conjunction with
PicardTools.
 Python scripts were used to compared the variant calling ﬁles from the diﬀerent pools.
2.2.3 Annotation of the comparisons
 NCBI e-utilities, speciﬁcally the Python API library, was used to retrieve the six hundred base
pairs of sequence around each pig variant identiﬁed by the comparisons (300 base pairs either
side of the SNP), see section 2.11 for more details on the comparisons.
 Blast [166]was used to increase the accuracy of the synteny mapping with the human using the
sequences retrieved. More details about this in section 2.11.3.
 Blastp [167] was used to compare the protein sequence of genes around amino acid substitution.
 The NCBI Python API was also used to parse the blast results and extract the positions of the
matches (of the blast) against the human
 R and the biomaRt [168, 169] module was used to retrieve annotations from the data, using the
SNP databases for human and pig, and updating data for the pig genome from SS 10.2 to SS 11.
 The Ensembl Perl compara API was also used to get syntenic regions: using the pig coordinates
to retrieve the corresponding syntenic blocks in the human.
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2.2.4 Data manipulation
 Python [170] scripts were used for data manipulation such as merging ﬁles, extracting data,
adding data and sorting ﬁles.
 The R package dplyr [171] was used to merge data in R, more speciﬁcally for merging genomic
intervals or tables with a large number of entries.
2.2.5 Genomic and pedigree plotting
 The R package Gviz [172] was used to plot genomic regions for the pig and human.
 The pedigree software used to draw the pedigree in order to select the animals is Madeline 2.0
[173]
 ggplot2 [174] was used to generate some of the QC plots
 TEQC [162] was used to generate plots for the sequencing capture QC
 QQman [175] was used to plot the Manhattan and QQ plots for the results of the FBAT study
2.3 Generation of the microarray data
This part of the work was performed by Claire Quilter and Kerry Harvey.
Each DNA sample was extracted and processed according to the manufacturer's instructions (Il-
lumina Inc, San Diego CA) for hybridisation on the microarray. The set of samples processed at
Cambridge were hybridised on the Porcine SNP60k version1 array by Illumina. The later set of data
generated at Cambridge was hybridised on the SNP60K version 2 by Illumina. This updated version
of the array contains a pool of common probes with the previous version of the array. It is possible to
combine both types by reducing the set analysed to the part common between both arrays.
The processing of both arrays versions followed a similar protocol: the extracted DNA is whole
genome ampliﬁed, then fragmented and hybridised overnight to the array. The hybridised product
goes through a one base extension for each probe to type the SNP of interest. Each SNP will be
represented by two diﬀerent probes on the array, one for each allele. Once the extension step is
completed the arrays are stained using two ﬂuorochromes, then scanned on the iScan Illumina scanner.
The scanned data are loaded into GenomeStudio for technical quality control. The data were then
exported and version 1 and version 2 data were merged together, resulting in a set of 1522 samples: of
these 54 were duplicate animals. In addition to this, the data provided by Genus added 547 animals
to the study for a total of 1976 animals. The Genus set was merged with the Cambridge set to provide
the data set used for the FBAT and PO tests.
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2.4 PLINK data format
The ﬁle format used for the PO and FBAT analysis, see section 2.6 and 2.7, is the PLINK format. The
PLINK format for the analysis consists in two ﬁles, the PED ﬁle and MAP ﬁle. The PED ﬁle consists
of the meta data columns followed by the SNP data. The meta data columns in the ﬁle are:
1. Family identiﬁer
2. Individual identiﬁer
3. Paternal identiﬁer
4. Maternal identiﬁer
5. Sex (1 = male, 2 = female, other = unknown)
6. Phenotype of interest
After the meta data columns, each genotype has two columns for each SNP, one for each allele present
in the individual.
The MAP ﬁle contains the coordinate of the SNP present in the PED ﬁle, the order of the rows in
the MAP ﬁle should match the order of the SNP in the PED ﬁle.
The MAP ﬁle columns for the SNP coordinates are:
1. Chromosome
2. SNP identiﬁer
3. Genetics distances (morgans)
4. Base-pair position (bp units)
For each of the lines studied (see section 2.1), a speciﬁc PED ﬁle was generated in order to test each
line apart from the other. The MAP ﬁle was common for all of the lines. Note that the FBAT software
need the MAP ﬁle to start with the SNP identiﬁer.
2.5 Data quality control
The quality control for the merged data sets was performed in PLINK [159], the arguments used were:
geno 0.05, hwe 0.0001, mind 0.1. The ﬁrst argument set the genotype missing rate, it is used to remove
any SNPs which were not called in 5% or more of the samples. The second is the threshold for the
Hardy Weinberg equilibrium test. It is used to test the distribution of the markers in the population
as it should follow the equation: p2 + 2pq+ q2 = 1 with p the frequency of the A allele, q the frequency
of the B allele for a AB genotype. Any marker deviating from this might be aﬀected by population
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stratiﬁcation or admixture and should be ﬁltered out. The third parameter is the missing rate for
individual samples. If a given sample has more than 10% of the SNPs not called it will be excluded
from the analysis. This QC was run for each line on the combined set of data set, combining the data
generated in Cambridge and provided by Genus PLC.
2.6 Parent of Origin analysis
The parent of origin analysis was performed in PLINK [159] using the ﬁltered data set as described
above, see section 2.3, using the following options in PLINK: poo, and tdt in order to use the trans-
mission disequilibrium test. The parent of origin analysis is similar to a normal transmission disequi-
librium test but considers the transmission from a heterozygous mother and father separately in order
to identify preferential transmission from one of the parents.
2.7 Family Based Association study
The family based association study was performed using the software FBAT based on the work in [50].
The input data is in the PLINK format, see section 2.4. Once the data loaded into the software, the
comparisons were performed using the 'fbat' command, setting the minimum number of informative
families to 10. The results were saved to a text ﬁle that was used for interpretation.
2.8 Selection of region of interest
The selection of the regions of interest and the design of the three sequence capture panels was done
by Claire Quilter based on the results from the previous study [2] and results from the work presented
here, the Family Based Association Test (see sections 2.7 and 3.1.5) and the Parent of Origin test (see
sections 2.6 and 3.1.6).
From the previous study [2], the top haplotype regions, with a −log10(pvalue) above 4, were se-
lected to design a capture set, called Capture 1. The regions selected are on chromosome 1 (65MB
and 74MB), chromosome 3 (26-27MB, 29-30MB, 36-37MB, 100MB and 131MB), chromosome 4 (1.9-
2.1MB, 5-5.2MB and 121MB), chromosome 6 (21MB), chromosome 10 (10MB), chromosome 12 (34MB,
62MB), chromosome 13 (22-23MB), chromosome 14 (24MB), chromosome 15 (17MB, 130MB, 137MB),
chromosome 18 (11MB and 18MB) . One of the regions for chromosome 3 was extended to included the
GP2/GPR139 region as it is a candidate region for puerperal psychosis. Figure 2.1 shows the number
of probes per chromosome, ﬁgure 2.2a and 2.2b the size of the probes across each chromosome. In total
the combined size of the targetted regions is 7,466,508 bases using Sus scrofa genome version 10.2 and
7,244,762 bases for Sus scrofa genome version 11.1 (via coordinates lift-over).
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Figure 2.1: Capture set 1: number of probes per chromosome. A probe is deﬁned as a sequencing
interval being captured by the panel
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(a) Overall boxplot, size in bp
(b) Zoomed boxplot, size in bp
Figure 2.2: Capture set 1: boxplots of the probes size per chromosome. 2.2a: overall boxplot, 2.2b:
zoomed, excluding probes bigger than 3000 base pairs.
The second capture set, Capture 2, was selected using the results from the family based association
test, it includes all the regions that returned a −log10(pvalue) above 4. It also includes regions that
were identiﬁed in a RNA sequencing pilot experiment [176] from on going work in the group. The
genes selected were the top 30 genes in the RNA sequencing comparison. The regions selected are on
chromosome 1 (13MB, 106MB, 121MB. 129MB, 135MB, 150MB, 191-192MB, 228MB, 244MB, 247MB
and 294-295MB), chromosome 2 (27MB, 36MB, 42MB, 82MB), chromosome 3 (22MB, 45MB, 75MB),
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chromosome 4 (4MB, 16MB, 83MB, 97MB, 113MB), chromosome 5 (3MB), chromosome 6 (21MB,
83MB, 90MB, 108MB, 112MB, 123MB, 157MB), chromosome 7 (3MB, 7MB, 9MB, 18MB, 23MB,
34MB, 59MB, 79-80MB, 89MB, 95MB, 106MB, 132MB), chromosome 8 ( 118-120MB), chromosome
9 (5MB, 9MB), chromosome 10 (16MB, 24MB, 43MB, 50MB), chromosome 11 (8MB, 21MB, 24MB),
chromosome 12 (10MB, 23MB, 54MB), chromosome 13 (11MB, 22MB, 45MB, 60MB, 149Mb, 190MB,
194MB, 202MB, 208MB, 213MB, 215MB), chromosome 14 (3MB, 15MB, 52MB, 66MB, 70MB, 126MB,
130MB, 134MB, 138MB, 150-151MB), chromosome 15 ( 11MB, 12MB, 22MB, 45MB, 132MB, 147MB),
chromosome 16 (21MB, 41MB, 44MB, 47MB, 53MB, 55MB, 85MB), chromosome 17 (37MB), chromo-
some 18 (14MB, 26MB, 41MB, 43MB, 50MB), chromosome X (113MB). Figure 2.3 show the number
of probes per chromosome; ﬁgure 2.4a and 2.4b the size of the probes across each chromosome. In
total the combined size of the targetted regions is 10,351,334 bases using Sus scrofa genome version
10.2 and 9,792,664 bases for Sus scrofa genome version 11.1 (via coordinates lift-over).
Figure 2.3: Capture set 2: number of probes per chromosome. A probe is deﬁned as a sequencing
interval being captured by the panel
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(a) Overall boxplot, size in bp.
(b) Zoomed boxplot size in bp
Figure 2.4: Boxplots of the probe size per chromosome for capture set 2, 2.4a: overall boxplot, 2.4b:
excluding probes bigger than 3000 base pairs.
The third and ﬁnal capture set, Capture 3, was designed from the results of the Parent of Origin
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(PO) results. The regions were selected by ﬁltering the results using a maternal chi square p-value
below 0.003, with the exception of 4 gene regions, 3 from chromosome 3 and one from chromosome
2. These region were over the selection threshold but not signiﬁcantly and contained gene of in-
terest. The regions captured are, chromosome 1 (29MB, 45MB, 65MB, 76MB, 92MB, 96MB, 102MB,
139MB, 181MB, 191MB, 193MB, 200MB, 250MB, 284MB), chromosome 2 (6MB, 12MB, 14MB, 27MB,
86MB, 112MB, 121MB, 125MB, 138MB), chromosome 3 (7MB, 14MB, 17-18MB, 19MB, 30MB, 31MB,
32MB, 45MB, 75MB, 106MB, 137MB), chromosome 4 (2MB, 10MB, 21MB, 33MB, 38MB, 77MB,
80MB, 83MB, 105MB, 119-120MB), chromosome 5 (1MB, 7MB, 66MB, 67MB, 99MB), chromosome
6 (14MB, 23MB, 38MB, 112MB, 157MB), chromosome 7 (63MB, 75MB, 95MB), chromosome 8 (15-
16MB, 89MB, 94MB, 117MB, 138MB), chromosome 9 (26MB, 33MB, 73MB, 102MB, 116MB, 120MB,
121MB, 128MB, 139-140MB, 149MB) chromosome 10 ( 36MB, 52MB, 55MB), chromosome 11 (22MB,
66MB), chromosome 12 (16MB, 41MB, 52MB), chromosome 13 (1MB, 7MB, 26MB, 38MB, 76MB,
77MB, 189-190MB, 202MB), chromosome 14 (17MB, 18MB, 34-35MB, 62MB, 79MB, 101MB, 113MB,
129MB), chromosome 15 (19MB, 46MB, 52MB, 143MB), chromosome 16 (32MB, 72MB, 74-75MB),
chromosome 17 (19MB, 23MB, 46MB, 53MB), chromosome 18 (1MB, 2MB, 8MB, 24MB, 49-50MB).
Figure 2.3 shows the number of probes per chromosome, ﬁgure 2.4a and 2.4b the size of the probes
across each chromosome. In total the combined size of the targetted regions is 13,347,528 bases using
Sus scrofa genome version 10.2 and 13,876,030 bases for Sus scrofa genome version 11.1 (via coordinates
lift-over).
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Figure 2.5: Capture set 3: number of probes per chromosome. A probe is deﬁned as an sequencing
interval being captured by the pane
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(a) Overall boxplot
(b) Zoomed boxplot
Figure 2.6: Boxplot of the probe size per chromosome for capture set 2, 2.6aoverall boxplot, 2.6b
boxplot removing probe longer than 3000 base pairs
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2.9 Sequencing of the regions of interest
2.9.1 Selection of the animals
Selection of the animals for sequencing was done using the pedigree information available. The animals
were segregated in individual families, the family tree was drawn using the software Madeline 2.0 [173].
In addition to having had at least one instance of infanticide, two diﬀerent criteria were applied to
select individuals:
1. Having an history of infanticide in the family. At least one of the female ancestors or descendants
of the selected animals need to have an incidence of infanticide.
2. Having several instances of infanticide. At least two episodes of infanticide are necessary to be
considered in this category.
For the ﬁrst criterion the animals were selected by generating pedigree trees for each of the families in
the study. An example of a relatively simple pedigree is shown in ﬁgure 2.7 while ﬁgure 2.8 shows a
more complex one. The rest of the pedigrees used are available in the supplementary ﬁgures.
In the example on ﬁgure 2.7, both selected animals have an history of aggression, they are cousins
and one of their dams (52832350) was also aggressive.
For the second criteria, we used the phenotypic information available to select animals which had
killed piglets in at least two litters.
Unfortunately not all the selected animals had enough DNA left to be used for sequence capture.
The number of animals available to build the pools for each line is summarized in table 2.1. For line
B and C the pools are as follow: pool one is composed of animals with an history of infanticide in their
family, pool two of animals that are serial oﬀenders and pools three and four are the controls. For line
D and H the animals with an history of infanticide were run in three diﬀerent pools. For line D pool
one, two and three were comprised of 24, 16 and 16 animals, pool four is for serial oﬀenders and ﬁve
and six the controls. For line H the ﬁrst 3 pools were also comprised of individuals with an history of
infanticide, pool one, two and three comprised 10, 13 and 9 individuals, pool four is the serial oﬀender
pool, and ﬁve and six the controls. The animals have to be divided into pools due to the technical
limits of the sequencer and in order to achieve suﬃcient coverage.
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Figure 2.7: Example of pedigree generated using Madeline 2.0. Family 700 for line B. The two selected
samples are denoted by a *. Each individual has three possible diﬀerent sources of pheno-
typic data, represented by a pie chart. A large version of the pie chart is displayed below
the pedigree for clarity. The Aﬀected number comes the ﬁrst data set phenotypic data
and is sometime incomplete, 0 is for non infanticide, 1 for infanticide. The aﬀected agg2
number follows the same convention and comes from the second set of annotations, that
was generally more complete. The Aﬀected_parity gives us the number of parities the
sow had, regardless of any infanticide event. The main diﬀerence between those phenotypic
data is that the information about the history of the samples typed was sometimes not
provided or accurate in the ﬁrst set of phenotypic data.
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Figure 2.8: Example of a more complex pedigree/family. For line H, this pedigree displays an example
of sharing of sires for this line.
Control pool 1 Control pool 2 Serial infanticide History of infanticide in the pedigree
Line B 25 25 6 4
Line C 25 25 4 12
Line D 22 22 14 46
Line H 25 25 4 32
Table 2.1: Animals pools
2.9.2 Library preparation and sequencing
The library preparation was done by Kerry Harvey and the sequencing done by the team of Cambridge
Genomic Services at the Department of Pathology.
The libraries were prepared according to the Agilent Sure Select protocol. Brieﬂy the DNA is sheared
and sequencing adapters are added to the DNA fragments, then the fragments are hybridised to DNA
baits which are biotinylated. The hybridised DNA is then puriﬁed using streptavidin coated magnetic
beads. Once the fragments are isolated the DNA baits are digested and the remaining DNA fragments
are ampliﬁed and ready to be sequenced. The libraries are sequenced using a paired end approach,
sequencing a 100 base pairs (bp) section from each end, resulting in two 100 bp reads per fragment.
Two raw sequence ﬁles are generated for each sample corresponding to read one and read two. For each
of the three capture sets, the pools were sequenced in two runs on the Illumina NextSeq® sequencer.
A total of 8 sequencing runs were performed. Once the sequencing was completed, the reads generated
were passed on for processing and variant calling.
2.10 Read processing and variant analysis using the Genome Analysis
Tool Kit (GATK)
Once the sequencing run completed, the read data were converted from the Illumina 'bcl' property
format to FastQ format using the bcl2fastq software (proprietary software from Illumina). The reads
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were processed via the pipeline described in ﬁgure 2.9. Starting with raw reads, the data were ﬁrst
put through the preprocessing and mapping step. This was followed by post processing to format the
data for variant calling in GATK [148]. The mapping was performed using the BWA mapping software
[144] and various checks were done on the data pre and post mapping. Post processing was done using
Picard tools [165] and GATK. Once the data were correctly formatted the variants could be called
using the Uniﬁed Genotype caller of the GATK suite. After calling, the variants were ﬁltered using
a set of ﬁlters in order to remove poor quality variants. The variant frequencies from the diﬀerent
pools were compared in order to identify markers that are behaving diﬀerently between infanticide and
normal pools of individuals.
Figure 2.9: Pipeline for sequencing data processing.
2.10.1 Read preprocessing and mapping
The read pre-processing consists of checking the quality of the reads prior to mapping. This is done
using FastQC, which generates various graphs and tables in order to assess the quality of the reads.
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A usual step to most sequencing data analysis is the trimming of the reads but for variant calling
this step is not beneﬁcial (see section 4.2.2 of the discussion), therefore it was skipped. After the raw
read quality control, the reads are mapped against the reference genome using the Burrows-Wheeler
Aligner (BWA) [144]. The reference genome used for this thesis was Sus scrofa 10.2, obtained from
the Ensembl website. The genome was download in FASTA format and indexed for use with BWA
(bwa index ). The BWA algorithm used for the mapping is bwa-mem. The output format after
mapping was Sequence Alignment Map, or SAM, format and was immediately converted to Binary
Alignment Map, or BAM, a compressed version of SAM, in order to save space. The SAM format is a
tab delimited ﬁle consisting of an optional header section and of an alignment section. Header lines are
deﬁned by a @ at the beginning of the line. The alignment lines consists of 11 mandatory columns:
1. QNAME: the query template name
2. FLAG: the bitwise ﬂag, deﬁning the mapping status of the segment
3. RNAME: the reference sequence name
4. POS: the 1 based leftmost mapping position
5. MAPQ: the mapping quality score
6. CIGAR: the CIGAR string, deﬁning the alignment status for each base in the segment
7. RNEXT: reference name of the mate read
8. PNEXT: Position of the mate read
9. TLEN: observed template length
10. SEQ: segment sequence
11. QUAL: Phred-scaled base quality score
Once mapping is completed, post mapping quality control steps are performed in order to determine
how well the sequence capture performed and how well the regions captured are covered. The R
package Target Enrichment Quality Control (TEQC) [162] was used to generate graphs to evaluate
the eﬃciency of the three capture sets and the quality of the sequencing coverage.
2.10.2 Post mapping processing
Once the mapping steps complete the mapped reads were processed in order to call variants with the
GATK suite. The ﬁrst step in this process is to sort and index the bam ﬁles for further processing,
this step is performed using samtools. The next step is to mark duplicated reads using PicardTools.
Marking duplicate reads is important in order to get a good estimate of allele frequencies for the
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variants. Duplicated reads are deﬁned as two pairs of reads that have the same start point for both
read one and read two. In other words; they represent the same fragment sequenced two times or more,
which will bias the variant calling and allele frequency estimation. The next step is to add read group
information. This step is required by GATK but is not essential. It consists on adding information
to the read ﬁles, to include the sample id, instrument used, library and pool. This step is critical for
consortium or large studies as the ﬁnal data set might come from several core labs. An important
step performed next is the read realignment. This step is performed in order to correct the alignment
of reads around indels and is essential when using the UniﬁedGenotype caller for variant calling. It
will identify intervals of the genome where indels are present (from a reference ﬁle) and realign those
regions with a local realignment algorithm that will correct any misalignments due to the presence of
indels in the read. This step was performed using IndelRealigner and the reference database used for
the indels was Sus scrofa dbSNP 145.
Once the reads have been realigned the next step is to perform the base quality score recalibration, or
BSQR, using BaseRecalibrator. This process is necessary because variant calling relies on the quality
scores attributed to the base by the sequencing instrument. However the instrument does not always
attribute the right scores to a base call due to the various sources of technical bias present in the
algorithms they use. This recalibration is important as the variant calling algorithm relies heavily
on the quality score to identify potential variants. BSQR uses an empirical approach and machine
learning in order to adjust the base quality score, which improves the quality of the variant called.
This is done in two steps: ﬁrst the model of covariation is built based on the data and known variants
if available, Sus scrofa dbSNP 145 was used as the reference, then the base quality scores are adjusted
according to the model generated.
Note that for all the post mapping processing and the variant calling, the parameter -L for the
GATK tool suite was used. This parameter takes as argument a bed ﬁle, a ﬁle containing the coordinate
of target regions in tab delimited format. For each capture set the ﬁle used for this argument is the
capture set bed ﬁle, which contains the coordinates of the probes used for the capture.
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Figure 2.10: Post mapping processing
2.10.3 Variant calling and ﬁltering
The ﬁnal steps of the GATK pipeline are to perform the variant calling, ﬁlter the variants and generate
lists. The variant calling was done with the UniﬁedGenotype caller, the reasons for this choice are
discussed in section 4.3.2.1. This algorithm calls the variant for each sample and can use a reference ﬁle
to help guide the variant calling. For this thesis the variant reference was the pig SNP database 145.
The ploidy of each of the pools was provided and the additional options used were: stand_call_conf
of 50.0 and stand_emit_conf of 10. The ﬁrst parameter is the minimum phred-scaller conﬁdence
threshold for the variant calling which will ﬂag any SNP below that phred score as ﬁltered. Any
variant with a phred score lower than stand_emit_conf of 10 will not be considered and is excluded
from the output.
After the variants are called the next step is to remove low quality and potential false positives from
the set. The ﬁltering was done using the VariantFiltration command and the following parameters:
 QD below 2; Quality by Depth, which is the variant conﬁdence score divided by the unﬁltered
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depth of the non homozygote reference samples, using variant matching the alternate allele. It is
used to normalised the variant quality in order to avoid bias due to deep coverage. Any variant
with a score below 2 is deemed to have a score too low compared to the depth of coverage based
on empirical evidence.
 FS above 60. FS represents the Fisher Strand which is used to asses the potential strand bias in
the variant. FS represent the phred-scaled probability of having strand bias at the variant locus,
that is the probability of observing a variant more or less often on the forward or reverse strand.
A locus with no strand bias will have a FS value close to 0. However most loci tend to have some
strand bias and based on empirical evidence the default value is set at 60.
 MQ below 40; MQ is the root mean square of the mapping quality over all the reads at the
given variant position. Instead of being a simple mean measurement, it includes the standard
deviation, which is useful to asses the level of variability within the reads for that locus. Low
standard deviation means that most of the data are close to the mean of the phred scaled quality
score. The typical value for MQ is around 60: the ﬁlter is therefore set at rejecting any variant
below 40.
 MQRankSum below -12.5; MQRankSum is the mapping quality rank sum test for mapping
quality. It compares the mapping quality of the reads supporting the reference allele against
the read supporting the alternate allele. A positive value shows that the reads supporting the
alternate allele have higher quality than the ones supporting the reference allele. A negative
value is the opposite, higher quality for the reference allele reads. If the quality scores for the
reads supporting both alleles are identical the value will be 0. The default value recommended
by the Broad Institute based on empirical observation is -12.5.
 ReadPosRankSum below -8.0; the read position rank sum compares the position in the reads of
the reference against the position of the variant allele. This measurement is meant to check for
a bias of the variant calling due to position of the alternate base in the reads. If a variant is
identiﬁed by bases mainly located towards the end of the reads, there are more chances that it is
due to sequencing errors as the quality of sequencing deteriorate. This deterioration of sequence
quality means that bases called at the end of the read are of lower quality than bases called at
the beginning of the read. If the value is negative it means that the alternate allele is found
more often at the end of the read compared to the reference allele. The recommended default
threshold by the Broad Institute is -8.
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2.11 Variant comparison and annotation
After the variants are called and ﬁltered the next step is to compare their frequency between the
aggressive and non aggressive pools. Once a list of potential targets has been identiﬁed the variants
are annotated using the most reliable source of information.
2.11.1 Comparing variants between pools
For each line and each capture the variants were compared after ﬁltering using the following approach:
First the variant data were split into three categories:
1. Category A compared both the serial aggressors and the individuals with a family history of
infanticide against the two control pools
2. Category B compared the serial aggressors against the two control pools
3. Category C compared the individuals with a family history of aggression against the two control
pools
The ﬁltered variant call ﬁles were ﬁrst merged for the diﬀerent pools into a unique ﬁle, and then the
average frequency of each variant computed. To ensure that the means are not misrepresenting the
data, a threshold of a maximum diﬀerence of 30% between the allele of pools of the same phenotypic
origin was set. This threshold was chosen based on the observation of the distribution of the diﬀerences
in allele frequencies between the pool, see section 2.11.4 of the results and 4.3.3 of the discussion. The
ﬁrst set of analysis was done using a hard threshold with the diﬀerences between the average of the
pool allele frequencies for the diﬀerent phenotype set to be at least 30% for category A and 50% for
Category B and C. These thresholds were chosen empirically, using the number of variants passing
ﬁlter as a guide to ﬁnd a middle ground in the number of variant selected.
Using the hard threshold selected a number of variants but another method to deﬁne the threshold
was devised, using the distribution of the diﬀerence in allele frequencies for all the variants for each of
the comparisons. First the set of variants were compared to generate the diﬀerence in allele frequency,
using the threshold of 30% as a cut-oﬀ for the maximum diﬀerence in allele frequency between pools
belonging to the same category. This threshold was chosen based on the variability present between
control pools, the majority of variants having a diﬀerence in frequency below 30% between the two
control sets (see Figure 3.37 in section 3.3.2). They also needed to pass the variant call ﬁltering in
at least one of the pools to be selected as a candidate. No thresholds were set for diﬀerence between
the control and infanticide pool. Instead, once generated for each category, for each line and for each
capture set, the ﬁles were merged per capture set and category, giving a total of nine ﬁles, three per
capture set, one per category and per capture set. The mean and standard deviation statistics of the
distribution of the allele frequency diﬀerence for all variants were calculated for each ﬁle. A threshold
70
2 Material and Methods
based on the speciﬁc distribution of the allele frequency diﬀerences was chosen: mean plus three
standard deviations. This should select the variants showing the highest diﬀerence in allele frequencies
based on the overall allele distribution for each capture set and each category (capture 1 category A,
capture 1 category B...). For more details about the choice of these thresholds, see the discussion in
section 4.3.3 . Any variant that passed these criteria was classiﬁed as a candidate variant.
2.11.2 Annotation and functional analysis of the variant
This method was devised to analyse the variants using the 10.2 version of the pig genome.
Once the candidate variants were categorised, the next step was to annotate them in order to ﬁnd any
functional impact they could have. Due to the state of the annotation of the pig genome, comparisons
with the human genome were performed in order to get a better understanding of their potential
impact. The pipeline for the annotation of the variants was as follow:
1. Using the location of the pig variant, the DNA sequence around the variant was retrieved. The
300bp upstream and downstream of the variant location were taken, which produced a 600bp
interval
2. The sequences were aligned against the human genome using BLAST [166] in order to identify
the matching region in the human. The following parameters were used, changed from default
in order to improve the search, looking for less similar sequence (between species):
a) Match/Mismatch sequence scoring changed from 2/-3 to 1/-1. Therefore a match scored
one instead of two and a mismatch is a penalty of minus one instead of minus three, making
match less important and being more lenient with mismatches.
b) Gap cost is changed: existence from 5 to 2 and extension from 2 to 1. This makes opening
a gap and extending it is less costly.
c) Searching for somewhat similar sequences (blastn), as pig sequences are compared to
human sequences.
d) Database used is 'Human Genomic plus Transcripts (G+T)'
3. Results were parsed to ﬁlter out weak matches, ﬁltering criteria were:
a) match length of 100bp between the query (pig SNP sequence) and the subject (human
genomic sequence)
b) expected value below 0.01, meaning we expect less that 1% chance of encountering a match
against this database per chance.
4. Biopython was then used to annotate the parsed blast results to determine if the sequence
matched in the human is in a gene, and if so, if it matches exonic or intronic sequences. The
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BLAST matches were separated in 3 ﬁles:
a) Exonic sequences
b) Intronic sequences
c) Not in a gene
5. For the exonic sequence, using the human coordinates and the R package biomaRt [168], the
ENSEMBL biomart database of genes (human and pig) and SNPs (human) were used to annotate
the data with:
a) pig gene using the pig SNP position
b) human syntenic gene using the pig SNP position
c) Human SNP(s) at a position +/- 10 base pairs of the position of pig SNP in the BLAST
alignment against the human.
d) Any functional consequences linked to the human SNP(s).
6. For the intronic variants and those not in genes, biomaRt was also used but this time we looked
for regulatory features using the regulatory features database to get the type of feature present
(if any) and identify any genes linked to the feature. The procedure was the following:
a) annotate the data using biomaRt to get the regulatory feature ID linked to the human
region in synteny with the pig genome
b) get all the genes linked to that regulatory feature using GeneCard (www.genecards.org
[177, 178])
c) Using DAVID (https://david.ncifcrf.gov/ [179]), the genes linked to the feature are curated
for any interesting traits or functions.
2.11.3 Updating coordinates to Sus scrofa genome release 11
During the later part of this work a new assembly of the Sus scrofa genome (SS 11) was released (see
discussion 4.2.5). The genomic positions of variants and capture set probes needed to be updated to
the new build coordinates. It is important to check each candidate variant genomic position against
the new build in order to look at potential new consequences for the region around it. The capture
probe coordinates were checked to make sure the target region was still the same as its original design.
A pipeline was designed to process the capture set data and the candidate variant using the biomaRt
package [169, 168], the Ensembl compara PERL API [152] and various python scripts to handle the
data. The Ensembl compara API was used to retrieve the human genomic coordinates from the pig
genomic coordinate, allowing pig genomic coordinates to be mapped to human ones.
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This pipeline was applied to the ﬁrst set of variant selected, using hard thresholds. Given the
relatively small number of variants selected using this data, it was necessary to try to annotate most
of them. For the variants selected using the threshold based on the distribution of allele frequency
diﬀerences, a simpler version of this pipeline was used (see next section 2.11.4).
The pipeline to update the candidate variant positions is as follows, in total 9 tables were put through
the pipeline, 3 for each capture set corresponding to each category (A, B or C):
1. The variants were processed using biomaRt to update their coordinates to SS 11 and ﬁnd any
human homologues:
a) The RefSNP or RS id was queried against biomart to get the updated position in SS 11 if
it is available
b) If no position was returned to the genomic coordinates of the variant are used to query for
an updated RS id and the coordinate in SS 11
c) If there was still no match the variant is ﬂagged for follow up with another method (see
below)
d) If new coordinates were found, they were used to query for any human homologous gene at
the SS 11 position.
2. Variants that did not update to SS 11 were submitted to the NCBI remap tool [180] in order to
update the coordinates
a) When several possible locations were obtained, the most likely location was curated manu-
ally by looking at the chromosome it mapped to, how similar in size was the mapped interval
to the size of the region targetted
b) Once a multiple locations entry had been resolved, the ﬂagged candidate variant followed
the same step as the other variants.
3. Using the pig variant coordinates the Ensembl compara perl API was used to get the correspond-
ing human syntenic blocks. Any variant that did not return any human coordinates still went
through the next steps but was run separately from variants with human coordinates.
4. For candidate variants updated with the compara API, the synteny coordinates were used to
query biomart using biomaRt to get any human gene mapping to that location
5. The SSC11 coordinates were used to get any pig genes mapping to that location.
6. The R package dplyr was used to merge the variants that had to be updated separately with the
other variants, creating an updated version of the input ﬁle.
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The pipeline to update the capture coordinates was very similar to what had been done to the candidate
variants. However there were some notable diﬀerences because the data were genomic intervals rather
than a single genomic location.
1. The ﬁles provided by Agilent gave coordinates for the probes covering a targetted region. Using
R dplyr the coordinates were grouped according to the region targetted, taking the minimum
and maximum coordinates of the probes for that region.
2. Contrary to the variant data, the capture region could not be updated eﬃciently using biomart,
so the NCBI remap tool was used to update the coordinate to SSC11:
a) When several possible locations were obtained, the most likely location was curated manu-
ally. This was done by looking at the chromosome it mapped to, and how close was the
mapped interval in relation to the size of the region targetted.
b) Once multiple locations entry had been resolved, the capture regions followed the same steps
as the rest of the capture regions.
3. Using the updated region coordinates, the Ensembl compara perl API was used to get the cor-
responding human syntenic blocks. Any region that did not return any human coordinates will
still go through the next steps
4. Given the size of the target regions, the API returned multiple blocks for each region submitted:
a) The data were ﬁrst sorted by genomic location and a cluster id was added to each line. If
the chromosomes were the same as the previous line and the diﬀerence between the end of
the previous block and the current one is less than 10000 bases, they were attributed the
same cluster id, otherwise a new id was generated.
b) The lines with the same cluster id were merged using dplyr and taking the minimum and
maximum coordinates for each entry with the same cluster id.
5. For candidate regions updated with the compara API, the synteny coordinates were used to
query biomart using biomaRt to get any human genes mapping to that location
6. For regions that have been updated to SSC11, the updated coordinates were use to get any pig
genes mapping to that location.
7. To check if the coordinates had changed dramatically the Gviz package was used to generate a
genomic region plot of:
a) The targeted region on SSC10.2 (original capture coordinates)
b) The targeted region on SSC11 (updated coordinates)
c) The targeted region corresponding to the syntenic region on the human genome.
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8. Comment is added to the ﬁle once the region has been checked against the genomic region plot
Finally the variant data was checked against the updated capture set to check if any candidate variants
were no longer within the targetted region.
2.11.4 Curation of SNPs and regions of interest
After the design of a new ﬁltering method (see section 2.11.1), a shorter version of the pipeline above
was used to simply update the SNPs to SSC11 using biomaRt and at the same time get the SIFT
prediction for the impact of the SNPs [181]. SIFT is an algorithm designed to identify potential
deleterious change in the amino acid (AA) chain of the protein, caused by a SNP allele. The individual
SNPs selected were SNP classed as missense SNP, causing a potential change in AA at this location.
SIFT can predict if the eﬀect might be deleterious but the prediction has a level of uncertainty. As
only a few SNPs were selected as missense, a more in depth analysis was required. In order to check if
there is a potential eﬀect on the protein structure and function, the following pipeline was applied to
candidate SNP.
1. SNP was queried using the Ensembl website
2. The alignment against other species (phylogenetic context) was used to check the consensus
sequences for the same gene for other species. The phylogenetic context displayed the alignment
of the SNP and the region around it against other species.
3. If the gene was unknown, the region comparison tool was used with the Human and Mouse
genomes in order to see if a known gene is present at the corresponding location in these genomes
4. To better estimate the impact of the of the amino acid change, the protein sequence around the
target amino acid was blasted against the protein database using the NCBI website, using the
default setting for blasting protein against protein.
5. The blast results were used to assess if the region of the protein is highly conserved or not.
6. The impact of the amino acid change was also evaluated by looking at their properties, notably
their charge, polarity and hydrophobic or hydrophilic nature.
For the regions where a large number of SNPs were identiﬁed, the following pipeline was used:
1. The regions and SNPs were plotted using the version 11 of the genome in order to identify genes
in their vicinity.
2. If no genes are presents, the region was queried in Ensembl for region comparisons with the
Human and the mouse.
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3. Any gene covered by the SNPs were queried in GeneCards [177] to look for any interesting
disorder or function,
4. The gene was also queried in the NCBI gene database, for both human and mouse to learn more
about their function
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3.1 Genotyping microarray results
3.1.1 Summary of the data available
Two sets of data were available for this study, one was generated in Cambridge and the other one
provided by Genus PLC. Tables 3.1 and 3.2 show the data available for each set. The sets were merged
to form one unique dataset that was then ﬁltered in order to perform the FBAT and PO tests.
Lines Control samples (females) Infanticide samples No status (female) Male samples Female samples Total
Line B 178 122 1 8 301 309
Line C 110 101 1 7 212 219
Line D 210 159 3 51 372 423
Line H 282 189 1 6 472 478
Table 3.1: Samples typed in Cambridge for the four lines, not status females are female with no entry
for the infanticide status.
Lines Control samples (females) Infanticide samples No status (female) Male samples Female samples Total
Line B 104 17 3 84 124 208
Line C 72 20 1 96 93 189
Line D - - - - - -
Line H 0 0 0 150 0 150
Table 3.2: Sample typed by Genus for the four lines, no status females are female with no entry for
the infanticide status.
3.1.2 Quality control
Using the pedigree information the data were ﬁltered to leave only the families with at least two
individuals, one of which must be an infanticide sow. The QC was then run on the data using the
parameters described in section 2.5 using PLINK. The summary of this QC is given in table 3.3.
Another QC step performed was to look at the Minor Allele Frequency (MAF). Table 3.4 summarises
the low MAF SNPs in the dataset, displaying the percentage of 0% MAF (homozygous SNP) and below
5% MAF (low frequency variant), up to a quarter of the SNP typed have low MAF (below 5%), making
them low frequency variants for these lines. After QC the data were loaded in FBAT and PLINK for
the PO analysis. FBAT returned some errors after the heritability checks within each family. Some
families had to be removed from the analysis as the number of errors proved too important, suggesting
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that the individual in these family might not be related. This can be caused by cross fostering, when a
piglet has moved to another dam before it could be recorded properly. Between 2 and 4 families were
removed from each line, the details of the families analysed in FBAT are given in table 3.5.
Lines Markers Samples Call rate HWE ﬁlter
Genotype Missing individual
Passed QC markers
missing (95%) ﬁlter (90%)
Line B 61062 206 96.80% 22 4473 0 56567
Line C 61062 158 95.71% 31 4251 0 56780
Line D 61062 188 95.83% 28 3915 0 57119
Line H 61062 297 95.80% 36 4342 3 56684
Table 3.3: Markers information for Family Based Association and Parent of Origin: HWE ﬁlters stands
for Hardy Weinberg ﬁlter which tests for the Hardy Weinberg equilibrium, The genotype
missing is the threshold for removing markers for which not all the individuals have a call
(5% of individual missing), the missing individual ﬁlter is to remove individuals for which
the overall call rate is below the threshold (10% or more missing).
Line Total Markers 0% MAF Below 5% MAF Percentage 0% Percentage 5%
B 56567 6325 14743 11.18 26.06
C 56780 9375 14628 16.51 25.76
D 57119 6779 12329 11.87 21.58
H 56684 6825 13085 12.04 23.08
Table 3.4: Table summarising low Minor Allele Frequency (MAF, the lowest allele frequency from each
SNP), number of SNPs with 0% MAF (homozygous SNPs) and less the 5% MAF.
Lines Total samples Families
Families with at least Families Infanticide Control
Males
Females with no
3 members removed females females phenotypic status
Line B 206 76 45 4 83 76 47 0
Line C 158 50 32 2 73 44 40 1
Line D 188 56 33 3 85 62 41 0
Line H 294 97 63 3 122 104 68 0
Table 3.5: Samples for family based association. Total number of samples represents the number of
samples belonging to a family. Families represent the total number of families in the set.
Families with at least 3 members represent families when more individuals have been typed
than the minimum of 2 (one parents can be missing). Family removed: the number of family
excluded due to heritability errors. Infanticide/Control female, the number of Infanticide
and Control females present in the families tested. Male: number of sires present in the set.
Females with no phenotypic status: females for which the aggressive status was unknown.
The QC of the genotyping data is good (see table 3.3) as the average sample call rate is above 95%
and only a few samples failed to meet our ﬁltering threshold of 95% call rate. Between 3% and 8%
of the samples were ﬁltered out at this stage. The Hardy-Weinberg test removed a small proportion
of the markers (less than one percent for all the samples). However the missing genotypes ﬁltering
removed around 7% of the markers for each line as they were typed in less than 5% of the samples.
This ﬁgure is consistent across the diﬀerent lines studied, therefore it is unlikely to be line speciﬁc, it
is more likely to reﬂect the quality of the markers present on the array. There is a strong possibility
that the markers removed did not get typed successfully because the design was based on a less reﬁned
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version of the genome. Therefore the target sequences might not be accurate, resulting in systemic
failure when typing these markers. After ﬁltering we were left with more than 92% of the markers for
the analysis.
For the FBAT and PO analysis the individual maximum percentage of missing SNP was set to 10%:
i.e, any individual with more than 10% of the SNP calls missing was excluded. This threshold was
chosen in order to not be too stringent, and retain some individuals with some SNP missing. The aim
was to have the highest possible number of individuals per families for analysis. Furthermore because
of the nature of the genome used to design the array (Sus scrofa 7) and the breeds selected for its
design; there is a chance that some of our lines will not match the reference breed. In our analyses we
have a mixture of pig breeds and lines (Duroc, Large White and Landrace), which could cause some
mismatch with the array. Only line H has lost individuals due to this ﬁlter (table 3.3). The failure of
these 3 samples is most likely due to the DNA sample quality.
Using biomart it is possible to check how many markers are still valid with the latest build of the
genome (table 3.6). For each line more than 87% of the SNPs are still found using Sus scrofa genome
build 11 (SS 11). Some of the SNP missing from the cross-referencing might because the SNP identiﬁer
has changed and is not being recognised as valid. Some SNPs might also have been invalidated. In
any case, around 50,000 SNPs are left to test in this data set for each of our lines.
Input SNP Valid in Biomart Percentage total
All array 61565 53855 87.5%
Line B 56567 49609 87.7%
Line C 56780 49789 87.7%
Line D 57119 50086 87.7%
Line H 56780 49789 87.7%
Table 3.6: SNP left after QC, used as a Biomart query and still present using version 11 of the pig
genome.
3.1.3 Pig array 60k from Illumina
For this study the genotyping data comes from 2 sources: the porcine 60k version 1 array from Illumina
(Genus PLC data and ﬁrst run of data from Cambridge) and the version 2 of the porcine 60k from
Illumina (second run of Cambridge data). The data from both sets were merged using the common
SNPs between the two arrays in order to generate the data set used for both set of analysis. The SNPs
remaining were therefore mostly those designed for version 1 of the array. The 60k version 1 array was
constructed in 2009 and the state of the pig genome at this point (version 7) was very fragmented.
While the design of the array described in [98] used the best technology available at the time, there are
several potential problems with the approaches taken, due to the limitations of the technology available
at the time. The reads used for the design were generated from ﬁve diﬀerent pools of animals, using
very short sequencing length (36bp) and low quality thresholds to identify polymorphic sites . Reads
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with a quality score above 10 were considered good enough to be used, whereas nowadays a minimum
quality score of 20 is recommended. Furthermore, the reference genome used for the alignments was
only sequenced at an average depth of 4 reads per bases, there is no mention of the depth of coverage
used for the selection of SNPs. Despite these drawbacks, the candidate SNPs were curated and passed
through several rounds of selection, which should improve their quality. Some issues are still left after
selection and visible when looking at the minor allele frequency (MAF) of the SNPs on the array for the
diﬀerent lines. As shown on table 3.4, there are between 11 and 16% of the SNPs that are homozygous
on the array. Furthermore, around a quarter of the SNPs have a MAF below 5%. This means the
minor allele frequency is very low for these SNPs in the lines studied, raising questions about their
usefulness to represent LD blocks. This will likely lower the numbers of LD blocks analysed with this
array for this thesis. It is expected that large gaps between SNPs will be present and some regions
of the genome will not be well covered. This can result in some of the LD blocks not being typed
properly, or missed entirely, although one mitigating factor is that in some of the breeds studied the
LD blocks appeared to be conserved over large intervals [182].
While the array has many potential drawbacks, it was still at the time of this study the best method
to perform a large scale investigation of the genetic causes of maternal infanticide. There was no
alternative other than typing each SNP individually, a much more expensive option.
3.1.4 FBAT and PO test and signiﬁcance thresholds.
Both tests were chosen due to the addition of data provided by Genus PLC. This additional data
completed families and pedigrees already available in the previous dataset from Quilter et al [2]. The
FBAT test is more appropriate for our dataset than a traditional association test as our data is
composed partially of families. The approach using unrelated individuals for a association test was
already done in Quilter et al [2]. Using another approach to query the data is a good way of conﬁrming
some of the results already found. Given that we had a good number of families, using tests designed
for this type of data was a logical step. Using the relationships present, it was expected that we would
have more power for the analysis. Another approach that we wanted to test on this type of data is
the preferential transmission of allele from mother to daughter. It was shown that this might be a
factor in the heritability of the infanticide trait [3]. In order to investigate this we used the PO test
and concentrated on the dam to daughter preferential transmission of alleles.
The number of families and samples selected for the FBAT and PO analysis are given in table 3.5 of
section 3.1.2. The number of families available for each line is between 50 and 97: two lines (line C and
D) have around 50 families while line B has 76 and line H has 96. When performing the test, FBAT
returns the number of families for which the association in the presence of linkage is found. For the
PO test, the ratio of transmitted allele (transmitted over un-transmitted allele) is also given. This can
be used to assess the likelihood of the results being of interest, if a large number of families supports
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the evidence for association, or, if the ratio of the transmitted over the un-transmitted allele is either
large or very small.
The aim of both of these tests is to identify or conﬁrm regions of the genome linked to maternal
infanticide, in order to use sequence capture to investigate these regions in more details and narrow
down variants. The variants identiﬁed will be used to reﬁne genes or regions of interest that might
play a key role in the maternal infanticide phenotype. There are several reasons why it would be
detrimental to be too stringent when ﬁltering the results of the FBAT and PO tests. To begin with,
the phenotype of interest exerts little selection pressure on the animals aﬀected, these animals come
from lines generated for their high breeding values and quality traits (e.g. meat and reproductive
trait). Such high value animals are unlikely to be culled unless they are extreme cases. Furthermore it
is also known from previous studies [2, 17, 80, 14], that several regions of the genome are aﬀected and
multiple variants in the genome might be linked to this phenotype. It is unlikely that the penetrance
of any of these variants or regions linked to this phenotype will be high, our trait of interest appears to
ﬁt the classic, multiple components phenotype. Therefore being too stringent while ﬁltering the results
could remove regions of interest. The FBAT and PO tests are therefore used primarily as a screening
tool.
The threshold chosen for the FBAT analysis is −log10(pvalue) > 4 which corresponds to a p-value of
1.10−4. There is no permutation or adjustment p-value available for the FBAT test unless the pedigree
approach is used. This threshold >4 is below the genome wide signiﬁcance level usually used in GWAS
and genome wide studies, which is 5.10−8or a −log10(p− value) > 7.3. For the PO test the threshold
was set at 0.03, which will result in a ratio of untransmitted over transmitted or transmitted over
untransmitted of at least 3/1. This will again identiﬁes a variety of regions that were targetted for the
sequence capture.
3.1.5 Family Based Association
The Family Based Association Test (FBAT) was used in order to test for association in the presence of
linkage using families present in the data set. Using the family structure present in the dataset made it
a diﬀerent and complementary approach from the previous study which looked at non related samples.
The results of the family based association study are as follow:
 For line B, 15 SNPs reached a signiﬁcance of 10−5(−log10(p − value) > 5), on 9 diﬀerent chro-
mosomes: chromosome 1, 2, 3, 5, 7, 10, 14, 15 and 17, see table 3.7.
 For line C, 8 SNPs reached a signiﬁcance of 10−5(−log10(p− value) > 5), on 5 diﬀerent chromo-
somes: chromosome 2, 7, 10, 15 and 18, see table 3.8.
 For line D, 29 SNPs reached a signiﬁcance of 10−5(−log10(p − value) > 5), on 12 diﬀerent
chromosomes: chromosomes 1, 2, 3, 5, 6, 7, 8, 9, 10, 14, 15, 17, see table 3.9.
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 For line H, 41 SNPs reached a signiﬁcance of 10−5(−log10(p − value) > 5), on 14 diﬀerent
chromosomes, chromosome 1, 2, 3, 4, 6, 7, 8, 9, 10, 13, 14, 15, 16, 18, see table 3.10.
Figures 3.1, 3.3, 3.5 and 3.7 shows the Manhattan plots for each of the lines (B, C, D and H). Figures
3.2, 3.4, 3.6 and 3.8 are the QQ plot for the FBAT p-value for each line. Table 3.11 displays the lambda
value for the QQ plot for the FBAT results. The lamda values are relatively close to one expected for
line H, for which some stratiﬁcation might be present as the value is above 1.1.
Marker RS Identity Chromosome
Position Number of s
p-value −log10(p− value)SS 11 informative families
ASGA0005756 rs80837832 1 219,114,187 43 5.60E-11 10.25
ALGA0102837 rs81329722 2 39,427,398 43 5.60E-11 10.25
MARC0009481 rs81257081 3 72,010,079 26 2.60E-06 5.59
M1GA0007286 rs81383309 5 5,672,567 41 1.55E-10 9.8
MARC0055096 rs80880714 7 9,057,028 36 2.02E-09 8.69
ALGA0039425 rs80873322 7 21,554,498 20 4.22E-06 5.37
BGIS0000098 - 7 NA 37 5.35E-09 8.27
ALGA0118632 rs81325586 10 14,208,472 25 5.73E-07 6.24
H3GA0033419 rs81439383 12 9,767,814 31 9.55E-06 5.01
ASGA0066525 rs80813041 14 123,010,045 36 2.02E-09 8.69
ALGA0085872 rs81453527 15 75,057,741 42 1.49E-10 9.83
ALGA0086085 rs80921770 15 79,583,768 37 1.21E-09 8.92
H3GA0044934 rs80926252 15 119,410,395 36 2.02E-09 8.69
MARC0083113 rs81266760 18 37,977,138 42 9.32E-11 10.03
ASGA0089892 rs81308090 18 39,430,154 43 5.60E-11 10.25
Table 3.7: FBAT line B results table. The Marker column show the Pig consortium ID used by Illumina
in their annotation ﬁle. The RS identity is the dbsnp id for the marker. Chromosome and
position SS11 give the pig chromosome and the position after remapping the position in
Sus Scrofa 10.2 to Sus Scrofa 11. The number of informative families shows the number of
families that contributed to the test for that marker. Finally the last two columns show the
p-value and −log10(p− value) for the FBAT test.
Marker RS Identity Chromosome
Position Number of
p-value −log10(p− value)SS 11 informative families
ALGA0102837 rs81329722 2 39,427,398 36 5.59E-11 10.25
H3GA0022731 rs80910844 7 100,110,224 30 2.43E-08 7.61
ALGA0118632 rs81325586 10 14,208,472 30 1.21E-09 8.91
ALGA0100690 rs81477669 10 45,783,989 27 6.03E-06 5.21
H3GA0044934 rs80926252 15 119,410,395 36 5.59E-11 10.25
MARC0083113 rs81266760 18 37,977,138 36 5.59E-11 10.25
ASGA0089892 rs81308090 18 39,430,154 36 5.59E-11 10.25
BGIS0000098 - 7 30 9.76E − 6 5
Table 3.8: FBAT line C results table. The Marker column show the Pig consortium ID used by Illumina
in their annotation ﬁle. The RS identity is the dbsnp id for the marker. Chromosome and
position SS11 give the pig chromosome and the position after remapping the position in
Sus Scrofa 10.2 to Sus Scrofa 11. The number of informative families shows the number of
families that contributed to the test for that marker. Finally the last two columns show the
p-value and −log10(p− value) for the FBAT test.
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Marker RS Identity Chromosome
Position Number of
p-value −log10(p− value)SS 11 informative families
ASGA0001011 rs80870251 1 10,968,552 27 5.73E-07 6.24
ASGA0004231 rs80794948 1 110,239,011 15 2.73E-06 5.56
ALGA0005867 rs80914010 1 125,222,441 34 2.05E-12 11.69
ALGA0114601 rs81343604 1 NA 16 7.10E-06 5.15
ASGA0005756 rs80837832 1 219,114,187 40 3.35E-11 10.47
DRGA0002016 rs80904152 1 223,861,733 22 1.50E-06 5.82
INRA0007489 rs319558321 1 262,121,588 19 1.50E-06 5.82
H3GA0006383 rs81356441 2 25,215,306 31 1.77E-09 8.75
ALGA0102837 rs81329722 2 39,427,398 40 3.35E-11 10.47
ALGA0018634 rs80784123 3 44,000,093 29 2.93E-09 8.53
M1GA0007286 rs81383309 5 5,672,567 40 3.35E-11 10.47
MARC0009578 rs81258152 6 120,053,311 16 4.22E-06 5.37
H3GA0018823 rs81391651 6 133,185,154 19 5.74E-06 5.24
H3GA0022731 rs80910844 7 100,110,224 34 2.96E-07 6.53
MARC0032237 rs80785162 8 111,171,988 26 2.28E-09 8.64
ALGA0054131 rs81414030 9 86,593,109 13 7.74E-06 5.11
ALGA0118632 rs81325586 10 14,208,472 40 3.35E-11 10.47
ALGA0100690 rs81477669 10 45,783,989 36 2.26E-12 11.65
MARC0016782 rs80799328 14 14,414,380 24 9.63E-07 6.02
ASGA0066525 rs80813041 14 123,010,045 40 3.35E-11 10.47
MARC0101508 rs81278062 15 10,585,538 25 1.14E-07 6.94
ALGA0085872 rs81453527 15 75,057,741 35 2.38E-06 5.62
ALGA0086085 rs80921770 15 79,583,768 40 3.35E-11 10.47
H3GA0044934 rs80926252 15 119,410,395 40 3.35E-11 10.47
MARC0039970 rs81233198 18 25,273,873 15 1.60E-06 5.79
MARC0083113 rs81266760 18 37,977,138 40 3.35E-11 10.47
ASGA0089892 rs81308090 18 39,430,154 40 3.35E-11 10.47
M1GA0023271 rs81470243 18 45,399,121 18 2.52E-06 5.6
H3GA0047065 rs81461972 - NA 35 7.55E-13 12.12
Table 3.9: FBAT line D results table. The Marker column show the Pig consortium ID used by Illumina
in their annotation ﬁle. The RS identity is the dbsnp id for the marker. Chromosome and
position SS11 give the pig chromosome and the position after remapping the position in
Sus Scrofa 10.2 to Sus Scrofa 11. The number of informative families shows the number of
families that contributed to the test for that marker. Finally the last two columns show the
p-value and −log10(p− value) for the FBAT test.
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Marker RS Identity Chromosome
Position Number of
p-value −log10(p− value)SS 11 informative families
ASGA0001011 rs80870251 1 10968552 24 4.46E-07 6.35
ALGA0005867 rs80914010 1 125222441 52 7.52E-06 5.12
ALGA0114601 rs81343604 1 NA 33 7.24E-10 9.14
DRGA0002016 rs80904152 1 223861733 20 2.73E-06 5.56
INRA0007489 rs319558321 1 262121588 24 7.24E-08 7.14
ALGA0102837 rs81329722 2 39427398 71 4.76E-18 17.32
ALGA0018634 rs80784123 3 44000093 39 5.62E-08 7.25
DIAS0000481 rs343661863 4 15671825 28 1.24E-06 5.91
ALGA0027584 rs81380005 4 103968409 22 3.41E-07 6.47
H3GA0052806 rs81334603 6 170305876 19 7.74E-06 5.11
H3GA0019527 rs80949107 7 3676156 37 4.33E-10 9.36
ALGA0038342 rs80872016 7 7273490 21 7.10E-06 5.15
ALGA0039425 rs80873322 7 21554498 23 5.73E-07 6.24
MARC0049081 rs80824189 7 73999704 27 9.46E-09 8.02
BGIS0000098 - 7 58 8.70E-06 5.06
M1GA0010553 rs80833324 7 88763190 39 1.52E-06 5.82
H3GA0022731 rs80910844 7 100110224 57 2.34E-10 9.63
DIAS0001763 - 8 NA 32 5.57E-06 5.25
ALGA0054131 rs81414030 9 86593109 18 1.62E-06 5.79
ALGA0118632 rs81325586 10 14208472 45 4.34E-12 11.36
H3GA0029984 rs81423899 10 38596942 38 3.02E-10 9.52
ALGA0100690 rs81477669 10 45783989 56 1.42E-21 20.85
DRGA0011972 rs80797698 13 9952427 60 3.78E-07 6.42
ALGA0069762 rs80911538 13 41069431 21 2.03E-07 6.69
ALGA0073309 rs81441892 13 185104190 24 3.38E-09 8.47
MARC0066830 rs81255192 13 192073106 20 4.59E-06 5.34
ALGA0074022 rs81443003 13 204827712 25 2.03E-07 6.69
MARC0031872 rs80919390 14 2704204 22 5.74E-06 5.24
ALGA0078467 rs80855882 14 65655137 56 2.98E-06 5.53
H3GA0042218 rs80915578 14 119983231 24 2.11E-08 7.68
MARC0101508 rs81278062 15 10585538 27 3.19E-07 6.5
ASGA0068898 rs81451733 15 19720520 30 3.38E-09 8.47
MARC0046889 rs81238797 15 39419144 20 2.73E-06 5.56
H3GA0044934 rs80926252 15 119410395 69 1.31E-17 16.88
ALGA0090556 rs81459227 16 44602169 31 1.41E-06 5.85
MARC0039970 rs81233198 18 25273873 34 1.21E-09 8.92
MARC0083113 rs81266760 18 37977138 71 4.76E-18 17.32
ASGA0089892 rs81308090 18 39430154 69 1.31E-17 16.88
MARC0002018 rs80830421 - 233795145 35 1.45E-07 6.84
MARC0026936 rs81293197 - NA 31 1.50E-08 7.82
H3GA0047065 rs81461972 - NA 20 2.10E-06 5.68
Table 3.10: FBAT line H results table. The Marker column show the Pig consortium ID used by Illu-
mina in their annotation ﬁle. The RS identity is the dbsnp id for the marker. Chromosome
and position SS11 give the pig chromosome and the position after remapping the position
in Sus Scrofa 10.2 to Sus Scrofa 11. The number of informative families shows the number
of families that contributed to the test for that marker. Finally the last two columns show
the p-value and −log10(p− value) for the FBAT test.
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Figure 3.1: Manhattan plot of the FBAT results for line B. The blue line shows the chosen threshold,
the red line is genome wide signiﬁcance.
Figure 3.2: QQ plot for the p-value of the FBAT test, for line B. Expected −log10(pvalue) against
observed −log10(pvalue). The lambda value for the p-value distribution is 1.034.
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Figure 3.3: Manhattan plot of the FBAT results for line C. The blue line shows the chosen threshold,
the red line is genome wide signiﬁcance.
Figure 3.4: QQ for the p-value of the FBAT test, plot for line C. Expected −log10(pvalue) against
observed −log10(pvalue). The lambda value for the p-value distribution is 1.099.
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Figure 3.5: Manhattan plot of the FBAT results for line D. The blue line shows the chosen threshold,
the red line is genome wide signiﬁcance.
Figure 3.6: QQ plot for the p-value of the FBAT test, line D. Expected −log10(pvalue) against observed
−log10(pvalue). The lambda value for the p-value distribution is 1.034.
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Figure 3.7: Manhattan plot of the FBAT results for line H. The blue line shows the chosen threshold,
the red line is genome wide signiﬁcance.
Figure 3.8: QQ plot for the p-value of the FBAT test, for line H. Expected −log10(pvalue) against
observed −log10(pvalue). The lambda value for the p-value distribution is 1.121.
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Line Lambda value
B 1.034
C 1.099
D 1.034
H 1.121
Table 3.11: Lambda value for the p-value distribution of the FBAT results for all the lines.
Using the threshold discussed in section 3.1.4, a small number of SNPs were identiﬁed as signiﬁcant
on a number of chromosomes. For lines B and C only a few SNPs, 15 and 8, were signiﬁcant, while
a larger number of SNPs were signiﬁcant for lines D and H, 29 and 41 respectively. These results ﬁt
well with the incidence of maternal infanticide in the lines studied, lines B and C having the lowest
incidence of maternal infanticide with around 5%, (4.8% and 5.9% for line B and C respectively) while
lines D and H have a higher incidence of maternal infanticide with 10.8% and 10.3% respectively. These
results do not correlate with the number of families present in each lines (see table 3.5 in section 3.1.2).
Lines B and H have the largest number of families present with 76 and 97 families respectively. Lines
C and D have a lower number of families with 50 and 56 respectively. There might be an impact from
the number of families with at least 3 members, as line H has the highest number of families with more
than three members: 63. However FBAT can infer missing genotypes if one of the parents is absent,
using heterozygote SNPs in the oﬀspring, which can mitigate some of the missing data for some of the
markers. The numbers of informative families for the signiﬁcant SNPs are fairly similar for lines B and
C (table 3.7 and 3.8), varying between 20 and 40. For line D, the numbers of informative families is
between 13 and 40 per signiﬁcant intervals (see table 3.9). Finally for line H the number of informative
families is between 71 and 19 (see table 3.10). There is no obvious corelation between these numbers
and the number of signiﬁcant results.
For all lines there are SNPs that reach genome wide signiﬁcance: 11 for line B, 6 line C, 15 for line
D and 17 for line H. These make up almost half of the total number of signiﬁcant SNPs passing our
threshold. Again the numbers are correlated with the incidence of maternal infanticide in the lines.
The Manhattan plots are used in genome wide genetics studies to show the regions of each chromo-
some where signiﬁcant SNPs are grouped, creating a peak of signiﬁcant SNPs. The Manhattan plots
for the FBAT results are displayed in section 2.7, ﬁgure 3.1, 3.3, 3.5 and 3.7. There was no group of
signiﬁcant SNPs per chromosome, as might be expected from a GWAS analysis. Only single SNPs
were reaching our threshold or genome wide signiﬁcance, which might be caused by several factors.
First, our phenotype of interest is probably linked to several genes across the genome which will likely
results in low penetrance of the variants in each region of interest. It can also be due to the array used
for this study (as discussed in section 3.1.3) as the design of the array means that LD blocks might
not always be typed properly or by several SNPs, which might explain why we did not see groups of
peaking in the Manhattan plots.
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3.1.6 Parent of Origin test
The parent of origin test was performed in order to identify markers and regions of the genome that
might be preferentially transmitted from mother to daughter.
The parent of origin test returned signiﬁcant results for almost all the chromosomes in the the pig
genome. Our signiﬁcance threshold for this test was set at p− value <= 0.003.
 For line B, 26 SNPs reached signiﬁcance on chromosome 1, 2, 3, 4, 6, 7, 8, 10, 11, 13, 14, 15 and
17, see table 3.12 for more details.
 For line C, 21 SNPs reached signiﬁcance on chromosomes 1, 2, 3, 4, 6, 8, 9, 10, 13, 14, 16, 17
and 18, see table 3.13 for more details.
 For line D, 22 SNPs reached signiﬁcance on chromosomes 1, 2, 3,4, 5, 6, 7, 9, 13, 15, 16 and 18
see table 3.9 for more details.
 For line H, 56 SNPs reached signiﬁcance on chromosomes 1, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 15, 16,
17 and 18 see table 3.14 for more details.
Figures 3.1, 3.12, 3.14 and 3.16 are the Manhattan plots for the parent of origin test for line B, C, D
and H respectively. Figures 3.11, 3.13, 3.15 and 3.17 show the QQ plot for the p-value of the parent
of origin test for each line. Table 3.15 show the lambda value linked to the QQ plot for the parent
of origin test. The lambda value suggest that restricting the set to heterozygous parents increase the
level of stratiﬁcation present in the data given that all of the lambda values are below 0.9.
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SNP ID Chromosome Position P-value maternal transmission Maternal transmitted : untransmitted counts
ASGA0001721 1 29,115,029 0.0007962 2.5:17.5
CASI0003440 1 250,635,066 0.0009111 0.5:11.5
ASGA0003663 1 92,026,588 0.001496 00:11
ALGA0113319 2 121,389,974 0.0007962 2.5:17.5
DIAS0004469 2 6,275,661 0.0009674 02:16
MARC0059849 2 125,760,041 0.002282 01:12
ALGA0018346 3 30,860,487 0.000685 1.5:15.5
MARC0009481 3 75,394,519 0.002282 01:12
ALGA0025931 4 80,915,079 0.0002896 2.5:19.5
ALGA0023973 4 21,978,564 0.001154 1.5:14.5
ALGA0035224 6 38,548,262 0.002282 01:12
INRA0026430 7 75,430,748 0.0009674 02:16
MARC0033269 8 138,870,354 0.001616 02:15
MARC0036135 10 55,403,526 0.0009674 02:16
ASGA0051058 11 66,142,455 0.0009111 02:15
ALGA0061364 11 22,730,003 0.001616 00:11
ALGA0074022 13 215,030,086 0.000532 17:02
ALGA0067709 13 7,175,532 0.0005791 02:15
H3GA0036785 13 77,651,252 0.001616 00:12
ASGA0062605 14 34,991,538 0.0009111 4.5:20.5
INRA0047046 14 129,849,565 0.001374 02:14
ALGA0075730 14 18,958,926 0.0027 00:11
ASGA0065780 14 113,376,632 0.0027 02:14
ALGA0101465 15 149,489,663 0.001496 0.5:11.5
MARC0045894 15 52,614,585 0.001616 02:15
ALGA0093735 17 23,923,753 0.001374 4.5:20.5
Table 3.12: Parent of origin results table for line B. The p-value is calculated for preferential maternal
transmission against paternal transmission. The transmitted: untransmitted count are for
the reference allele against the alternative allele. The 0.5 values are assigned when the
parents of an individual are both heterozygotes.
SNP ID Chromosome Position P-value maternal transmission Maternal transmitted : untransmitted counts
ASGA0003310 1 76,114,707 0.00225 17.5:3.5
ASGA0009211 2 12,927,978 0.002282 01:12
ASGA0010625 2 86,139,077 0.00286 16:03
ASGA0094535 3 7,784,004 0.002282 01:12
ALGA0017723 3 14,332,984 0.0009111 11:00
H3GA0011907 4 10,423,196 0.002282 01:12
INRA0015059 4 83,749,465 0.002838 04:18
ASGA0096127 6 14,598,312 0.002183 15.5:2.5
ALGA0049156 8 117,824,360 0.00286 03:16
ALGA0056155 9 73,923,049 0.00286 03:16
MARC0082453 9 102,552,703 0.0009111 11:00
ASGA0044289 9 121,182,071 0.00286 03:16
H3GA0030271 10 52,456,152 0.00225 17.5:3.5
ALGA0070825 13 76,614,616 0.002282 01:12
MARC0066830 13 202,381,472 0.0009111 00:11
DRGA0014290 14 101,566,065 0.00225 17.5:3.5
DRGA0016061 16 32,726,222 0.001616 02:15
DRGA0016602 17 19,801,781 0.002282 01:12
ALGA0095454 17 53,299,192 0.0027 00:09
DRGA0016933 18 24,930,075 0.00225 17.5:3.5
M1GA0023271 18 50,032,308 0.0003115 00:13
Table 3.13: Parent of origin results for line C. The p-value is calculated for preferential maternal trans-
mission. The transmitted: untransmitted count are for the reference allele against the
alternative allele. The 0.5 values are assigned when the parents of an individual are both
heterozygotes.
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SNP ID Chromosome Position P-value maternal transmission Maternal transmitted : untransmitted counts
ALGA0002856 1 45,648,377 0.001063 18:03
ALGA0114601 1 181,402,872 0.0009111 00:11
DIAS0004495 1 245,008,421 0.0004653 01:15
H3GA0006383 2 27,576,958 4.23E-06 01:24
ASGA0104575 2 138,422,188 0.000685 15.5:1.5
ASGA0082103 3 19,116,155 0.001063 18:03
ALGA0018634 3 45,593,990 1.08E-05 1.5:23.5
ASGA0021239 4 105,898,886 0.000685 15.5:1.5
ASGA0021997 4 119,974,157 0.0027 02:14
H3GA0015082 5 1,087,963 0.0027 02:14
ASGA0026863 5 99,716,210 0.0027 02:14
MARC0009578 6 112,552,637 0.002569 0.5:10.5
H3GA0019527 7 3,813,663 0.001496 0.5:11.5
ASGA0092371 9 120,274,192 0.001616 02:15
DRGA0013265 13 190,391,508 0.0027 14:02
MARC0066830 13 202,381,472 0.000512 0.5:13.5
ALGA0074022 13 215,030,086 0.0027 00:09
MARC0101508 15 11,904,651 6.33E-05 00:16
ALGA0085056 15 46,315,392 0.0027 02:14
ASGA0073960 16 72,751,299 0.0027 02:14
ASGA0074106 16 75,024,639 0.001616 15:02
MARC0039970 18 26,878,437 0.0009111 00:11
Figure 3.9: Parent of origin results for line D. The p-value is calculated for preferential maternal trans-
mission. The transmitted: untransmitted count are for the reference allele against the
alternative allele. The 0.5 values are assigned when the parents of an individual are both
heterozygotes.
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SNP ID Chromosome Position P-value maternal transmission Maternal transmitted : untransmitted counts
DRGA0000439 1 33,957,887 0.002263 07:24
DRGA0000977 1 65,306,294 0.001946 1.5:13.5
ALGA0005867 1 139,478,386 5.36E-07 06:40
ALGA0114601 1 181,402,872 5.51E-09 00:34
INRA0005278 1 191,640,018 0.001154 1.5:14.5
INRA0005299 1 193,664,917 0.001154 1.5:14.5
INRA0005383 1 200,443,140 0.002497 06:22
DRGA0002016 1 250,323,029 2.73E-06 00:22
ALGA0009384 1 284,399,778 0.001946 1.5:13.5
ALGA0009414 1 284,478,293 0.001154 1.5:14.5
ALGA0017693 3 14,134,797 0.001565 10:00
H3GA0008948 3 17,859,317 0.001069 22:05
ALGA0018634 3 45,593,990 5.31E-05 03:24
MARC0053170 3 77,889,376 0.001015 06:24
DRGA0004106 3 106,777,915 0.00286 03:16
ALGA0021723 3 137,881,512 0.001154 1.5:14.5
ASGA0017039 4 2,225,565 0.00286 03:16
INRA0013709 4 38,857,169 0.001225 6.5:24.5
ALGA0025762 4 77,502,926 0.001595 06:23
ASGA0020726 4 96,803,099 0.002263 24:07
INRA0018313 5 7,507,469 0.001069 05:22
ASGA0025833 5 66,355,133 0.0027 09:00
ASGA0025896 5 67,510,148 0.0027 09:27
ALGA0034926 6 23,679,290 0.000532 00:12
H3GA0052806 6 157,353,343 4.59E-06 00:21
ASGA0034277 7 63,617,428 0.001911 6.5:23.5
M1GA0010553 7 95,143,760 2.21E-06 3.5:31.5
ASGA0037929 8 15,992,070 0.001946 1.5:13.5
ASGA0090387 8 89,832,296 0.002967 6.5:22.5
ALGA0113503 8 94,427,398 0.001946 1.5:13.5
MARC0002586 9 26,578,970 0.001225 6.5:24.5
ALGA0113506 9 33,331,814 0.001946 1.5:13.5
MARC0091645 9 128,963,159 0.001946 1.5:13.5
DRGA0009874 9 140,003,794 0.0027 09:00
ALGA0106214 9 149,004,810 0.0003182 3.5:21.5
ASGA0047525 10 36,537,382 0.001154 1.5:14.5
ASGA0047527 10 36,556,089 0.001154 1.5:14.5
H3GA0029984 10 43,738,907 2.31E-06 1.5:26.5
H3GA0033690 12 16,816,869 0.001911 6.5:23.5
H3GA0056180 12 41,548,842 0.001341 01:13
H3GA0034644 12 52,042,303 0.001069 05:22
DRGA0011849 13 978,869 0.001911 6.5:23.5
ALGA0068980 13 26,957,024 0.0007829 6.5:25.5
ALGA0069602 13 38,756,938 0.001154 1.5:14.5
MARC0020205 13 189,818,417 0.0008561 4.5:21.5
MARC0066830 13 202,381,472 7.74E-06 00:20
H3GA0040445 14 62,339,756 0.001565 10:00
ALGA0078822 14 79,562,216 0.0027 09:27
MARC0101508 15 11,904,651 5.75E-06 02:26
ALGA0084124 15 19,520,226 0.00112 7.5:26.5
ASGA0092912 15 143,902,435 0.0027 05:20
H3GA0054837 16 75,201,733 0.001946 1.5:13.5
H3GA0048171 17 29,170,040 0.001154 1.5:14.5
ALGA0095137 17 46,692,167 0.0022 4.5:19.5
ALGA0124479 18 2,082,165 0.002967 6.5:22.5
ASGA0078760 18 8,770,985 0.002282 12:01
Table 3.14: Parent of origin results for line H. The p-value is calculated for preferential maternal
transmission. The transmitted: untransmitted count are for the reference allele against
the alternative allele. The 0.5 values are assigned when the parents of an individual are
both heterozygotes.
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Figure 3.10: Manhattan plot for line B, parents of origin test, the blue line shows the threshold chosen
to select target SNPs. The genome wide signiﬁcance threshold is not displayed as it oﬀ
the chart
Figure 3.11: QQ plot for the p-value of the parent of origin test, for line B. Expected −log10(pvalue)
against observed −log10(pvalue). The lambda value for the p-value distribution is 0.879.
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Figure 3.12: Manhattan plot for line C, parent of origin test, the blue line shows the threshold chosen
to select target SNPs. The genome wide signiﬁcance threshold is not displayed as it oﬀ
the chart.
Figure 3.13: QQ plot for the p-value of the parent of origin test, for line C. Expected −log10(pvalue)
against observed −log10(pvalue). The lambda value for the p-value distribution is 0.879.
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Figure 3.14: Manhattan plot for line D, parent of origin, the blue line shows the threshold chosen to
select target SNPs. The genome wide signiﬁcance threshold is not displayed as it oﬀ the
chart.
Figure 3.15: QQ plot for the p-value of the parent of origin test, for line D. Expected −log10(pvalue)
against observed −log10(pvalue). The lambda value for the p-value distribution is 0.8242.
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Figure 3.16: Manhattan plot for line H, parent of origin test, the blue line shows the threshold chosen
to select target SNPs, the red line is genome wide signiﬁcance.
Figure 3.17: QQ plot for the p-value of the parent of origin test, for line H. Expected −log10(pvalue)
against observed −log10(pvalue). The lambda value for the p-value distribution is 0.799.
Line lambda
B 0.879
C 0.879
D 0.824
H 0.799
Table 3.15: Lambda value for the p-value distribution of the parent of origin test, all lines.
Selecting SNPs according to the thresholds deﬁned earlier in this section and discussed in section
3.1.4, a similar number of SNPs were selected for lines B, C and D with around 20 SNPs for each.
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Line H stands out with 56 SNPs selected. This might be the consequence of the higher number of
families available, or rather mother-daughter pairs that were studied, as line H has the largest number
of families among the lines, with 96. Our signiﬁcance threshold is fairly lax: however some of the SNPs
identiﬁed are common with the FBAT analysis. Similarly to the FBAT analysis, the PO analysis was
designed in order to identify regions of interest for the sequence capture. The ratio of preferential
transmission from mother to daughter for one allele compared to the other varies between 34:1 to 3:1.
The Manhattan plots are similar to the the FBAT ones with no clear peaks of several consecutive
SNPs. As the threshold for signiﬁcance is lower, the SNPs selected are closer to the background noise of
non signiﬁcant SNPs. Again this might be due to the low penetrance of SNPs linked to our phenotype
of interest or the nature of the array. Furthermore, we were being quite lenient for the ﬁltering of this
results as the regions and genes identiﬁed will be used for the design of the capture set which will allow
us to conﬁrm or exclude the candidate regions previously identiﬁed.
3.2 Sequencing data QC
3.2.1 Run and mapping metrics
As discussed in material and methods, the animals were divided between diﬀerent pools. For line B
and C the ﬁrst pool is composed of animals with a history of infanticide sows in their family, pool 2 for
sows who have several infanticide episodes and pool 3 and 4 for control samples. Lines D and H have
3 pools for animals with a history of infanticide (pool 1, 2 and 3), pool 4 is for the serial infanticidle
and pool 5 and 6 for controls.
3.2.1.1 Read quality
The mean read quality scores for the pool in each of the capture sets are displayed in ﬁgure 3.18. The
quality is generally above a Qscore of 30 for all the samples. A Qscore of 30 represents a 1 in a 1000
chance of having a wrong base call. The capture 1 set has slightly lower quality reading than the other
two capture sets. The per base sequence quality score is given in ﬁgures 3.19a and 3.19b for capture
set 1line B, the rest of the plots are available in the supplementary material. All of the samples share
a similar pattern for these plots.
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(a) Read quality score for capture 1, for read 1 and read2.
(b) Read quality score for capture 2, read 1 and read2.
(c) Read quality score for capture 3, read 1 and read 2.
Figure 3.18: Read quality score for the capture set. Figure 3.18a for capture 1, Figure 3.18b for capture
2 and Figure 3.18c for capture 3
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(a) Read 1 quality score per based, capture set 1 line B
(b) Read 2 quality score per base, capture set 1 line B
Figure 3.19: Read quality score per base, read 1 and read 2 of capture set 1 line B
3.2.1.2 Mapping QC
The number of reads for each of the capture and pool is summarized in ﬁgures 3.20, 3.21 and 3.22 for
capture set 1, 2 and 3 respectively. The pools are the same as presented before. The same ﬁgures for
read 1 and read 2 individually are available in the supplementary material. The capture set 1 is the
one showing the largest amount of variation for the number of reads mapped to the genome. It varies
between 30 million to 150 million per samples.
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Figure 3.20: Number of reads mapped from both ends (Read 1 and Read 2) for Capture set 1; pools
1, 2, 3 and lines B, C, D and H. Two sets of data are displayed for read passing ﬁlter
(PF, passing Illumina chastity ﬁlter, see section 4.2.3.1). In red are all the reads PF that
aligned and in blue are the high quality (HQ) reads PF that aligned. High quality is
deﬁned by a mapped quality score of 20 (Q20) or above . This represents 1/100 or smaller
chance of the alignment being wrong.
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Figure 3.21: Number of reads mapped from both ends (Read 1 and Read 2) for Capture set 2; pools
1, 2, 3 and lines B, C, D and H. Two sets of data are displayed for read passing ﬁlter
(PF, passing Illumina chastity ﬁlter, see section 4.2.3.1). In red are all the reads PF that
aligned and in blue are the high quality (HQ) reads PF that aligned. High quality is
deﬁned by a mapped quality score of 20 (Q20) or above . This represents 1/100 or smaller
chance of the alignment being wrong.
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Figure 3.22: Number of reads mapped from both ends (Read 1 and Read 2) for Capture set 3; pools
1, 2 and 3 and lines B, C, D and H. Two sets of data are displayed for read passing ﬁlter
(PF, passing Illumina chastity ﬁlter, see section 4.2.3.1). In red are all the reads PF that
aligned and in blue are the high quality (HQ) reads PF that aligned. High quality is
deﬁned by a mapped quality score of 20 (Q20) or above . This represents 1/100 or smaller
chance of the alignment being wrong.
Tables 3.16, 3.17 and 3.18 give the summary of the number of reads mapped for each capture set,
combining read 1 and read 2. Passing ﬁlter high quality aligned reads are reads aligning with an quality
score (Qscore) above 20.
 Capture set 1, average number of reads passing ﬁlter mapped: 81,681,252, minimum 42,266,915
reads and maximum 152,667,192. Average percentage read aligned is 97% . For high quality
read the average number of aligned reads is 68,890,382 reads, minimum 35,786,637 reads and
maximum 127,159,614 reads.
 Capture set 2, average number of reads passing ﬁlter mapped is 72,457,794, the minimum number
of reads mapped is 55,729,390 and the maximum 108,435,627. The average percentage of aligned
read is 98%. High quality reads the average number of aligned reads is 57,168,410 with a minimum
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of 43,923,060 and a maximum of 85,187,732 reads.
 Capture set 3, average numbe of reads passing ﬁlger mapped is 64,030,227, the minimum number
of reads mappis is 35,543,830 and the maximum 91,433,220. The average percentatage of read
aligned is 98.1%. High quality reads the average number of aligned reads is 57,664,615 with a
minimum of 32,054,462 and a maximum of 82,476,830 reads.
Lines TOTAL_READS
PF_READS PCT_PF_READS PF_HQ_READS PF
aligned aligned aligned MISMATCH_RATE
Line H-pool1-capture1 75,088,750 73,327,924 0.9766 62,997,796 0.0101
Line H-pool2-capture1 83,379,614 81,383,067 0.9761 69,429,083 0.0103
Line H-pool3-capture1 67,990,646 66,452,833 0.9774 55,922,274 0.0106
Line H-pool4-capture1 56,327,248 55,023,992 0.9769 46,530,743 0.0105
Line H-pool5-capture1 57,058,626 55,578,500 0.9741 47,240,597 0.0113
Line H-pool6-capture1 71,676,552 69,898,000 0.9752 59,427,771 0.0104
Line B-pool1-capture1 137,314,694 133,121,532 0.9695 112,316,531 0.0127
Line B-pool2-capture1 110,235,764 106,933,563 0.97 89,472,228 0.0128
Line B-pool3-capture1 94,566,318 91,792,575 0.9707 76,896,859 0.0128
Line B-pool4-capture1 138,370,378 134,476,470 0.9719 113,246,554 0.0126
Line C-pool1-capture1 157,301,982 152,667,192 0.9705 127,159,614 0.013
Line C-pool2-capture1 84,948,514 82,485,978 0.971 69,202,084 0.0126
Line C-pool3-capture1 88,607,772 86,006,584 0.9706 71,825,218 0.0141
Line C-pool4-capture1 103,359,932 100,497,895 0.9723 84,713,674 0.0125
Line D-pool1-capture1 43,378,990 42,266,915 0.9744 35,786,637 0.0107
Line D-pool2-capture1 54,861,480 53,609,029 0.9772 45,524,947 0.0109
Line D-pool3-capture1 59,594,480 58,121,745 0.9753 49,595,063 0.0119
Line D-pool4-capture1 67,319,302 65,585,312 0.9742 55,673,911 0.0108
Line D-pool5-capture1 70,140,066 68,279,765 0.9735 57,156,781 0.0113
Line D-pool6-capture1 57,437,276 56,116,171 0.977 47,689,276 0.0107
Table 3.16: Capture 1, read 1 and read 2 combined, mapping statistics. TOTAL_READS is the total
number of reads generated passing ﬁlter. PF_READS aligned the number of reads passing
ﬁlter aligned. PCT_PF_READ aligned is the percentage of reads passing ﬁlter aligned.
PF_HQ_READS aligned is the number of reads passing ﬁlter aligned and considered to
be of high quality. PF MISMATCH_RATE is the percentage of mismatches in the reads
passing ﬁlter.
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Lines TOTAL_READS
PF_READS PCT_PF_READS PF_HQ_READS PF
aligned aligned aligned MISMATCH_RATE
Line H-pool1-capture2 93,025,096 91,594,335 0.9846 72,378,498 0.0061
Line H-pool2-capture2 68,337,872 67,095,960 0.9818 53,439,245 0.0062
Line H-pool3-capture2 68,414,060 67,236,953 0.9828 52,651,322 0.0065
Line H-pool4-capture2 56,878,630 55,729,390 0.9798 43,923,060 0.0065
Line H-pool5-capture2 63,228,748 62,122,086 0.9825 48,495,196 0.0065
Line H-pool6-capture2 64,582,542 63,649,267 0.9855 50,525,936 0.0060
Line B-pool1-capture2 74,177,346 72,740,408 0.9806 57,747,087 0.0065
Line B-pool2-capture2 66,656,046 65,357,046 0.9805 51,877,093 0.0065
Line B-pool3-capture2 61,852,196 60,692,535 0.9813 48,225,325 0.0064
Line B-pool4-capture2 76,755,578 75,456,834 0.9831 60,347,383 0.0063
Line C-pool1-capture2 73,501,254 71,824,670 0.9772 56,412,312 0.0073
Line C-pool2-capture2 77,280,472 75,858,941 0.9816 59,401,054 0.0070
Line C-pool3-capture2 69,341,074 68,140,278 0.9827 53,200,939 0.0069
Line C-pool4-capture2 72,893,000 71,596,541 0.9822 56,590,495 0.0067
Line D-pool1-capture2 73,722,136 71,966,577 0.9762 56,578,548 0.0068
Line D-pool2-capture2 83,885,058 82,091,472 0.9786 64,885,960 0.0065
Line D-pool3-capture2 74,011,940 72,651,369 0.9816 57,164,190 0.0064
Line D-pool4-capture2 110,664,764 108,435,627 0.9799 85,187,732 0.0065
Line D-pool5-capture2 74,257,008 72,271,579 0.9733 56,995,236 0.0067
Line D-pool6-capture2 73,238,120 71,838,954 0.9809 56,661,413 0.0063
Table 3.17: Capture 2, read 1 and 2 combined, mapping statistics. TOTAL_READS is the total
number of reads generated passing ﬁlter. PF_READS aligned the number of reads passing
ﬁlter aligned. PCT_PF_READ aligned is the percentage of reads passing ﬁlter aligned.
PF_HQ_READS aligned is the number of reads passing ﬁlter aligned and considered to
be of high quality. PF MISMATCH_RATE is the percentage of mismatches in the reads
passing ﬁlter.
Lines TOTAL_READS
PF_READS PCT_PF_READS PF_HQ_READS PF
aligned aligned aligned MISMATCH_RATE
Line H-pool1-capture3 74,867,550 73,104,287 0.9764 65,732,765 0.0085
Line H-pool2-capture3 53,778,638 52,656,091 0.9791 47,746,163 0.0083
Line H-pool3-capture3 65,054,464 63,736,784 0.9797 57,489,322 0.0084
Line H-pool4-capture3 49,278,188 48,259,756 0.9793 43,451,734 0.0084
Line H-pool5-capture3 67,599,424 66,019,235 0.9766 59,321,419 0.0088
Line H-pool6-capture3 60,046,120 58,845,062 0.9800 53,420,134 0.0083
Line B-pool1-capture3 55,924,538 55,096,376 0.9852 49,785,634 0.0063
Line B-pool2-capture3 89,544,320 88,146,755 0.9844 79,035,370 0.0065
Line B-pool3-capture3 36,073,302 35,543,830 0.9853 32,054,462 0.0064
Line B-pool4-capture3 57,614,252 56,832,081 0.9864 51,406,889 0.0063
Line C-pool1-capture3 93,458,664 91,433,220 0.9783 82,476,830 0.0090
Line C-pool2-capture3 61,589,512 60,327,979 0.9795 54,284,495 0.0089
Line C-pool3-capture3 81,305,174 79,342,297 0.9759 70,643,145 0.0092
Line C-pool4-capture3 65,680,586 64,362,304 0.9799 58,239,392 0.0087
Line D-pool1-capture3 88,065,810 86,746,177 0.9850 78,063,598 0.0059
Line D-pool2-capture3 64,940,980 63,913,754 0.9842 57,643,778 0.0060
Line D-pool3-capture3 55,108,940 54,210,065 0.9837 48,966,302 0.0060
Line D-pool4-capture3 58,824,874 57,916,962 0.9846 51,847,229 0.0060
Line D-pool5-capture3 71,074,430 69,803,072 0.9821 62,796,187 0.0063
Line D-pool6-capture3 55,273,464 54,308,452 0.9825 48,887,455 0.0062
Table 3.18: Capture 3, read 1 and 2 combined mapping statistics. TOTAL_READS is the total num-
ber of reads generated passing ﬁlter. PF_READS aligned the number of reads passing
ﬁlter aligned. PCT_PF_READ aligned is the percentage of reads passing ﬁlter aligned.
PF_HQ_READS aligned is the number of reads passing ﬁlter aligned and considered to
be of high quality. PF MISMATCH_RATE is the percentage of mismatches in the reads
passing ﬁlter.
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3.2.1.3 Sequence duplication levels.
The level of duplication for the 3 capture sets is plotted in ﬁgures 3.23, 3.24 and 3.25 for capture sets
1, 2 and 3 respectively. The levels of duplications are fairly similar between samples, with a peak for
ﬁve to ten percent of the reads being duplicated between 10 and 50x. Tables 3.19, 3.20, 3.21 show the
percentage of reads left after deduplication, the total number of reads and the estimated number of
read after deduplication. This estimate is based on a sample of 100,000 reads. The percentage of reads
left is between 40% and 75% and the spread of reads in the pools after demultiplexing is estimated at
between 11 millions to 48 millions reads.
Line and pool Read Percentage left after deduplication Total number of read Read left after deduplication
line-B-pool1 R1 58.79 68,657,347 40,363,654
line-B-pool1 R2 60.46 68,657,347 41,510,232
line-B-pool2 R1 62.46 55,117,882 34,426,629
line-B-pool2 R2 63.68 55,117,882 35,099,067
line-B-pool3 R1 64.64 47,283,159 30,563,834
line-B-pool3 R2 65.69 47,283,159 31,060,307
line-B-pool4 R1 61.5 69,185,189 42,548,891
line-B-pool4 R2 62.71 69,185,189 43,386,032
line-C-pool1 R1 59.85 78,650,991 47,072,618
line-C-pool1 R2 61.69 78,650,991 48,519,796
line-C-pool2 R1 66.7 42,474,257 28,330,329
line-C-pool2 R2 67.49 42,474,257 28,665,876
line-C-pool3 R1 68.13 44,303,886 30,184,238
line-C-pool3 R2 69.96 44,303,886 30,994,999
line-C-pool4 R1 64.69 51,679,966 33,431,770
line-C-pool4 R2 65.83 51,679,966 34,020,922
line-D-pool1 R1 73.18 21,689,495 15,872,372
line-D-pool1 R2 73.36 21,689,495 15,911,414
line-D-pool2 R1 69.99 27,430,740 19,198,775
line-D-pool2 R2 70.31 27,430,740 19,286,553
line-D-pool3 R1 69.45 29,797,240 20,694,183
line-D-pool3 R2 69.87 29,797,240 20,819,332
line-D-pool4 R1 66.85 33,659,651 22,501,477
line-D-pool4 R2 66.97 33,659,651 22,541,868
line-D-pool5 R1 67.48 35,070,033 23,665,258
line-D-pool5 R2 67.9 35,070,033 23,812,552
line-D-pool6 R1 68.67 28,718,638 19,721,089
line-D-pool6 R2 68.63 28,718,638 19,709,601
line-H-pool1 R1 62.96 37,544,375 23,637,939
line-H-pool1 R2 62.96 37,544,375 23,637,939
line-H-pool2 R1 63.36 41,689,807 26,414,662
line-H-pool2 R2 63.48 41,689,807 26,464,689
line-H-pool3 R1 67.61 33,995,323 22,984,238
line-H-pool3 R2 67.93 33,995,323 23,093,023
line-H-pool4 R1 69.24 28,163,624 19,500,493
line-H-pool4 R2 69.07 28,163,624 19,452,615
line-H-pool5 R1 68.04 28,529,313 19,411,345
line-H-pool5 R2 68.35 28,529,313 19,499,785
line-H-pool6 R1 67.02 35,838,276 24,018,813
line-H-pool6 R2 67.39 35,838,276 24,151,414
Table 3.19: Capture 1 duplication estimation table. The value are calculated based on a subset of a
100,000 reads by fastQC
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Line and pool Read Percentage left after deduplication Total number of read Read left after deduplication
Line_B-pool1 R1 45.91 37,088,673 17,027,410
Line_B-pool1 R2 49.49 37,088,673 18,355,184
Line_B-pool2 R1 48.72 33,328,023 16,237,413
Line_B-pool2 R2 51.92 33,328,023 17,303,910
Line_B-pool3 R1 48.89 30,926,098 15,119,769
Line_B-pool3 R2 52.21 30,926,098 16,146,516
Line_B-pool4 R1 44.18 38,377,789 16,955,307
Line_B-pool4 R2 47.59 38,377,789 18,263,990
Line_C-pool1 R1 53.97 36,750,627 19,834,313
Line_C-pool1 R2 57.8 36,750,627 21,241,862
Line_C-pool2 R1 48.1 38,640,236 18,585,954
Line_C-pool2 R2 52.33 38,640,236 20,220,435
Line_C-pool3 R1 48.25 34,670,537 16,728,534
Line_C-pool3 R2 52.15 34,670,537 18,080,685
Line_C-pool4 R1 49.2 36,446,500 17,931,678
Line_C-pool4 R2 52.95 36,446,500 19,298,422
Line_D-pool1 R1 49.2 36,861,068 18,135,645
Line_D-pool1 R2 52.94 36,861,068 19,514,249
Line_D-pool2 R1 44.67 41,942,529 18,735,728
Line_D-pool2 R2 48.3 41,942,529 20,258,242
Line_D-pool3 R1 44.8 37,005,970 16,578,675
Line_D-pool3 R2 48.6 37,005,970 17,984,901
Line_D-pool4 R1 37.93 55,332,382 20,987,572
Line_D-pool4 R2 42.39 55,332,382 23,455,397
Line_D-pool5 R1 47.32 37,128,504 17,569,208
Line_D-pool5 R2 51.5 37,128,504 19,121,180
Line_D-pool6 R1 43.2 36,619,060 15,819,434
Line_D-pool6 R2 47.31 36,619,060 17,324,477
Line_H-pool1 R1 42.38 46,512,548 19,712,018
Line_H-pool1 R2 46.49 46,512,548 21,623,684
Line_H-pool2 R1 51.76 34,168,936 17,685,841
Line_H-pool2 R2 55.47 34,168,936 18,953,509
Line_H-pool3 R1 48.4 34,207,030 16,556,203
Line_H-pool3 R2 52.5 34,207,030 17,958,691
Line_H-pool4 R1 57 28,439,315 16,210,410
Line_H-pool4 R2 60.07 28,439,315 17,083,497
Line_H-pool5 R1 50.37 31,614,374 15,924,160
Line_H-pool5 R2 54.22 31,614,374 17,141,314
Line_H-pool6 R1 48.59 32,291,271 15,690,329
Line_H-pool6 R2 52.33 32,291,271 16,898,022
Table 3.20: Capture 2 duplication table. The value are calculated based on a subset of a 100,000 reads
by fastQC
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Line and pool Read Percentage left after deduplication Total number of read Read left after deduplication
Line_B-pool1 R1 56.33 27,962,269 15,751,146
Line_B-pool1 R2 58.83 27,962,269 16,450,203
Line_B-pool2 R1 48.49 44,772,160 21,710,020
Line_B-pool2 R2 51.85 44,772,160 23,214,365
Line_B-pool3 R1 65.95 18,036,651 11,895,171
Line_B-pool3 R2 68.01 18,036,651 12,266,726
Line_B-pool4 R1 55.51 28,807,126 15,990,836
Line_B-pool4 R2 58.1 28,807,126 16,736,940
Line_C-pool1 R1 50.96 46,729,332 23,813,268
Line_C-pool1 R2 53.81 46,729,332 25,145,054
Line_C-pool2 R1 57.51 30,794,756 17,710,064
Line_C-pool2 R2 60.2 30,794,756 18,538,443
Line_C-pool3 R1 54.62 40,652,587 22,204,443
Line_C-pool3 R2 58.03 40,652,587 23,590,696
Line_C-pool4 R1 57.47 32,840,293 18,873,316
Line_C-pool4 R2 59.8 32,840,293 19,638,495
Line_D-pool1 R1 47.54 44,032,905 20,933,243
Line_D-pool1 R2 50.75 44,032,905 22,346,699
Line_D-pool2 R1 54.4 32,470,490 17,663,947
Line_D-pool2 R2 57.2 32,470,490 18,573,120
Line_D-pool3 R1 57.91 27,554,470 15,956,794
Line_D-pool3 R2 60.5 27,554,470 16,670,454
Line_D-pool4 R1 54.79 29,412,437 16,115,074
Line_D-pool4 R2 57.71 29,412,437 16,973,917
Line_D-pool5 R1 52.94 35,537,215 18,813,402
Line_D-pool5 R2 56.26 35,537,215 19,993,237
Line_D-pool6 R1 57.43 27,636,732 15,871,775
Line_D-pool6 R2 60.56 27,636,732 16,736,805
Line_H-pool1 R1 55.05 37,433,775 20,607,293
Line_H-pool1 R2 57.54 37,433,775 21,539,394
Line_H-pool2 R1 60.11 26,889,319 16,163,170
Line_H-pool2 R2 62.23 26,889,319 16,733,223
Line_H-pool3 R1 56.45 32,527,232 18,361,622
Line_H-pool3 R2 59.19 32,527,232 19,252,869
Line_H-pool4 R1 61.49 24,639,094 15,150,579
Line_H-pool4 R2 63.71 24,639,094 15,697,567
Line_H-pool5 R1 56.72 33,799,712 19,171,197
Line_H-pool5 R2 59.61 33,799,712 20,148,008
Line_H-pool6 R1 57.61 30,023,060 17,296,285
Line_H-pool6 R2 59.78 30,023,060 17,947,785
Table 3.21: Capture 3 duplication table. The value are calculated based on a subset of a 100,000 reads
by fastQC
3.2.2 Capture quality control
Summary metrics for the each capture set after deduplication are displayed in tables 3.22, 3.23, 3.24
for the diﬀerent pools of sequenced animals in capture sets 1, 2 and 3. The metrics in the table are
fr, ft, enrichment, average coverage, sd coverage and the 25th, 50th, 75th and 100th percentile. fr
represent the fraction of reads mapping to the targetted area (capture set target). For the ﬁrst capture
set the average is 0.5 so around 50% of the reads map to the capture area, it increases to 64% (0.64)
of reads for capture 2 and 66% (0.66) for capture set 3. For oﬀ the shelf capture kits, it is expected
to get between 60% to 80% capture eﬃciency [183], however our sequence capture is a custom design
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and based on a fragmented genome build as described in section 1.7, the oﬀ target eﬀect might be
greater. For a more detailed discussion about this, see section 4.2.4. ft represents the fraction of reads
mapping to the rest of the genome. This is really small, less than one percent for all capture sets but it
is expected due to the capture strategy used. The enrichment value is calculated as the ratio between
fr/ft. The enrichment values are on average 368, 387 and 365 for the pools in capture set 1, 2 and 3
respectively. The next value is the average coverage for the targeted bases in each pool. The average
coverage for the pools for each capture set are 900, 874 and 748 for set 1, 2 and 3. The corresponding
standard deviation averages are 457, 394 and 266. The percentile data can be used to identify any
skew in the data. For all the capture sets the median (50th percentile) is relatively close to the average
coverage. The 100th percentile shows the maximum coverage for the pool and some of the values are
very high compared to the mean (around 10 times more). The ﬁgure suggests that the capture set
performed relatively well, at least half of the reads mapping to targetted region. The coverage of the
the targeted region is very high with at least 748 reads on average covering the targetted region. The
25thpercentile is still relatively high, with an average of 584, 595 and 539, suggesting that the lower
range of the coverage is still high.
Sample Name fr ft enrichment average coverage sd coverage 25% 50% 75% 100%
Line H-pool1-capture1 0.5792 0.0014 429 953 461 629 945 1257 10934
Line H-pool2-capture1 0.5390 0.0014 399 983 494 633 966 1300 10251
Line H-pool3-capture1 0.4785 0.0014 354 715 361 465 699 938 11762
Line H-pool4-capture1 0.4990 0.0014 370 616 305 409 607 804 11237
Line H-pool5-capture1 0.5458 0.0014 404 682 353 440 662 892 9052
Line H-pool6-capture1 0.5134 0.0014 380 803 381 534 799 1057 9734
Line B-pool1-capture1 0.5059 0.0014 375 1511 786 972 1477 1984 21226
Line B-pool2-capture1 0.4722 0.0014 350 1138 609 728 1109 1490 19988
Line B-pool3-capture1 0.4583 0.0014 339 945 478 619 929 1237 20574
Line B-pool4-capture1 0.4790 0.0014 355 1446 717 952 1434 1904 25132
Line C-pool1-capture1 0.4488 0.0014 332 1544 804 993 1517 2035 26313
Line C-pool2-capture1 0.4555 0.0014 337 845 427 546 832 1116 14437
Line C-pool3-capture1 0.4383 0.0014 325 849 436 550 830 1112 14579
Line C-pool4-capture1 0.4615 0.0014 342 1040 511 681 1030 1371 15217
Line D-pool1-capture1 0.5083 0.0014 377 482 249 314 470 630 8623
Line D-pool2-capture1 0.5092 0.0014 377 613 321 397 600 803 10640
Line D-pool3-capture1 0.5452 0.0014 404 711 355 467 699 932 11520
Line D-pool4-capture1 0.5233 0.0014 388 772 405 495 745 1011 13326
Line D-pool5-capture1 0.4513 0.0014 334 694 378 437 667 908 14922
Line D-pool6-capture1 0.5150 0.0014 381 649 311 437 643 848 11001
Table 3.22: Summary of capture statistics for capture set 1 and the diﬀerent pools for each line. The
statistics reported are fr: fraction of reads covering the target and ft fraction of reads
covering the genome. Enrichiment is the ratio: fr/ft. Coverage metrics are: average cov-
erage: average coverage for the target bases and sd coverage: coverage standard deviation.
The last 4 columns display the 25th, 50th (median) , 75th and 100th percentile for coverage.
112
3 Results
Sample Name fr ft enrichment average coverage sd coverage 25% 50% 75% 100%
Line H-pool1-capture2 0.6665 0.0017 403 1147 603 774 1144 1511 84120
Line H-pool2-capture2 0.6310 0.0017 381 794 365 526 790 1054 6945
Line H-pool3-capture2 0.6287 0.0017 380 795 336 557 795 1027 5605
Line H-pool4-capture2 0.5906 0.0017 357 620 268 432 616 800 11011
Line H-pool5-capture2 0.6380 0.0017 385 746 330 520 740 959 13053
Line H-pool6-capture2 0.6873 0.0017 415 821 394 535 811 1092 19751
Line B-pool1-capture2 0.6643 0.0017 401 909 432 595 898 1210 6319
Line B-pool2-capture2 0.6715 0.0017 406 826 373 558 822 1088 5199
Line B-pool3-capture2 0.6826 0.0017 412 780 343 537 777 1017 4986
Line B-pool4-capture2 0.7065 0.0017 427 1000 474 650 984 1332 6934
Line C-pool1-capture2 0.5488 0.0017 331 742 329 515 745 967 18073
Line C-pool2-capture2 0.5997 0.0017 362 855 379 588 859 1121 10325
Line C-pool3-capture2 0.6308 0.0017 381 807 353 564 808 1043 13608
Line C-pool4-capture2 0.6183 0.0017 373 831 377 557 828 1097 7709
Line D-pool1-capture2 0.6135 0.0017 370 833 357 579 828 1080 4380
Line D-pool2-capture2 0.6414 0.0017 387 991 420 690 988 1291 6173
Line D-pool3-capture2 0.6530 0.0017 394 897 386 622 891 1164 5379
Line D-pool4-capture2 0.6482 0.0017 391 1325 590 912 1304 1705 19930
Line D-pool5-capture2 0.6360 0.0017 384 864 375 598 856 1117 5537
Line D-pool6-capture2 0.6648 0.0017 402 900 403 610 890 1176 13525
Table 3.23: Summary of capture statistic for capture set 2 and the diﬀerent pools for each line. The
statistics reported are fr: fraction of reads covering the target and ft fraction of reads
covering the genome. Enrichiment is the ratio: fr/ft. Coverage metrics are: average cov-
erage: average coverage for the target bases and sd coverage: coverage standard deviation.
The last 4 columns display the 25th, 50th (median) , 75th and 100th percentile for coverage.
Sample Name fr ft enrichment average coverage sd_coverage 25% 50% 75% 100%
Line H-pool1-capture3 0.6938 0.0019 358 839 486 596 828 1038 12441
Line H-pool2-capture3 0.7297 0.0019 377 636 377 446 626 788 9688
Line H-pool3-capture3 0.7130 0.0019 368 753 438 531 739 934 12048
Line H-pool4-capture3 0.7083 0.0019 366 566 345 405 555 692 9254
Line H-pool5-capture3 0.7004 0.0019 362 766 435 543 749 945 12445
Line H-pool6-capture3 0.7328 0.0019 379 714 380 501 706 893 9312
Line B-pool1-capture3 0.7142 0.0019 369 651 250 474 661 828 3351
Line B-pool2-capture3 0.6974 0.0019 360 1019 381 755 1034 1286 4912
Line B-pool3-capture3 0.7187 0.0019 371 423 159 312 428 535 2135
Line B-pool4-capture3 0.7232 0.0019 374 679 262 491 690 867 3392
Line C-pool1-capture3 0.7161 0.0019 370 1084 433 795 1093 1362 7288
Line C-pool2-capture3 0.7007 0.0019 362 700 285 502 705 889 3987
Line C-pool3-capture3 0.6615 0.0019 342 870 347 629 873 1103 4277
Line C-pool4-capture3 0.7210 0.0019 373 768 306 553 776 976 3978
Line D-pool1-capture3 0.7083 0.0019 366 1018 457 740 1014 1269 9618
Line D-pool2-capture3 0.7088 0.0019 366 751 360 548 750 932 8439
Line D-pool3-capture3 0.7082 0.0019 366 637 293 463 637 794 6568
Line D-pool4-capture3 0.6961 0.0019 360 669 377 480 656 822 9851
Line D-pool5-capture3 0.6907 0.0019 357 797 563 575 780 963 15583
Line D-pool6-capture3 0.6979 0.0019 361 628 375 454 620 769 10076
Table 3.24: Summary of capture statistic for capture set 3 and the diﬀerent pools for each line. The
statistics reported are fr: fraction of reads covering the target and ft fraction of reads
covering the genome. Enrichiment is the ratio: fr/ft. Coverage metrics are: average cov-
erage: average coverage for the target bases and sd coverage: coverage standard deviation.
The last 4 columns display the 25th, 50th (median) , 75th and 100th percentile for coverage.
Chromosome coverage bar plot for the reads mapped and the targeted regions are represented in
ﬁgures 3.29, 3.30, 3.31 for one sample (line B pool1) for the 3 capture sets. The same plot for the
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other samples are provided in supplementary data. The plots show the fraction of total reads mapping
to each chromosome and the fraction of reads mapping to the targetted region for each chromosome.
The fraction of reads on target and reads mapped to chromosome are not always the same but are
closely correlated. Some chromosomes have reads mapping to them while there are no targetted reads
on them, suggesting some oﬀ target eﬀects. There are also reads mapping to regions that were not on
the capture list. This is expected given the fraction of reads on target shown in the summary tables,
depending on the capture set a large fraction of reads might be oﬀ target, see section 4.2.4 for the
discussion about capture sets.
Figure 3.26: Capture 1 chromosome bar plot for line B pool . The green bars represent the reads
fraction mapped to each chromosome and in yellow are the read fraction mapped to
targetted regions.
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Figure 3.27: Capture 2 chromosome bar plot for line B pool1. The green bars represent the fraction of
reads mapped and in yellow are the fraction of targetted regions.
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Figure 3.28: Capture 3 chromosome bar plot for line B pool1, The green bars represent the reads
mapped and in yellow are the targetted regions.
Coverage distributions for reads on target for pool 1, line B are shown in ﬁgures 3.29,3.30,3.31 for
capture set 1, 2 and 3. For the other pools and lines the plots are in supplemental material. The
threshold for good coverage was set at 20x (20 bases depth for a given location). All of the capture
sets achieve this for a large fraction of the target base coverage. Coverage was generally very high as
seen in tables 3.22, 3.23 and 3.24. Capture set 1 had the highest coverage of all of the capture sets
and capture set 3 the lowest. According to ﬁgure 3.29, capture 1 had more than 50% of target based
covered at more than 1500x, only a very small fraction of the regions, around one percent, are covered
at less than 20X. The highest coverage for a fraction of the regions reached more than 3500X. For
capture set 2, 50% or more of the target regions were covered by at least 500X, again only a small
fraction of the regions, around one percent, was covered by less than 20X. The highest coverage was
above 2000X. Finally for capture 3 the coverage was not as deep but remained very high. Half of
the targetted regions are covered by more than 600X, while the upper end of the coverage is lower
compared to the other two capture sets, it reached 1300x. At the lower end of the coverage, a slightly
larger proportion of the target regions were covered with less than 20X, but it remains a very small
proportion, around two to three percent.
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Figure 3.29: Coverage distribution for capture 1 line B pool1. The blue histogram shows the distri-
bution of coverage, the y-axis for this being on the left side. The yellow line shows the
coverage relative to the cumulative fraction of target bases, the y axis being on the right
side. The dotted line shows the target 20x coverage.
Figure 3.30: Coverage distribution for capture 2 line B pool1. The blue histogram shows the distri-
bution of coverage, the y-axis for this being on the left side. The yellow line shows the
coverage relative to the cumulative fraction of target bases, the y axis being on the right
side. The dotted line shows the target 20x coverage.
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Figure 3.31: Coverage distribution for capture 3 line B pool 1. The blue histogram shows the distri-
bution of coverage, the y-axis for this being on the left side. The yellow line shows the
coverage relative to the cumulative fraction of target bases, the y axis being on the right
side. The dotted line shows the target 20x coverage.
Normalised coverage plots for pool 1 line B are shown for all capture sets on ﬁgures 3.32, 3.33 and
3.34. The normalised coverage is calculated by taking the per base coverage and dividing it by the
average coverage for all targetted bases. As it is not dependent on the number of reads, it makes it
easier to compare data between samples. The graphs show that the coverage is uniform and behaves
similarly for all the capture sets. More than 80 percent of the data is covered by at least half of the
average coverage value for all of the capture sets.
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Figure 3.32: Normalised coverage plot for capture set 1, pool 1 line B.The y axis represents the fraction
of target base covered and the x axis the normalised coverage. The normalised coverage is
calculated by dividing the coverage of a given base by the average coverage of the whole
sample. At 0.5 the fraction of bases covered will be covered by at least half of the average
while at 1 it will be covered by at least the average.
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Figure 3.33: Normalised coverage plot for capture set 2, pool1 line B. The y axis represents the fraction
of target base covered and the x axis the normalised coverage. The normalised coverage is
calculated by dividing the coverage of a given base by the average coverage of the whole
sample. At 0.5 the fraction of bases covered will be covered by at least half of the average
while at 1 it will be covered by at least the average.
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Figure 3.34: Normalised coverage plot for capture set 3, pool1 line B. The y axis represents the fraction
of target base covered and the x axis the normalised coverage. The normalised coverage is
calculated by dividing the coverage of a given base by the average coverage of the whole
sample. At 0.5 the fraction of bases covered will be covered by at least half of the average
while at 1 it will be covered by at least the average.
3.3 Mapped reads processing and variants analysis.
The GATK part of the analysis pipeline produced variants ﬁles for each sequencing pool that was
processed. The GATK pipeline is described in details in section 2.10.
3.3.1 Quality score recalibration
The graph below shows the results of applying the quality score recalibration on pool1 of line B for
capture 1: the other ﬁles for the other capture sets are available in supplementary data. The accuracy
plot shows the diﬀerence between the empirical value and the reported quality score, negative values
meaning that the the reported score is higher than the empirical one. Figure 3.35 shows that the
quality score before correction is higher than the one after correction.. In ﬁgure 3.36 almost all of the
graphs show that the quality score before recalibration was higher than the one after recalibration.
The spread of the scores was also smaller before adjustment. Only when looking at the mean quality
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score can we see that in some contexts the quality score before recalibration was lower.
Figure 3.35: Quality score before and after recalibration. Each column of the graph represent a poten-
tial deviation from the reference sequence. In order: base substitution, base insertion and
base deletion. The ﬁrst row displays the graph for the empirical score (calculated using
machine learning) against reported quality score. The second row displays the quality
score accuracy according to the cycle of the reads, the positive values on the X axis being
the ﬁrst read and the negative values being the second read. The Y axis represents the
accuracy score calculated by subtracting the reported (observed) quality score from the
empirical score, a negative value representing over conﬁdent quality score. The last row
display the quality score accuracy according to the context covariate which are the 3 bases
before it. All of the of the data suggest that the reported quality score is higher than it
should be.
122
3 Results
Figure 3.36: Quality scores before and after recalibration. Each column relates to a particular event,
in order: base substitution, base insertion and base deletion. The ﬁrst row shows the
distribution of the quality score before and after recalibration. The second row, the mean
quality score before and after in relation to the read cycle, positive values on the X axis
representing the ﬁrst read, negative values the second read. The third row shows the mean
quality score in relation to the 3 bases preceding the base of interest.
3.3.2 Variant calling
The number of variants called for each capture set and each pool before and after ﬁltering is given in
table 3.25. The numbers in this table were computed after the variant discovery was completed.
Table 3.27 contains the number of variants after grouping per category as described in the material
and methods, see section 2.9.1. The numbers are calculated from the updated table with variant
remapped to build 11 of the genome, see section 2.11.3 for more details about updating the coordinates
to build 11. A unique variant corresponds to a variant with a unique position in the genome: variants
sharing the same location are removed from the counting.
Figures 3.37, show the density distribution of the diﬀerence in allele frequencies between the control
pools and between the control pools and infanticide pools. The ﬁgure (a) displays the diﬀerence in
allele frequencies between the control for each capture set, grouping all the variants from all the lines.
The ﬁgure (b) plots the diﬀerence in allele frequencies for each of the capture sets and each category
within that set. For both ﬁgures the vertical lines show mean plus 3 standard deviations, for each
capture set for the ﬁrst ﬁgure and for each capture set and category for the second one.
Figures 3.38, 3.39, 3.40, 3.41, 3.42 and 3.43 display the histogram of the repartition of the diﬀerence
in allele frequency between the control pool for each capture set and each line.
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Table 3.26 shows the results of a mock selection of the variant based on the control pools.
Tables 3.28, 3.29, 3.30, 3.31, 3.32, 3.33, 3.34, 3.35, 3.36 show the percentage of selected variants
using the ﬁltering criteria to identify variants with diﬀerence in allele frequencies between control and
infanticide pools. The percentage is calculated after the variant coordinates have been updated to the
version 11 of the genome. The numbers are similar for the same category between the capture sets.
All the variant ﬁles used to generate these graphs and tables are available in the supplementary
material attached to this thesis.
Figure 3.38: Histogram of within control pools allele frequency diﬀerence for line B and C capture set
one. X axis displays the diﬀerence in allele frequency between the control pools. Y axis:
count refer to the number of SNPs.
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Figure 3.39: Histogram of within control pools allele frequency diﬀerence for line D and H capture set
one. X axis displays the diﬀerence in allele frequency between the control pools. Y axis:
count refer to the number of SNPs.
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Figure 3.40: Histogram of within control pools allele frequency diﬀerence for line B and C capture set
2. X axis displays the diﬀerence in allele frequency between the control pools. Y axis:
count refer to the number of SNPs.
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Figure 3.41: Histogram of within control pools allele frequency diﬀerence for line D and H capture set
2. X axis displays the diﬀerence in allele frequency between the control pools. Y axis:
count refers to the number of SNPs.
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Figure 3.42: Histogram of within control pools allele frequency diﬀerence for line B and C capture set
3. X axis displays the diﬀerence in allele frequency between the control pools. Y axis:
count refer to the number of SNPs.
130
3 Results
Figure 3.43: Histogram of within control pools allele frequency diﬀerence for line D and H capture set
3. X axis displays the diﬀerence in allele frequency between the control pools. Y axis:
count refer to the number of SNPs.
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Capture set Total unique variants
Selected Percentage
(mean + 3sd) selected from total
Capture 1 30660 867 2.8%
Capture 2 26231 828 3.1%
Capture 3 48441 1932 4%
Table 3.26: Results of the mock selection of the variants on the control pools for each capture set. The
total number of variant can include variant duplicates found in several lines. Selection is
done using the mean of the allele diﬀerence for all the line in the capture set and adding 3
standard deviation of the allele diﬀerence.
Pools Unique variants
Threshold
Number of target SNPs Percentage of total
Mean + 3 sd
Capture set 1 category A 27714 0.2617 1067 3.8
Capture set 1 category B 28738 0.3692 1041 3.6
Capture set 1 category C 28046 0.3455 1175 5
Capture set 2 category A 22872 0.2773 782 3.4
Capture set 2 category B 23343 0.3564 966 4.1
Capture set 2 category C 23172 0.3760 1511 6.5
Capture set 3 category A 42855 0.2645 1307 3
Capture set 3 category B 44175 0.3878 1894 4.3
Capture set 3 category C 43327 0.3576 2068 4.7
Table 3.27: Variants after grouping into categories and target identiﬁed for each category.
Target chromosome
Overlap capture set Overlap capture set Percentage overlap
and variants selected variant target to all variants
1 1049 0 0
3 13771 160 1.16
4 2828 171 6.05
6 416 19 4.57
10 149 5 3.36
12 2482 198 7.98
13 894 4 0.45
14 890 246 27.64
15 1648 105 6.37
18 1617 58 3.59
Table 3.28: Target capture overlap summary, Capture set 1 category A. For each chromosome the
table shows: the number of variants identiﬁed within the capture intervals, the number of
selected variant in the capture intervals, and lastly the percentage of selected variants to
all variants on the chromosome.
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Target chromosome
Overlap capture set Overlap capture set Percentage overlap
and variants selected variant target to all variants
1 1087 1 0.09
3 15496 423 2.73
4 2981 284 9.53
6 467 2 0.43
10 149 0 0
12 2911 96 3.3
13 958 3 0.31
14 899 69 7.68
15 1710 49 2.87
18 1630 15 0.92
Table 3.29: Target capture overlap summary, Capture set 1 category B. For each chromosome the
table shows: the number of variants identiﬁed within the capture intervals, the number of
selected variants in the capture intervals, and lastly the percentage of selected variants to
all variant on the chromosome.
Target chromosome
Overlap capture set Overlap capture set Percentage overlap
and variants selected variant target to all variants
1 1062 0 0
3 14239 334 2.35
4 2939 49 1.67
6 431 236 54.76
10 148 1 0.68
12 2824 20 0.71
13 952 311 32.67
14 920 153 16.63
15 1679 49 2.92
18 1631 8 0.49
Table 3.30: Target capture overlap summary, Capture set 1 category C. For each chromosome the
table shows: the number of variants identiﬁed within the capture intervals, the number of
selected variants in the capture intervals, and lastly the percentage of selected variants to
all variants on the chromosome.
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Target chromosome
Overlap capture set Overlap capture set Percentage overlap
and variants selected variant target to all variants
1 5203 11 0.21
2 1079 4 0.37
3 769 0 0
4 1645 0 0
5 1244 6 0.48
6 1050 0 0
7 3553 69 1.94
8 465 57 12.26
9 1554 1 0.06
10 912 18 1.97
11 1121 28 2.5
12 792 16 2.02
13 3364 44 1.31
14 3128 9 0.29
15 1661 2 0.12
16 1141 74 6.49
17 42 0 0
18 1049 6 0.57
Table 3.31: Target capture overlap summary, Capture set 2 category A. For each chromosome the
table shows: the number of variants identiﬁed within the capture intervals, the number of
selected variants in the capture intervals, and lastly the percentage of selected variants to
all variants on the chromosome.
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Target chromosome
Overlap capture set Overlap capture set Percentage overlap
and variants selected variant target to all variants
1 3706 280 7.56
2 1164 6 0.52
3 821 113 13.76
4 860 1 0.12
5 1349 63 4.67
6 888 7 0.79
7 3975 15 0.38
8 474 4 0.84
9 13 0 0
10 969 69 7.12
11 1505 6 0.4
12 638 50 7.84
13 2483 170 6.85
14 2060 65 3.16
15 676 40 5.92
16 502 3 0.6
17 54 1 1.85
18 953 1 0.1
Table 3.32: Target capture overlap summary, Capture set 2 category B. For each chromosome the
table shows: the number of variants identiﬁed within the capture intervals, the number of
selected variants in the capture intervals, and lastly the percentage of selected variants to
all variants on the chromosome.
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Target chromosome
Overlap capture set Overlap capture set Percentage overlap
and variants selected variant target to all variants
1 3679 126 3.42
2 1160 0 0
3 818 2 0.24
4 863 0 0
5 1391 3 0.22
6 884 139 15.72
7 3870 80 2.07
8 475 22 4.63
9 12 1 8.33
10 964 51 5.29
11 1529 645 42.18
12 658 43 6.53
13 2405 300 12.47
14 1962 4 0.2
15 631 23 3.65
16 490 11 2.24
17 48 0 0
18 925 16 1.73
Table 3.33: Target capture overlap summary, Capture set 2 category C. For each chromosome the
table shows: the number of variants identiﬁed within the capture intervals, the number of
selected variants in the capture intervals, and lastly the percentage of selected variants to
all variants on the chromosome.
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Target chromosome
Overlap capture set Overlap capture set Percentage overlap
and variants selected variant target to all variants
1 4285 63 1.47
2 3851 221 5.74
3 3538 46 1.3
4 2809 156 5.55
5 1304 2 0.15
6 987 18 1.82
7 202 0 0
8 2783 121 4.35
9 5298 68 1.28
10 1763 168 9.53
11 804 59 7.34
12 908 27 2.97
13 2751 40 1.45
14 2220 5 0.23
15 2081 8 0.38
16 1327 98 7.39
17 911 53 5.82
18 1991 72 3.62
Table 3.34: Target capture overlap summary, Capture set 3 category A. For each chromosome the
table shows: the number of variants identiﬁed within the capture intervals, the number of
selected variants in the capture intervals, and lastly the percentage of selected variants to
all variants on the chromosome.
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Target chromosome
Overlap capture set Overlap capture set Percentage overlap
and variants selected variant target to all variants
1 4495 212 4.72
2 4003 165 4.12
3 3906 32 0.82
4 3057 488 15.96
5 1403 34 2.42
6 1041 1 0.1
7 219 0 0
8 2847 51 1.79
9 6325 222 3.51
10 1833 151 8.24
11 832 4 0.48
12 1063 2 0.19
13 2873 190 6.61
14 2415 9 0.37
15 2322 10 0.43
16 1419 56 3.95
17 1123 34 3.03
18 2122 157 7.4
Table 3.35: Target capture overlap summary, Capture set 3 category B. For each chromosome the
table shows: the number of variants identiﬁed within the capture intervals, the number of
selected variants in the capture intervals, and lastly the percentage of selected variants to
all variants on the chromosome.
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Target chromosome
Overlap capture set Overlap capture set Percentage overlap
and variants selected variant target to all variants
1 4319 41 0.95
2 4036 356 8.82
3 3697 209 5.65
4 2807 1 0.04
5 1193 0 0
6 988 4 0.4
7 200 0 0
8 2584 0 0
9 4944 2 0.04
10 1801 734 40.76
11 825 5 0.61
12 957 58 6.06
13 2857 157 5.5
14 2346 198 8.44
15 2153 13 0.6
16 1416 29 2.05
17 954 20 2.1
18 2128 129 6.06
Table 3.36: Target capture overlap summary, Capture set 3 category C. For each chromosome the
table shows: the number of variants identiﬁed within the capture intervals, the number of
selected variants in the capture intervals, and lastly the percentage of selected variants to
all variants on the chromosome.
3.3.3 SNP of interest
Tables 3.37 and 3.38 display the SNPs identiﬁed using the variable threshold that were identiﬁed as
missense according to the SIFT prediction. The large majority of this SNP are found on line B and
C, the two dam lines. The number of SNP identiﬁed in each capture set goes from 8 for capture set
1 to 12 and 15 for capture set 2 and 3 respectively. Two SNPs (rs332900783 and rs 81209170) were
found in common between two capture sets, capture set 2 and three for category A. The highest allele
frequency diﬀerent between the pools for these SNPs is 58.7% and the lowest 26.6%. To assess the
potential impact of the SNPs, they were checked using a manual approach (see section 2.11.4).
3.3.4 Capture set 1 examples of regions of interest.
The region of interest were selected for capture set 1 as region with a large number of SNPs present
and covering gene or region of interest. Figures 3.44 and 3.45 show two examples of regions of interest
selected for capture set 1 category B and C. The rest of the selected region are discussed in section
4.3.6 and the genomic plots provided in supplementary material.
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3.3.5 Capture 2 examples of regions of interest.
Region of interests for capture set 2 were selected in a similar fashion as for capture set 1. Figures 3.46
and 3.47 show two examples of regions of interest selected for capture set 2 category B and C. The rest
of the selected region are discussed in section 4.3.6 and the genomic plots provided in supplementary
material.
3.3.6 Capture set 3 regions of interest
Region of interests for capture set 3 were selected in a similar fashion as for capture set 1. Figures 3.48
and 3.49 show two examples of regions of interest selected for capture set 3 category B and C. The rest
of the selected region are discussed in section 4.3.6 and the genomic plots provided in supplementary
material.
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4 Discussion
The discussion focuses on the results of the diﬀerent approaches that were used for this study. The ﬁrst
part of the discussion investigates the genotyping results from the two tests, Family Based Association
Test (FBAT) and Parent of Origin (PoO), for potential targets of interest linked to the phenotype of
maternal infanticide. The second part of the discussion focuses on the sequence capture sets designed
using the genotyping results. The approach used to get the variants and annotate them is scrutinised
and the regions of interest identiﬁed are investigated for biological functions potentially linked to the
phenotype of interest.
4.1 Genotyping study
4.1.1 Genes of interest from the FBAT approach
In order to interpret the results of the FBAT analysis, SNPs showing signiﬁcance in several lines were
investigated for genes of interest in their vicinity. To investigate the function of the gene related to the
SNP, various resources were used. First, the SNPs was called up in Ensembl [152] [184] to see if it was
within a gene of interest or close to one. If no genes were found or genes of unknown functions were
present, the genomic comparison tool available was used to investigate whether there was a known
gene at the corresponding location in the human or mouse genome. If so, it is likely that the region
in the pig covers the same gene. Once the gene was identiﬁed, the gene symbol was used to query
gene cards [177, 178] and the NCBI gene database [185] in order to learn more about its function. The
most interesting regions are summarised in table 4.1. Note that all SNPs that were above our ﬁltering
threshold (see section 3.1.5), were used to design the sequence capture panel.
Some of the SNPs identiﬁed by the FBAT test did reach genome wide signiﬁcance and are in regions
with genes linked to brain function. Some of these SNPs reach genome wide signiﬁcance in several
lines, such as SNPs on chromosome 2, 3, 10 and 18.
On chromosome 2, one SNP, rs81329722, reached genome wide signiﬁcance in all the lines. It is an
intron variant of the gene NAV2 (neuron navigator 2). This gene plays a role in cellular growth and mi-
gration. It is also expressed in the brain in human and mouse, has been linked to age onset Alzheimer's
disease in human [186], cranial nerve development in mouse [187] and in the cerebellar development
and neurological disease called ataxia [188]. Ataxia is characterised by a lack of coordination in muscle
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movement.
The SNP on chromosome 3, rs80784123, reached genome wide signiﬁcance on both lines D and H.
It is intronic to the gene TTL which stands for tubulin tyrosine ligase. It is expressed in the brain
in both human and mouse and has been linked to several psychological disorders in human, such as
conduct disorder, suicide and alcohol dependency [189].
On chromosome 10, the SNP of interest, rs81325586, reached genome wide signiﬁcance in all lines.
It is an intronic SNP located in the PARP1 gene. This gene codes for a chromatin associated enzyme
which modiﬁes nuclear protein by poly-ADP-ribosylation. It is involved in cell proliferation, cell
diﬀerentiation and the repair of damaged DNA. It is expressed in the brain of the human and mouse.
Interestingly in the mouse it has been linked to neuron healing [190], long term memory [191]. It is
also involved in human in neurodegeneration, Alzheimer's and Parkinson's diseases [192, 193]. This
gene has a key role in the function of neurons and their health.
The last two SNPs to reach genome wide signiﬁcance in all of the lines are located on chromosome
18, rs81266760 and rs81308090. The ﬁrst SNP is not located in a gene but is downstream of SEPT7,
septin 7. There is not a clear function for the protein produced but it contains a GTP binding motif. It
is expressed in the brain in both human and mouse. This gene has been linked to the CDC42 signalling
pathway which is involved in the pathology of schizophrenia and Alzheimer's disease. [194, 195]. The
second SNP to reach genome wide signiﬁcance on chromosome 18 is located in an intron of the gene
BMPER, which stands for BMP binding endothelial regulator. Again the gene is expressed in the brain
in mouse and human. A GWAS in human has linked this gene to Alzheimer's disease [196].
Two other chromosomes have results linked to interesting genes, chromosomes 1 and 15. Although
the SNPs did not reach genome wide signiﬁcance, they passed our ﬁltering threshold in more than one
line.
For chromosome 1, two SNPs are signiﬁcant in two lines, lines D and H. The ﬁrst SNP, rs80904152,
is an intronic variant in the gene TRPM3 which is expressed in the brain in human and mouse. The
protein produced by this gene is a transient receptor potential channel which is cation-selective and
functions to mediate calcium entry into the cells. Interestingly it is regulated by progesterone [197],
which might indicate a role in pregnancy and potentially during labour and birth. As discussed in the
previous studies section 1.4.2, progesterone blockade during late pregnancy leads to abhorrent maternal
behaviours, including infanticide [58]. Furthermore, increases in levels of progesterone and oestrogen
have been linked to increased levels of aggression in the pig [9]. The second SNP, rs319558321, is also
signiﬁcant for both lines D and H: it reaches genome wide signiﬁcance for line H. This SNP is in the
TTLL11 gene (tubulin tyrosine ligase like 11). It is expressed in the brain and codes for an enzyme.
Variants in this gene have been reported to inﬂuence intelligence and cognition [198, 199].
On chromosome 15, the SNP of interest, rs81278062, is an upstream variant near the gene LRP1B
and passes our threshold for lines D and H. It codes for a low density lypoprotein receptor, which
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is expressed in the brain in human and mouse. This gene has been shown to be associated with
Alzheimer's disease in Caribbean Hispanic individuals [200] and is also involved in cognitive decline in
ageing [201].
Interestingly most of the SNPs that are found in only two lines are found in lines D and H, the lines
that have the highest incidence of infanticide of the four studied.
Unfortunately none of the variants listed has any coding consequence on the gene in which they are
located in or close to. While this is disappointing, it is important to keep in mind that the genome
annotation of the pig is not as good as the human and mouse. These annotations are the results
of an automated annotation pipeline (see section 1.7 and 4.2.5). Often the pig genome has an un-
characterised gene at a SNP location, but when comparing the region with the human and mouse
genome, it becomes clear what that gene might be. As long as the pig genome is not well curated
it will be diﬃcult to assess the impact variants will have on it. It can be expected that the SNP
consequences might also be inaccurately predicted due to the state of the gene annotations on the pig
genome. Furthermore, the selection of SNPs for the construction of the array was not done to select
SNPs that are in genes but markers that will help type LD blocks, also called tag SNPs. As such
it is expected that a lot of markers will not map in genes. The sequence capture set was designed to
target gene regions close to our candidate SNPs.
Finally, caution is required when drawing conclusions from this set of results as our threshold for
selection is below the accepted genome wide signiﬁcance. Despite this, there is a subset of SNPs
reaching genome wide signiﬁcance in several lines, and some of these genes have interesting functions
and have been associated with pathology in the brain. This results were investigated further using
another technology, sequence capture. The selection of the regions and the sequencing process is
detailed in sections 2.8, 2.9.1 and 2.10.
4.1.2 Parent of origin genes and region of interest
The annotation method for these results is the same as used for the FBAT results (see section 4.1.1).
A summary of some of the SNPs and regions of interest is given in table 4.2. Some of the SNPs
are common to the ones found in the FBAT analysis, including those that reached genome wide
signiﬁcance in the FBAT study. The SNP on chromosome 3, intronic to the gene TTL reached genome
wide signiﬁcance for the FBAT test. For the PO test, it was found to pass our threshold on the
same tow lines: D and H. As discussed in section 4.1.1, this gene is involved in several psychological
pathologies such as conduct disorder, suicide and alcohol dependency [189]. Two more SNPs also
reached genome wide signiﬁcance in the FBAT analysis and passed our threshold in the PO analysis.
They map to chromosome 7 and chromosome 18. The ﬁrst SNP, rs80949107, is an intergenic variant
located downstream of the NRN1 gene (neuritin 1). It encodes a member of the neuritin family which
is expressed in diﬀerentiating neurons during the development of the central nervous system. It is
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expressed in the brain in human and mouse. GWAS studies have identiﬁed various variants in this
gene relating to schizophrenia, cognitive function [202, 203] and bipolar disorder [204]. The second
SNP on chromosome 18, rs81233198, is also intergenic. It is located upstream of the gene PTPRZ1,
which is exclusively expressed in the brain and encodes a member of the receptor protein tyrosine
phosphatase family. It might be involved in the regulation of speciﬁc developmental processes in the
central nervous system. Interestingly this gene has been linked to schizophrenia in human [205].
Some other SNPs are in common with the FBAT results but did not reach genome wide signiﬁcance.
There is one SNP, rs80904152, in common on chromosome 1 and mapping in the gene TRPM3. Another
SNP, rs343881480, is in the same region and passed our threshold, but was not signiﬁcant in the FBAT
analysis. This SNP is intergenic according to its position in the pig genome but comparisons with
the human and mouse genomes put it in the TRPM3 gene, as well. As discussed before (see section
4.1.1), TRPM3 is not well characterised but it is regulated by progesterone which means it could be
involved in pregnancy and birth [197] and progesterone levels and has been linked to infanticide [58]
and aggression in the pig [9]. Another SNP that is signiﬁcant in the FBAT results and passed our
threshold for the PO, rs81278062, is located on chromosome 15 and in the LRP1B gene. As discussed
in the section about the FBAT results (4.1.1), this gene has been shown to be linked to Alzheimer
Disease and cognitive decline in ageing [200, 201].
Other SNPs are speciﬁc to the PO analysis and map onto or are close to interesting genes. Two
SNPs on chromosome 3, rs81373475 and rs81374014, are very close to each other and are intron variants
of the gene AUTS2. This gene has been linked to neurodevelopment and is expressed in the brain in
human and mouse. It has been linked by association to schizophrenia [206], and exonic deletions in this
gene resulted in developmental delay and intellectual disability in Chinese patients [207]. In the mouse,
it has correlated with impaired emotional control and cognitive memory [208], and has been shown to
be expressed in regions of the brain involved in autism [209]. Another interesting SNP, rs81334603, is
found on chromosome 6 also passed our threshold for the FBAT analysis, but did not reach genome
wide signiﬁcance. It is an intergenic variant close to the KCNQ4 gene, which encodes for a potassium
channel which plays a critical role in neuronal excitability. It is expressed in the brain in human and
mouse and has been linked to depression like behaviour in mice [210]. A ﬁnal SNP, rs80833324, is
returned in both the FBAT and PO analyses is located on chromosome 7 and is an upstream variant
of the gene PLEKHG3. This gene is not well characterised but it is expressed in the brain in both
human and mouse, it also a candidate gene for autism risk [211]. Two other interesting SNPs that
passed the threshold only for the PO analysis are found on chromosome 16 and are relatively close
to each other, rs81461904 and rs81306856. The ﬁrst one is an intron variant of the MFAP3 gene,
which is expressed in the brain but very little is known about its function. The second SNP is also an
intron variant but of the gene GRIA1, which encodes for a glutamate receptor. These receptors are
the predominant excitatory neurotransmitter receptors in the mammalian brain. It is expressed in the
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brain for both human and mouse. Several studies have linked this gene to depression and schizophrenia.
One study in a Korean population [212] has found that this gene was associated with a susceptibility to
schizophrenia. Another study [213] looked at the linkage of this gene in families with patients suﬀering
from bipolar disorder. Several SNPs were linked in these families to GRA1 suggesting a potential
inﬂuence of this gene on the disease.
Overall the PO analysis did conﬁrm ﬁve of our candidates discovered with the FBAT analysis. Six
other interesting SNPs were also identiﬁed, which is not surprising given that the analysis method is
diﬀerent from the FBAT approach. However given the relatively lax threshold, these results need to be
conﬁrmed. This will be done by sequencing of the region of interest using sequence capture as detailed
in sections 2.8, 2.9.1 and 2.10.
SNP id CHR SSC10 Map Coordinate T.U_MAT CHISQ_MAT P_MAT line SNP type Gene
rs80904152 1 250,323,029 00:22 22 2.73E-06 H Intron variant TRPM3
rs343881480 1 250,635,066 00:11 11 0.0009111 B Intergenic variant TRPM3
rs81373475 3 14,134,797 10:00 10 0.001565 H Intron variant AUTS2
rs81374014 3 14,332,984 11:00 11 0.0009111 C Intron variant AUTS2
rs80784123 3 45,593,990 1.5:23.5 19.36 1.08E-05 D Intron variant TTL
rs80784123 3 45,593,990 03:24 16.33 5.31E-05 H Intron variant TTL
rs81334603 6 157,353,343 00:21 21 4.59E-06 H Intergenic variant KCQN4
rs80949107 7 3,813,663 1.5:12.5 10.08 0.001496 D Intergenic variant NRN1
rs80833324 7 95,143,760 3.5:31.5 22.4 2.21E-06 H Upstream gene variant PLEKHG3
rs81278062 15 11,904,651 00:16 16 6.33E-05 D Upstream gene variant LRP1B
rs81278062 15 11,904,651 02:26 20.57 5.75E-06 H Upstream gene variant LRP1B
rs81461904 16 75,024,639 15:02 9.941 0.001616 D Intron variant MFAP3
rs81306856 16 75,201,733 1.5:13.5 9.6 0.001946 H Intron variant GRIA1
rs81233198 18 26,878,437 00:11 11 0.0009111 D Intergenic variant PTPRZ1
Table 4.2: Parent of origin regions of interest. CHR is the pig chromosome for the SNP, T.U_MAT
is transmitted over untransmitted allele, CHISQ_MAT is the Chi squared score for the
transmission of this allele and P_MAT is the associated p-value.
4.2 Sequence capture data
In this section, the quality and quantity of the sequencing data generated will be scrutinized and
discussed. The eﬃciency of the capture set will be assessed and the latest release of the pig genome
will be discussed within the context of this study.
4.2.1 Selection of the animals
The animal selection proved to be challenging for several reasons. First, the large number of animals
available for selection in each line meant that manual selection using the information from the pedigree
ﬁles would be very long and diﬃcult. The initial approach was to write a script in order to select
families with certain criteria but the lack of visualisation proved problematic. It was diﬃcult to see the
relationship between animals due to the complexity of some of the pedigrees. What was needed was a
way of plotting the various pedigrees. Most pedigree software are relatively simple and will not allow
plotting of more than a single parameter linked to individual family members. Another problem was
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due to the fact that some sires were shared between families, which posed diﬃculties for some of the
software packages. After some research Madeline 2.0 [173] was identiﬁed as it could plot the families in
the way needed. It allowed plotting of several parameters for each animal. Once plotted, each family
had to be curated manually for individuals matching our selection criteria, see section 2.9.1. This was
a lengthy process but made easier as all the information was present on the pedigree plots.
4.2.2 Read quality and pre-mapping trimming
For all three capture sets the quality of the reads is very high (ﬁgure 3.18), most reads having an
average quality score above Q30 on both sequenced reads. The quality for read two can often be lower
than the read quality for read one, but for this data set it is very similar: read two quality is slightly
lower but the diﬀerence is marginal (see ﬁgure 3.19). Furthermore the sequencing length does not
appear to have an impact on the read quality. Despite using a longer sequencing length of 100 base
pairs (bp), compared to the standard 75bp, the extra 25bp do not have a large impact on the data
quality.
An usual, pre-processing, the step prior to read mapping is to perform read trimming, which removes
any remaining adapter sequences and will trim low quality bases from the ends of the reads. This step
is usually necessary to avoid adapter sequences interfering with the mapping, or low quality bases
compromising the mapping of the reads to the reference genome. The biggest impact of non trimmed
reads is on the mapping eﬃciency which tends to drop due to the presence of adapter sequences
and/or low quality bases in the read. However there is also a risk of trimming bases that are partially
matching the adapters. By default most trimming software will remove a single matching base from
the end of the read. Therefore a potential loss of information is possible. Quality trimming can be
beneﬁcial for the mapping, especially when the quality score drops towards the end the read, which
can cause mismatches when erroneous bases are called. Our data is of very good quality, only a small
proportion of reads have their quality score dropping below Q20 towards the end of the reads, and this
holds for both read 1 and read 2 (See ﬁgure 3.19). The small drop in quality is not high enough to
justify trimming. This avoids the removal of accurate bases that have been called with a lower quality
score. Given the depth of reads obtained and the relatively small regions targetted, the coverage (see
section 4.2.4) is high enough to compensate for the slight drop in quality towards the end of the reads.
Furthermore, low quality score alignments are assessed when variants are called. Poor quality mapping
should not result in miss-called variants in the set. Another potential issue caused by low quality bases
is a drop in read complexity which might result in reads mapping to multiple locations in the genome.
Read complexity represents the diversity of the bases making up the read, a longer read being more
diverse than a smaller one. By trimming the low quality bases, a read can become small enough to
map to multiple sites in the genome. Erroneous base calls can have a similar eﬀect depending on the
mapping quality. The read length (also called sequencing length) of 100bp should help alleviate some
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of these issues as the reads will be inherently more complex than 75bp reads. Therefore it should be
easier to avoid the multiple mapping issue. Finally, the user guide for picard tools, which is used to
prepare the aligned reads for GATK, advises not to trim reads because low quality bases are useful to
the base quality score recalibration. It was decided to skip the trimming step prior to the mapping of
the read on the reference genome for this project.
4.2.3 Sequence mapping
The mapping of the read sequences to the reference genome was the longest computing step of the
whole analysis, a total of 60 pools needed to be mapped using a single node. It took several weeks to
map all the samples as only three or four samples (pools) could be mapped in parallel.
4.2.3.1 Mapping eﬃciency
The mapping eﬃciency is high. For reads passing the Illumina ﬁlter (also known as a chastity ﬁlter),
we have a 97 to 98% average of aligned reads. The chastity of a cluster is deﬁned by the ratio between
the brightest base and the sum of the brightest and the second brightest bases intensity. Clusters pass
the ﬁlter if this ratio is not below 0.6 for more than 1 base during the ﬁrst 25 cycles [214]. Reads
(clusters) removed by this ﬁlter are usually ambiguous. This might be caused by two clusters merging
together, and therefore emitting mixed signals as two fragments or more are sequenced at the same
time. Overall the percentage of reads aligned is higher than we would have obtained from a whole
genome approach, for which the mapping eﬃciency is typically around 70 to 80% [215]. The eﬃciency
for whole genome mapping is lower because more ambiguous reads are present: regions with repeats
or low complexity regions result in reads being discarded because they map at several locations. Due
to the short size of reads it is not possible to resolve their placement within repeated regions. Whole
genome mapping uses a masked genome to avoid regions with repeat sequences. Therefore, reads from
these regions will be ignored and fall into the category of unmapped reads. If the unmasked genome
is used, the reads originating from repeat regions will map to several locations in the genome, or if
the repeat structure is unknown, stack in a speciﬁc location. In either case, the reads cannot be used.
In the former case the reads are discarded, in the later case the majority of them will be ﬁltered out
during deduplication. One of the beneﬁts of using sequence capture is its selective nature and the way
the capture sets are designed (repeats are usually masked for the design). The sequences captured are
usually speciﬁc to the regions they target and therefore result in a better mapping eﬃciency.
4.2.3.2 Read numbers
Another important aspect is the number of reads obtained which will impact on the depth of coverage
of the target regions. The number of reads obtained for each of the pools and each of the capture
sets is high and should result in high coverage given the size of the regions targetted. The minimum
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number of reads passing the ﬁlter and were mapped for all capture sets and all pools is for capture set
3, line D, pool 3 with 35.7 million reads. The highest number of reads mapped is for capture 1, line
C pool 1 with 152.6 million reads. The average number of mapped reads is 81.6 million for capture
set 1, 72.4 million for capture set 2 and 64 million for capture set 3. The range of values for the
number of mapped reads is large, from 35 million to 152 million, and correlate with the number of raw
reads. This repartition is the consequence of the pooling of the libraries. Each of the sample (pool)
libraries was prepared individually and pooled together before sequencing. To get a good balance of
the individual libraries in the ﬁnal pool, each library needs to be accurately quantiﬁed. Unfortunately
most methods have a degree of uncertainty, therefore the pool of libraries is never perfectly balanced.
If several sequencing runs of the same library are planned, the pooling can be adjusted between the
runs, but this was not the case for our set of libraries. A lower number of reads mapped will result
in a lower coverage of the regions targetted. However despite some of the pools having signiﬁcantly
fewer reads mapped, the coverage remains high because the regions targetted are small in relation to
the number of bases covering them (see discussion in section 4.2.4).
4.2.3.3 Duplication levels
Duplication can be a problem when calling variants as it leads to biases in allele representation or
the calling of erroneous variants. If a read with a replication error from a PCR duplication gets
over-represented during the sequencing and this is not addressed, it could pass as a genuine variant.
Duplicate reads can also bias the allele frequency estimation, so it is necessary to remove them. Du-
plicate reads are reads for which the starting mapping coordinates are identical, therefore they are
believed to come from the same library fragment. The duplication levels in our data set are large:
between 30% to 60% of reads are duplicate reads. This amounts to a large loss of information and
could be problematic. However these high levels of duplication are caused by two combined factors.
The ﬁrst one is that the capture targets only cover a very small part of the genome: the combined
size of the sequences captured for each capture set is quite small, between 7.5MB and 13MB. The
second factor is that the number of reads obtained for each pool is large, as discussed in the previous
section. Combining these two factors, it is expected that a large number of reads will be covering the
same fragment several times. However, it is still expected that a high coverage will be achieved after
deduplication. Even for the pool with the smallest number of reads, Capture set 3, line D, pool 3
at 35.7 millions reads, with only 60% of reads left after deduplication, more than 21.4 million unique
reads remain to cover a capture size of 13MB. Given that the reads are paired end 100bp, this amounts
to a total of almost 4.3GB to cover 13MB, giving around 330 folds (X) coverage for the bases in the
region. Thus, the depth of coverage can be expected to be very high for the captured region, which
will improve conﬁdence in the variants detected.
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4.2.4 Sequence capture set: capture eﬃciency and coverage
Our sequence capture sets were design using three diﬀerent sources, the ﬁrst capture set, capture set
1, was designed using candidates region found by Quilter et al [2]. The second capture set, capture
set 2, was designed using the FBAT results presented in this work. Finally, the last capture set,
capture set 3, was constructed using the PO results also presented in this work. The number of
probes per chromosome will vary widely between the diﬀerent capture sets due to the total number
of regions of interest identiﬁed .Capture set 1 has a large number of probes on chromosome 3, one
of the target regions is important as it is syntenic to a region on the human chromosome 16, which
has been shown to be related to puerperal psychosis [90]. Of the 11426 probes in this capture set,
7094 are targetting regions on chromosome 3, representing 62% of the total number of probes. The
probes on chromosome 3 are divided across several regions, the biggest targetting the region between
26MB to 30MB, a region in which a lot of potential target genes were identiﬁed in [2]. Further along
chromosome 3, a smaller region is targetted at around 35MB. It covers RBFOX1. Two more regions
further down the chromosome are located at 100Mb and 131MB. Chromosome 1 is the second largest
target, represented by 1226 probes covering intervals at 17MB, 65MB, 74MB. The other chromosomes
selected (4, 6, 10, 12, 13, 14, 15 and 18) have a much lower number of probes and regions targetted,
varying from 31 to 713 probes with an average of 388 per chromosomes. For capture set 2 a total of
8456 probes target the regions of interest. The largest number of probes was found on chromosome
1 and chromosome 7 with 2166 and 1476 probes representing 26% and 17.4% of the total number
of probes, the other chromosomes (2,3,4,5,6,8,9,10,11,12,13,14,15,16,17,18,X) have between 3 and 832
probes with an average of 283 probes per chromosome. The last capture set, capture set 3, is probably
the most balanced in regards to the number of probes per chromosome with a total of 6636 probes.
Two chromosomes are more represented that the others, they are chromosomes 1 and 9 with 981 and
935 probes each, representing 15% and 14% of the total number of probes. The other chromosomes
vary between 677 and 81 probes with an average of 295 probes.
The total number of probes decreases with each capture set from 11426 to 6636. Despite the decrease
in the number of probes, the size of the targetted regions increased with each capture set. For capture
set 1, the size of the probes varies between 200-300bp to up to 2000-3000bp with the interquartile range
covering 200 to 600bp (ﬁgure 2.2). For capture set 2 (ﬁgure 2.4) the range of sizes covered is similar but
the interquartile range is shifted upwards, toward 700bp. For capture set 3 the trend continues with
the the interquartile range spreading from 300bp to 1000bp. Therefore despite having signiﬁcantly less
probes than capture set 1, capture set 2 and 3 can select larger intervals of the genome.
Interestingly capture set 1 also has the lowest eﬃciency of capture compare to the other two sets.
The fraction of reads covering the targetted regions (table 3.22) is between 43% and 58%, while for
capture set 2 the values range between is 55% and 69% (table 3.23). Finally, capture set 3 (table 3.24)
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is the best performer, as the fraction of reads covering targets ranges between 69% and 72%. This
is a much narrower range than the other capture sets. One possible explanation is that the protocol
became more familiar for the operator, and therefore the eﬃciency increased. All the capture library
work was carried out by the same person, Kerry Harvey. However the fact that the probes are longer
for capture sets 2 and 3, along with the increase in capture eﬃciency points towards a better probe
design, resulting in a better eﬃciency of capture. As the design of the diﬀerent capture sets were
separated by signiﬁcant amounts of time, typically several months, it is likely that the technology
provider improved their pipeline for probe design and eﬃciency.
The reads not covering the regions of interest were discarded for this analysis. Their origins could
be multiple. They could arise through some oﬀ target selections. In eﬀect the baits can capture a
sequence with a partial match that maps to another location of the genome. There is also a strong
possibility that contamination from genomic DNA, DNA from other regions could pass through the
selection step, and therefore be ampliﬁed and sequenced, resulting in the observed oﬀ target eﬀects.
Finally some target regions have genes in them and the baits could be capturing sequences from loci
of families members present in diﬀerent locations on the genome.
The eﬃciency of capture for capture set 1 could be problematic for downstream analysis as a large
number of reads are lost as they do not cover the target regions. However after checking the coverage
distribution for the fraction of reads covering the probes (see ﬁgures 3.29, 3.30 and 3.31), capture set
1 has the best depth of coverage of all three sets with up to 3500X coverage and a peak at 1500X.
Capture 2 and 3 go up to maximum 2000X and 1400X coverage respectively, and have peaks occur at
a 100X and 700X. All three capture sets achieve at least 20X for almost all of the target bases. The
normalised coverage plots (ﬁgures 3.32, 3.33 and 3.34) show that the coverage is uniform, and that
at least 80% of the data is covered by more that the average coverage value for each of the sets: i.e.
almost all of the targetted regions have very good coverage.
In conclusion, all of the capture sets perform well and achieve relatively good capture eﬃciency.
Thanks to the small combined sizes of the regions targetted, very deep coverage of these regions is
achieved ,which makes variant calling more accurate. It will also help ensure that the alleles coming
from the animals in the diﬀerent pools will be well represented providing better estimates of the allele
frequency for the population the pool represents.
4.2.5 Sus scrofa genome release 11
During the course of this work a new version of the pig genome (11) was released by Swine Genome
Consortium [150]. This new assembly of the genome highly improved on the one used for the majority
of the work in this thesis. To produce this new assembly long reads were used. The sequencing was
done using the Paciﬁc Bioscience (PacBio) single-molecule real-time (SMRT) sequencing which allows
for very long reads (over 10 kilo bases (kb) on average with a maximum of 60kb and with a N50 of
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more than 20kb) but at the price of a higher error rate (11% to 15%), although this can be moderated
by several passes of the same molecule. [216].
The resulting genome is a much better assembly than the previous one (see section 1.7). With 65X
coverage, it consists of 20 chromosomes and 583 unplaced scaﬀolds whereas the previous assembly had
almost 8 times more unplaced scaﬀolds, 4562. The total number of base pairs and the golden path
length are both lower at 2,478,44,698bp and 2,501,912,388bp. Given the long reads the assembly should
produce a lower number of contigs and scaﬀolds, and both should be longer in size. The number of
scaﬀolds drops by more than ten fold from 9906 to 706. The scaﬀolds N50 is greatly improved from
576,008bp to 88,231,837bp. The L50 is reduced from 1,303 to 9 scaﬀolds. Therefore a smaller number
of scaﬀolds covers larger regions of the genome which improves the accuracy of the genome build. The
number of gaps between scaﬀolds is greatly reduced from 5323 to 93 and the total gap length is also
reduced. For 10.2 the gaps length was 289,373,899bp and for 11.1 it is 29,864,64bp, almost a 10 folds
diﬀerence. The release 11 of the pig genome is therefore less patchy, with fewer uncertain or uncovered
areas. Regarding contigs, their numbers between the two releases dropped immensely from 243,021
to 1,118, with the N50 increased from 69,503bp to 48,231,277bp and the L50 dropped from 8,632 to
15 contigs. The contigs forming the scaﬀolds are much larger and the statistics reﬂect that. The use
of a technology with longer read produced more continuous scaﬀolds and contigs as reﬂected by the
increase in the N50 and the decrease in the L50.
The number of annotated genes is also slightly higher in this build with 22,452 coding genes, 3,250 non
coding genes, 178 pseudo-genes and a total of 49,448 transcripts. The annotation pipeline is similar
to the one described in section 1.7 but with more sequences coming from various RNA sequencing
(RNASeq) data and additional long reads from the PacBio system. The increase in the number of
genes identiﬁed is modest, less than a thousand, but the increase in the number of transcripts is large,
with almost twenty thousand more transcripts identiﬁed.
This latest release of the pig genome is a great improvement on the previous build and is a much
more detailed and accurate representation. Two individuals were used to produce this build, the same
Duroc as for build 10.2 but also a Duroc/Landrace/Yorkshire cross. This is an improvement but we
can still expect some discrepancies when aligning other breeds to this genome, one of the lines used in
this thesis is a Large White. The variant annotations might also still not be accurate for other breeds.
The next release will hopefully incorporate more breed data, making work on animals from a diﬀerent
origin easier and providing a better reference for researchers.
Unfortunately for our study, the new release happened quite late in the project. Repeating the
alignment steps and variant calling at this stage would have taken months, time that was unfortunately
not available. Despite this drawback, the new release was still useful, as the variant locations and
annotations were updated to the latest build and used to look in more details at some of the regions
identiﬁed. Given that most of the variants identiﬁed by our sequencing studies are known variants,
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updating their coordinates will help reﬁne the results and pinpoint the genes these variants might
inﬂuence.
The capture set probe coordinates were also updated to the latest version, in order to check the
impact of the new build on the regions targetted and the genes of interest. Genomic regions were
plotted for the targetted regions designed from the release 10.2 against the corresponding chromosome
segments from 11 and against the syntenic region from the human (details of the annotation pipeline
is given in section 2.11.3 of the material and methods). Figure 4.1 show an example of one region of
particular interest, the RBFOX1 region, on the three genomes used for annotation, Sus scrofa 10.2 (SS
10.2), Sus scrofa 11 (SS 11) and Human 38 (HG38). The coordinates of the regions between SS 10.2
and SS 11 are shifted by 1MB but on SS 11 we can see that the gene of interest (RBFOX1 ) is covered
partially while the locus registered on SS 10.2 is uncharacterised. This uncharacterised gene could be
RBFOX1 as a search for this gene in the 10.2 build does not return any hits, but the comparison with
the syntenic human genome region shows RBFOX1 in that region. This highlight another issue with
the annotation of the pig genome. Being mostly automated, with no manual curation, the annotation
might not always be accurate. For example in ﬁgure 4.1 we can see that RBFOX1 is a large gene in
human HG38 whereas it is relatively small in SS 11. Given that the human and the pig genome are
very close genetically [217] and that the annotations used to highlight the corresponding human region
rely on synteny and alignment between the two genomes, it is likely that the gene structure will be
similar. In conclusion, the pig annotations might not be very accurate, but using the corresponding
human region might give us more insight about the structure of a gene of interest.
Ideally the best outcome would have been to remap all the samples to the new build of the genome.
This would be especially true for a diﬀerent sequencing approach than sequence capture. For a whole
genome approach it would have been essential to remap all the reads, as a lot of unmapped reads might
be aligned to the new build. For a targetted approach, remapping of all the reads is not a necessity.
If the reads mapped successfully based on the capture design of SS 10.2, it means that the design is
sound as the sequences were successfully captured and therefore the design would still be valid in SS
11. If a target probe or region has no reads mapping to it, the design based on SS 10.2 was probably
not accurate. Another round of design for these regions based on the new build might improve their
capture. In order to assess this in more detail, the coverage of individual probes was investigated for
all the capture sets and pools. Tables 4.3, 4.4, 4.5 and 4.6 display the fraction of probes for diﬀerent
percentages of probe length covered. The percentage of lengths covered are 0% , below 30%, below
50%, below 90% and above 90%. All of the capture sets have at least 98% of their probes where at least
90% of the probe length is covered by one read. In addition, the average coverage, median coverage
and minimum coverage for the probes covered for at least 90% of their length is also displayed. The
average and median coverage are very high for all capture sets. The minimum coverage can drop very
low (3 reads) but given the median values (always above a 1000 reads), it is safe to assume that the
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coverage of this set of probes is very high. Therefore it is not necessary to remap to version 11 of
the genome, most of our capture regions should be well covered. The only problematic issue is if the
annotation shifts signiﬁcantly, the captured region might not match close to our genes of interest any
more. In this case the only solution would be to redesign the capture set using the new version of the
genome.
Figure 4.1: Example of capture set probe region with position in three diﬀerent genomes from bottom
to top: Sus scrofa release 10.2, Sus scrofa release 11 and Human release 38. Note that the
gene is ﬂipped in the pig compared to the human (red arrow).
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Pools 0 coverage below 30% below 50% below 90% above 90%
average coverage median coverage min coverage
above 90% above 90% above 90%
Line B pool 1 capture 1 0.13 0.19 0.27 0.57 99.42 6064.49 2769 7
Line B pool 2 capture 1 0.11 0.18 0.25 0.65 99.35 4563.69 2086 7
Line B pool 3 capture 1 0.10 0.16 0.22 0.56 99.44 3794.39 1741 3
Line B pool 4 capture 1 0.11 0.17 0.23 0.59 99.38 5800.68 2646 14
Line B pool 1 capture 2 0.25 0.37 0.52 1.48 98.50 5813.97 3651 7
Line B pool 2 capture 2 0.21 0.35 0.46 1.18 98.81 5272.58 3306 8
Line B pool 3 capture 2 0.20 0.31 0.41 0.88 99.11 4959.85 3135 9
Line B pool 4 capture 2 0.19 0.30 0.38 0.86 99.14 6370.22 3959 7
Line B pool 1 capture 3 0.21 0.24 0.29 0.56 99.44 5982.64 3446 7
Line B pool 2 capture 3 0.18 0.21 0.26 0.45 99.53 9356.78 5380 20
Line B pool 3 capture 3 0.20 0.23 0.27 0.51 99.49 3883.66 2232 12
Line B pool 4 capture 3 0.18 0.21 0.26 0.50 99.49 6242.23 3517 11
Table 4.3: Line B probe coverage for all capture sets. Each column displays the percentage of coverage
of the probes, the percentage of the probe's sequence covered by at least one read. The
average, median and minimum coverage for probe at least 90% covered is also displayed.
For line B all the capture set have at least 98% of the probes covered at more than 90%
Pools 0 coverage below 30% below 50% below 90% above 90%
average coverage median coverage min coverage
above 90% above 90% above 90%
Line C pool 1 capture 1 0.11 0.18 0.26 0.66 99.34 6185.72 2826 9
Line C pool 2 capture 1 0.12 0.18 0.26 0.73 99.26 3388.50 1567 4
Line C pool 3 capture 1 0.10 0.17 0.25 0.67 99.32 3407.91 1551 5
Line C pool 4 capture 1 0.13 0.18 0.26 0.57 99.43 4180.06 1937 4
Line C pool 1 capture 2 0.22 0.34 0.45 1.17 98.82 4753.66 2953 7
Line C pool 2 capture 2 0.21 0.38 0.50 1.27 98.73 5480.80 3440 8
Line C pool 3 capture 2 0.26 0.35 0.48 1.15 98.85 5168.04 3196 4
Line C pool 4 capture 2 0.20 0.37 0.45 1.10 98.89 5316.06 3301 5
Line C pool 1 capture 3 0.18 0.21 0.24 0.47 99.52 9956.60 5659 21
Line C pool 2 capture 3 0.21 0.24 0.29 0.59 99.41 6436.54 3662 10
Line C pool 3 capture 3 0.20 0.21 0.24 0.44 99.55 7993.41 4592 12
Line C pool 4 capture 3 0.17 0.21 0.24 0.45 99.53 7056.89 4000 6
Table 4.4: Line C probe coverage for all capture sets. Each column displays the percentage of coverage
of the probes, the percentage of the probe's sequence covered by at least one read. The
average, median and minimum coverage for probe at least 90% covered is also displayed.
For line C all the capture set have at least 98% of the probes covered at more than 90%.
Pools 0 coverage below 30% below 50% below 90% above 90%
average coverage median coverage min coverage
above 90% above 90% above 90%
Line D pool 1 capture 1 0.13 0.20 0.27 0.60 99.39 1933.59 892 2
Line D pool 2 capture 1 0.14 0.18 0.27 0.60 99.40 2456.37 1111 3
Line D pool 3 capture 1 0.10 0.15 0.21 0.55 99.44 2849.38 1308 6
Line D pool 4 capture 1 0.11 0.14 0.23 0.56 99.44 3089.87 1419 3
Line D pool 5 capture 1 0.10 0.18 0.25 0.60 99.39 2776.64 1253 5
Line D pool 6 capture 1 0.10 0.16 0.23 0.55 99.44 2600.52 1198 5
Line D pool 1 capture 2 0.17 0.26 0.38 0.84 99.15 5298.53 3342 12
Line D pool 2 capture 2 0.21 0.30 0.37 0.89 99.11 6306.72 3997 12
Line D pool 3 capture 2 0.18 0.27 0.38 0.86 99.12 5701.80 3599 7
Line D pool 4 capture 2 0.20 0.30 0.38 0.91 99.08 8411.30 5217 9
Line D pool 5 capture 2 0.19 0.32 0.40 0.91 99.08 5502.87 3452 6
Line D pool 6 capture 2 0.20 0.28 0.35 0.85 99.12 5714.27 3631 10
Line D pool 1 capture 3 0.20 0.21 0.27 0.47 99.53 9346.25 5361 10
Line D pool 2 capture 3 0.20 0.24 0.29 0.53 99.46 6898.77 3964 23
Line D pool 3 capture 3 0.20 0.23 0.29 0.51 99.49 5852.13 3327 6
Line D pool 4 capture 3 0.20 0.23 0.27 0.50 99.50 6141.30 3545 2
Line D pool 5 capture 3 0.21 0.23 0.27 0.47 99.53 7335.80 4137 12
Line D pool 6 capture 3 0.18 0.23 0.29 0.51 99.49 5769.24 3239 8
Table 4.5: Line D probe coverage for all capture sets. Each column displays the percentage of coverage
of the probes, the percentage of the probe's sequence covered by at least one read. The
average, median and minimum coverage for probe at least 90% covered is also displayed.
For line D all the capture set have at least 98% of the probes covered at more than 90%.
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Pools 0 coverage below 30% below 50% below 90% above 90%
average coverage median coverage min coverage
above 90% above 90% above 90%
Line H pool 1 capture 1 0.10 0.17 0.24 0.52 99.48 3814.03 1750 6
Line H pool 2 capture 1 0.11 0.14 0.22 0.52 99.48 3938.69 1769 3
Line H pool 3 capture 1 0.11 0.15 0.23 0.55 99.45 2862.29 1315 5
Line H pool 4 capture 1 0.10 0.16 0.23 0.56 99.44 2471.97 1140 5
Line H pool 5 capture 1 0.11 0.18 0.25 0.60 99.40 2726.34 1250.5 4
Line H pool 6 capture 1 0.10 0.15 0.23 0.55 99.43 3226.56 1476 8
Line H pool 1 capture 2 0.22 0.33 0.43 1.05 98.94 7322.24 4552 16
Line H pool 2 capture 2 0.25 0.34 0.46 1.12 98.84 5086.74 3154.5 7
Line H pool 3 capture 2 0.20 0.35 0.43 1.03 98.95 5081.47 3189 5
Line H pool 4 capture 2 0.18 0.28 0.35 0.83 99.17 3943.07 2454.5 7
Line H pool 5 capture 2 0.22 0.33 0.44 0.98 98.99 4754.84 2962 8
Line H pool 6 capture 2 0.20 0.31 0.38 0.82 99.17 5232.68 3236.5 7
Line H pool 1 capture 3 0.21 0.24 0.29 0.54 99.46 7709.16 4360 19
Line H pool 2 capture 3 0.20 0.24 0.29 0.53 99.46 5843.64 3238.5 20
Line H pool 3 capture 3 0.21 0.24 0.30 0.51 99.47 6913.85 3917 9
Line H pool 4 capture 3 0.20 0.23 0.26 0.53 99.46 5196.68 2930.5 7
Line H pool 5 capture 3 0.21 0.23 0.27 0.47 99.53 7035.24 4003 10
Line H pool 6 capture 3 0.20 0.23 0.27 0.47 99.53 6551.80 3654 19
Table 4.6: Line H probe coverage for all capture sets. Each column displays the percentage of coverage
of the probes, the percentage of the probe's sequence covered by at least one read. The
average, median and minimum coverage for probe at least 90% covered is also displayed.
For line H all the capture set have at least 98% of the probes covered at more than 90%.
4.3 Genome Analysis Tool Kit (GATK) and variant processing
4.3.1 Post mapping read processing
Once read mapping is completed, the aligned reads have to be processed through the GATK pre-
processing steps in order to make sure that the input data used for the variant calling is of good
quality. The deduplication step removed a lot of reads, but large numbers are still left for each of our
pools, which should give us enough depth for accurate variant calling. The depth of sequencing must
be high enough to unsure that every animal in the pool is suﬃciently represented to contribute in a
signiﬁcant manner to the estimation of the allele frequencies within the phenotypic group it represent.
As discussed previously (section 4.2.4) the coverage is very deep and therefore should not have a
negative inﬂuence on the variant calling.
Once duplicate reads are removed, the next step is to realign the reads around indels. This is an
important step as read mapping will be aﬀected by the presence of structural variants (insertions and
deletions, also called indels) and some reads might be discarded, or get low quality scores, because
of the presence of indels. Correcting potential misalignments is done by the realignment step of the
GATK pipeline, using a reference ﬁle of structural variants. Our reference ﬁle for structural variants
for the pig is from dbSNP, version 145, which is based on the genome build SS 10.2. As discussed in
the introduction (see section 1.7), this reference has a large number of gaps and scaﬀolds not placed
on the genome yet. Therefore some of the structural variants will be uncharacterised or belong to
scaﬀolds that have not been placed. The consequence of the patchwork nature of this genome is that
uncharacterised indels present in our data will be unaﬀected by the remapping step, which might
reduce the mapping quality for these locations.
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The next important step is the read quality score recalibration. The mapping quality score is a phred
score. It uses the same scale as the read quality discussed previously and can be used in the same
way. A read quality of 30 has a one in a thousand chance of being wrong. Mapping quality consists
of diﬀerent source of mapping error, contamination, heuristic error (error caused by the alignment
method) and error caused by the repetitiveness of the reference (see main text and supplementary text
[218]). The ﬁrst two components are diﬃcult to estimate, but the last can be estimated. The error for
bwa-mem is estimated by 10/log10∗ [log4∗(S1−S2)− log(nsub)] with S1 being the best alignment score
and S2the second best and nsubthe number of suboptimal alignments for a given read. According to
[144], bwa tends to overestimate slightly the quality score. While this is not a huge problem, according
to the GATK developers, the quality score is often overestimated around base deletions , insertions or
substitutions. Therefore, around known locations with this type of event, GATK will adjust the quality
score. For this adjustment the software needs a reference ﬁle in order to know which loci have to be
adjusted. The reference used is Sus scrofa dbSNP 145. Similarly to the indel reference, this version
of dbSNP is based on SS 10.2, which will have the same drawbacks discussed for the read realignment
recalibration. Despite of these drawbacks it was still beneﬁcial to proceed with the recalibration for
bases covering known variants at the time this step was performed.
For both the realignment and base recalibration steps, the nature of the data helps alleviate some of
issues raised above. Given that we are not using a whole genome approach but a targetted approach,
it is less likely that our variants will fall into an unplaced scaﬀold or into a gap between scaﬀolds. If
a read maps to a target region, this region should not be a region of uncertainty. As discussed in the
section on release 11 of the pig genome (section 4.2.5), a very small proportion of the capture probes
have no, or a small proportion of, reads covering them. Most regions for the capture sets are well
covered. Therefore it is unlikely that targetted regions are problematic. If the probes targetting the
region were designed on erroneous sequences, the results would be that no reads are mapping to the
region. Therefore it can be assumed that targetted regions in this study are fairly well characterised
since the capture was successful and the mapping to these regions was good. Structural and sequence
variants should therefore be well characterised.
The quality scores before and after recalibration show that, as expected the aligner overestimated
the read mapping scores around structural and sequence variants (see ﬁgures 3.35, 3.36) which is the
outcome that was expected.
4.3.2 Variant calling and pooled samples
4.3.2.1 Algorithm discussion
The GATK suite has several algorithms for variant calling, the most recent one is the HaplotypeCaller
[219]. Its strength comes from calling variants on several samples at the same time. HaplotypeCaller
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works in four steps. First it determines active regions using the aggregated data from the diﬀerent
samples. Active regions are regions with substantial variations compared to the reference, therefore
excluding regions of high similarity to speed up the process. Next it determines haplotypes by building
an assembly (DeBruijn graph) graph using the reference as a template. Nodes in the graph correspond
to mismatches with the reference, and HaplotypeCaller selects the most likely graph using the weight
of evidence, i.e. the number of reads supporting each graph. Once the graphs are built, the next step
is to evaluate each haplotype. In order to perform this evaluation the reads are aligned against each of
the possible haplotypes using PairHMM, HMM stands for Hidden Markov Models. These models use
available information to infer missing information. For example if indoors with no windows, one can
infer that it is raining outside if someone comes in with wet shoes. This might be wrong for several
reasons but it is a reasonable assumption under normal circumstances. The PairHMM uses the base
quality score for the HMM, it helps to infer if the variant is likely to be real or not. The last step
is to assign the genotype back to the individual samples, which is done using a Bayesian approach to
compute likelihood ratios. The strength of this approach is the combination of data from a cohort of
samples and using it to call variants. The whole process is broken down into several steps. First calling
the variants on individual samples and generating the variant ﬁles for each sample to then consolidate
them together and do a joint cohort variant calling. This produces raw variants that can be ﬁltered
using several diﬀerent methods. The advantage of the HaplotypeCaller method compared to previous
algorithms such as the UniﬁedGenotyper is that it is better at calling insertions and deletions, as they
are part of the Hidden Markov Models whereas the UniﬁedGenotyper does not model insertions or
deletions.
Unfortunately for this study the use of HaplotypeCaller was not possible. The ﬁrst step of the variant
calling, calling variants for individual samples proved too problematic for our samples. As our samples
are made from pools of several individuals, one of the parameters we had to change is the ploidy (the
number of chromosomes). The smallest pool had four animals and the largest had 46, which means
the ploidy varied between eight to 92 chromosomes. This resulted in problems using HaplotypeCaller
as our computing node was running out of resources. Our initial computing node had 125 GB of
RAM which was thought to be suﬃcient. However while running this step the node kept crashing
due to a lack of memory. Upon investigation it was noticed that the crash occurred at a particular
locus. The parameters of the step were modiﬁed to skip this locus but this only shifted the problem
to another locus. After excluding several loci it was decided that this approach was unsustainable.
Another solution was to upgrade the available resources. The node was upgraded to double its memory
at 250GB. Unfortunately the software was still crashing due to a lack of memory. Another computing
node was found to run this step, with 500GB of RAM, but again the software was running out of
memory. At this point the GATK developers advised us to use an alternative and older algorithm
available that can cope with this high level polyploidy, the UniﬁedGenotyper [149].
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The UniﬁedGenotyper is a simpler variant caller compared to the HaplotypeCaller but it can handle
the very large ploidy present in our samples. It is a permissive caller and therefore will call large
amounts of variants, and some will be false positive. It can call variants in multiple samples at the
same time but for the animal pools that were used, and because of the large ploidy in some of them,
it was deemed preferable to call variants on individual pool. The UniﬁedGenotyper performed well on
all the pools and no issues with memory usage were encountered while running it on our cluster node.
4.3.2.2 Variant ﬁltering
Because of the use of the UniﬁedGenotyper, the choice of ﬁltering was limited to hard ﬁlters. It was not
possible to use the most advanced ﬁltering tools based on machine learning as they require several sets
of high quality known variants to train the model. Typically, for human the sets come from dbSNPs,
the 1000 genomes project, genome in a bottle, etc... Unfortunately such sets are not available for
the pig yet, only dbSNP has been released and its content might not be the most accurate for all
of our lines, as it is based on the Duroc reference. Thus the use of hard ﬁlters was the only choice
available. The values used for ﬁltering (see section 2.10.3) are the ones recommended by the GATK
team. They are standard values for ﬁltering and should give a good balance to ﬁlter the variants called.
Using these ﬁltering parameters will avoid being too stringent which would miss potentially interesting
polymorphisms.
The number of raw variants ranges between 23,000 and 57,000 per pool across all capture set (see
table 3.25). Overall capture set 2 has the lowest number of raw variants called with 609,533 and
capture set 3 has the largest with 976,980. After ﬁltering, the lowest quantity of variants is still for
capture set 2 with 385,016 and the largest for capture set 3 with 655,310. The ﬁltering does remove
between 30% to 40% of the variants, but the precise fraction of variants found and ﬁltered between
samples varies. For capture sets 1 and 2 the number of variants found and ﬁltered is fairly similar. For
capture set 3 however it is higher by at least 10,000. This might be a consequence of the size of the
regions targetted. For capture set 1 the probes target 7MB, for capture set 2 10MB and capture set
3 13 MB. Surprisingly despite the diﬀerence in capture size between capture set 1 and 2, and 2 and
3, the number of variants found after ﬁltering is similar for capture set 1 and 2 but much larger for
capture set 3.
The number of variants found for each capture set generally correlates well with the number of
probes targetting a given chromosome. The only exception to this is from capture set 1, where the
number of variants found for chromosome 1 for the diﬀerent pools is lower than for other chromosomes.
Chromosomes 4, 12, 15 and 18 have a higher number of variants identiﬁed compared to chromosome
1 despite having around half of the number probes targetting chromosome 1.
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4.3.3 Variant comparisons
As described in section 2.11.1, the variants were compared between pools in three categories. Cat-
egory A compared all the infanticide pools against the control pools, category B compared the serial
infanticide pools against the controls, and category C compared the pools with a family history of
infanticide to the controls pools. The ﬁrst category helps to identify variants and regions that are
common between the serial infanticide animals and the animals with a family history of infanticide.
The category B and C prospects will identify variants and regions that are more speciﬁc to the strength
of the trait for the serial oﬀenders or linked to heritability for the family history pools. In order to
chose the thresholds for the comparisons, the control pools were used to checked the repartition of the
diﬀerence in allele frequency (see ﬁgures 3.37, 3.38, 3.39, 3.40, 3.41, 3.42 and 3.43). The variations in
allele frequencies between the two control pools for the various capture sets are fairly similar following
their repartition. The number of variants with small diﬀerences in allele frequency is large and the
number of variants with large diﬀerences in allele frequency is small. Most of the diﬀerences in allele
frequencies are found to be below 30% (0.3).
Because most of the variability between the two control pools is segregated below 30%, the base
threshold for removing highly variable variants between pools of the same category is set at 30% for
both the control and the infanticide pools. Due to the lower number of individuals in some of the
infanticide pools, the allele frequency variations between infanticide pools of the same category are
more pronounced (see supplementary data).
To compare allele frequencies between controls and infanticide pools two approaches were taken.
The ﬁrst approach used hard thresholds for the comparisons between infanticide and control pools.
The ﬁrst threshold was set at 30%, the same as the within pool cut oﬀ. The approach worked well for
category A (comparing control pools against infanticide pools) but returned a large number of variants
for categories B and C. Therefore the threshold was increased to 50% allele frequency diﬀerence between
the control and infanticide pools.
The second approach used a more variable threshold based on the distribution of the diﬀerences in
allele frequency of the variants (see section 2.11 for details). The distribution of the allele diﬀerences
between the control pools, for each capture set, and the distribution of the allele diﬀerences between
infanticide and control pools, for the diﬀerent capture set and category, reveal some interesting inform-
ation. The allelic diﬀerences between the control pools for each line already revealed that most of the
allele variation is found to be below 30%. Grouping the control pools per capture set conﬁrmed that
trend. The threshold of mean plus three standard deviation was just above the 30% allele frequency
diﬀerence (see ﬁgure 3.37). When grouping the lines per capture set and category, and comparing
infanticide against controls (see ﬁgure 3.37), a similar picture emerges but the allele diﬀerences are
more important. For the category A pools, the thresholds of mean plus three standard deviation for
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each capture set is similar to the one obtained when comparing the control pools. For category B and
C the thresholds are higher and the distributions have a longer tails. There are multiple potential
reasons for this. First, the pool number are not balanced between the lines and categories. While the
control pool have 25 animals in each of them, the infanticide pools have more variable numbers. The
serial infanticide pools have a low number of individuals with 4, 6, 14 and 4 animals for line B, C, D
and H respectively. The family history of infanticide pools have more animals with 4, 12, 36 and 32
animals for line B, C, D and H respectively. This imbalance in the number of animals in the pools will
results in more extreme allele frequency from pools with a small numbers of animals compare to pools
with a larger numbers of animals. Furthermore, for category A, we are comparing two pools against
two pools which might give a better estimate of the allele diﬀerences and reduce any outlier eﬀect. For
categories B and C, the two control pools are in some case compared against a single infanticide pool.
Indeed for line B and C there are only a single infanticide pool in each category, while for lines D and
H, several infanticide pools are available for category C (family history of infanticide). The presence
of single pools in categories when comparing the allele frequencies will results in more extreme values.
Therefore the overall distribution will be inﬂuenced by these extreme values. It is also worth noting
that category A groups the two infanticide sets, serial infanticide and family history which could lessen
any speciﬁc eﬀect caused by alleles linked solely to one of the two categories. The fact that the res-
ults of the selection of the variant in category C has a large proportion of variants selected on some
chromosomes (see tables 3.30, 3.33 and 3.36 ) when using the variable thresholds, seems to suggest
that these might be some category speciﬁc eﬀects. This might not be visible for the hard threshold
approach as it might be too stringent for the eﬀect to appear.
The control pools were also used for a mock comparison, to compare the proportion of selected
variants with the comparisons against the infanticide pools (see tables 3.26 and 3.27). The percentage
of selected variants in the mock comparison is lower by one to two percent for capture sets 1 and 2, but
are similar for capture set 3. The comparisons with the infanticide pools are selecting more variants
than the comparisons between two similar pools.
The thresholds based on the distribution of the allele frequency diﬀerences, using mean plus three
standard deviations, selected a much higher number of variants. The thresholds were usually lower
than the hard thresholds that were chosen before. It was decided to use this method of ﬁltering
to select variants and regions of interest. The percentage of selected variants is similar between the
diﬀerent capture sets and categories. Category A selecting between 3 to 3.8% of the total number
of variants, between 3.6 and 4.3% for category B and between 4.7 and 6.5% for category C. It is
interesting that the highest number of variants selected is for category C, which compares the control
pools with the ones for individuals with an history of infanticide. Some chromosomes in this category
have a very large number of variants selected. For capture 1 category C, the number of variants
selected on chromosome 6 represent 50% of the total number of variants present, furthermore 32% of
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the polymorphisms on chromosome 13 were selected for the same capture set and category. For capture
2 category C, 42% of the variants on chromosome 11 were selected. For capture 3 category C, again
we have 26% of the variants on chromosome 6 selected and 34% for chromosome 10. It is interesting
that this skew in selected variants proportions are happening only for category C and not for any of
the other categories. Therefore these regions might be of interest as they are clearly outliers when
compared to other chromosomes and other categories.
On the other hand, some target regions did not select any variants. This is expected, all of the
target regions identiﬁed using the genotyping data might not be relevant. The genotyping tests were
used to identify potential regions of interest but not all were expected to be relevant after a more
in depth investigation. It was not expected that a large number of variants will be of interest, the
variants identiﬁed will help reﬁning the regions of interest and investigate them in more details. Using
annotation pipelines and updating the coordinate to the version 11 of the genome (see section 2.11.2
and 2.11.3), the variants selected can be investigated in more details to evaluate their consequences on
the genes present in the region.
4.3.4 Variant annotation
The variants annotation has proven to be one of the most challenging steps of this work. When the
ﬁrst set of results was curated, only version 10.2 of the pig genome was available. The annotations
were poor and making sense of the results proved to be diﬃcult. It was decided to develop a pipeline
to compare the variants to the human genome in order to see if any gene or human variant of interest
was located in the corresponding region of the human genome. Thankfully, homology information and
alignments between the pig and human genomes were available for this task. This allowed correspond-
ences matching between pig and human, but sometime the alignments were poor. A more bespoke
annotation pipeline was needed and the pipeline detailed in section 2.11 was designed. This pipeline
was applied to the hard threshold results. It was a lengthy process, as for each gene identiﬁed, its
function needed to be curated manually. While this part of the work was on going, the new version of
the pig genome was released and it was decided to change the annotation pipeline in order to use this
updated reference. The objective was to update the coordinates of the variants to the new version of
the genome and hopefully get better gene annotations. The ﬁrst attempt to update the coordinates
worked relatively well but some SNPs were lost during the process. Because the data used were from
the hard thresholds initially applied, there were only a small number of SNPs selected, and losing
even a fraction of them could be problematic. The pipeline described in section 2.11.3 was designed
in order to try to update as many variants as possible. The pipeline is complex and applying it for
each capture set, line and category was a long process. Soon after completion of this step the protocol
was inspected for a less arbitrary ﬁltering method that could be applied to select the variants. The
thresholds based on the distribution of the data were implemented, and instead of trying to update
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all the SNPs, it was decided to simply update the coordinates to version 11 of the genome. This was
done by querying Ensembl biomart using the R package and the SNP identiﬁcation lists to get back
the coordinates in version 11 of the genome. Any SNP lost was probably not very interesting, if it
was not a valid SNPs in the latest version of the genome, its interpretation would have be diﬃcult.
Plotting the region where the SNPs were located also helped for the interpretation and identiﬁcation
of genes. The gene function was followed up manually, as described in section 2.11.4. This means that
a lot of the work that went into the interpretation and curation of the ﬁrst set of variants, and the
more bespoke pipelines used to update the variants, have not been applied to the ﬁnal set of results.
These processes can still be applied in future work or used to update variants in other species that
might not yet have beneﬁted from an improved genome.
4.3.5 Missense SNPs and their targets
Reminder of the categories used: for category A all the infanticide pools were compared against the
control pools. For category B the infanticide pool containing serial infanticide animals was compared
to the controls and for capture C the pools with animals with a family history of infanticide were
compared to the control pools.
In this section, the impact of SNPs located in genes was investigated. Using the SIFT algorithm
[181], it was possible to highlight SNPs that could have a potential impact on the protein encoded by
the gene. The SNPs classiﬁed as missense were investigated (see tables 3.37 and 3.38 for details about
them). The pipeline described in section 2.11.4 was used to evaluate their potential impact. They
have been divided into three sections. The ﬁrst one detailed the most interesting SNPs and genes, the
second genes that might be good candidate but for which there was not enough evidence to link to our
phenotype of interest. Finally, the third section discussed SNPs and genes that were unlikely to be
of interest. Figure 4.2 and 4.3 gave an example of the alignments used to investigate the amino acid
change. Figure 4.2 showed an example of a conserved region while ﬁgure 4.3 an example of a poorly
conserved region. Table 4.7 gave a summary of the SNP of interest and the target category they belong
to.
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Figure 4.2: Example of a conserved region, protein ASPM. Blastp results of the reference protein
against the non redundant database. The substitution is deleterious, the original AA is N
(asparagine, highlighted in red) and change to K (lysine). The AA and the region around
it are well conserved. The top ten hits are, in order: Sus scrofa (Pig), Physeter catadon
(sperm whale), Balaenoptera acutorostrata scammoni (minke whale), Heterocephalus glaber
(naked mole rat) ,Condylura cristata (star nose mole), Fukomys damarensis (Damara mole-
rat). Some are present twice: Physeter catadon: position 2 and 3, Heterocephalus glaber:
position 5 and 6, Condylura cristata: position 8 and 9.
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Figure 4.3: Example of a poorly conserved region, protein CLIC6. Blastp results of the reference protein
against the non redundant database. The substitution is from serine (highlighted in red)
to arginine, S to R. The AA substitution doesn't seem to be major as arginine can be seen
to be present in other species. The region around the substitution is not well conserved.
The top 10 hits are, in order: Ceratotherium simum simum (white rhino), Lipotes Vexilifer
(Chinese river dolphin), Mustela putorius furo (ferret), Desmondus rotundus (Common
vampire bat), Enhydra lutris kenyoni (sea otter), Propithecus coquereli (Coquerel's sifaka),
Leptonychotes weddelli (weddell seal), Ailuropoda (panda), Rhinolophus sinicus (horseshoe
bat). Propithecus coquereli is present twice (position 6 and 7).
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ID CHR POS Average diﬀerence Origin Line Gene Priority target
rs337246460 1 81,891,724.00 0.275(A), 0.4(B) Cap3 cat A, B C TSPYL4
rs321068974 1 81,892,394.00 0.43 Cap3 cat B C TSPYL4
rs80970369 1 81,892,966.00 0.41 Cap3 cat B C TSPYL4
rs327767403 1 81,908,800.00 0.39 Cap3 cat B C TSPYL1
rs325683130 4 109,665,261.00 0.425 Cap3 cat B C CYMP
rs339852659 4 109,671,858.00 0.455 Cap3 cat B C CYMP
rs342388220 4 111,042,820.00 0.525 Cap 1 cat B C WDR47 **
rs332510157 4 111,098,594.00 0.5 Cap 1 cat B C CLCC1 *
rs321660613 4 111,116,353.00 0.274(A), 0.42(B) Cap 1 cat A,B C GPSM2 **
rs342779307 5 5,742,422.00 0.292 Cap2 cat A D MCAT *
rs330946522 5 5,751,299.00 0.587 Cap2 cat B B MCAT *
rs340611738 6 15,036,652.00 0.4 Cap3 cat C B PMFBP1 *
rs333510524 6 15,036,654.00 0.4 Cap3 cat C B PMFBP1 *
rs333013901 9 67,604,156.00 0.2785 Cap3 cat A C Unknown (PCNP)
rs339509635 9 93,078,330.00 0.455 Cap3 cat C B ABCB1 **
rs332900783 9 117,216,372.00 0.29, 0.29 Cap2, 3 cat A C, B TNN
rs319385750 10 14,222,171.00 0.41 Cap2 cat C B PARP1 **
rs340769264 10 14,222,231.00 0.4 Cap2 cat C B PARP1 **
rs328408424 10 19,989,785.00 0.365 Cap2 cat B H ASPM **
rs340828634 10 19,997,880.00 0.365 Cap2 cat B H ASPM **
rs321307993 12 40,037,442.00 0.405 Cap3 cat C B NLE1
rs334711032 12 50,073,425.00 0.266, 0.408 Cap3 cat A, C B, C ZZEF1 *
rs81438217 12 59,139,527.00 0.285 Cap 1 cat A, B B TRPV2 **
rs325360794 12 59,371,738.00 0.3075 Cap 1 cat A,B C NCOR1 **
rs81438358 12 59,376,875.00 0.28 Cap 1 cat A C NCOR1 **
rs692365780 12 59,418,694.00 0.3935 Cap 1 cat C D TTC19 *
rs346399941 13 198,251,410.00 0.47 Cap2 cat B C CLIC6
rs337655527 13 203,339,714.00 0.37 Cap2 cat B C IGSF5 *
rs328154476 14 49,484,969.00 0.36 Cap2 cat B C ADORA2A **
rs81209170 16 69,125,456.00 0.306 Cap2 cat A C FAM114A2
rs81209170 16 69,125,456.00 0.306 Cap3 cat A B FAM114A2
rs694857226 17 32,583,104.00 0.39 Cap2 cat B C AVP **
rs324827243 17 41,286,600.00 0.46 Cap3 cat B C KIAA1755 *
Table 4.7: Summary table of the SNPs of interest. Average diﬀerence gives the allele frequency dif-
ference between control pools and infanticide pool(s). The origin column the capture set
for which the SNP was found, line the line in which it was found. Priority shows which
category it belongs to: ** is high priority target, * potential target and blank is for unlikely
candidates.
4.3.5.1 Priority candidate genes and SNPs
One of the most interesting regions highlighted by the missense SNPs is located in chromosome 4 and
covers four genes, CYMP, WDR47, CLC1 and GPSM2. Two of these genes are good candidates,
WDR47 and GPSM2. Both variants were selected for line C and capture set 1 category B, and also
category A for the variant within GPSM2.
The ﬁrst SNP, rs342388220, is located inWDR47 (WD repeat domain 47) is an interesting candidate.
The reference allele is an adenine (A) while the alternative is a guanine (G). In other species a G is
present at this location. The allele frequencies in the infanticide animals is prevalently the alternative
allele (G) while the reference control has predominately the reference allele (A). The amino acid (AA)
substitution is from glutamate to lysine which is a major change from acidic (negatively charged) to
basic (positively charged) in the polypeptide chain. Furthermore, the reference AA is lysine for the
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pig, but the blastp alignments reveal that the most prevalent AA at that location is glutamate. The
region is also highly conserved. Given that the control pools have a higher frequency for the reference
allele, they will have lysine at this location while the infanticide pigs will have a glutamate. The
impact of this substitution is hard to predict but it could have consequences on the protein coded by
this gene. While this gene and its protein are poorly characterised, the gene is highly expressed in the
brain of the mouse at the embryonic stage and in adult mice. Mouse knockouts of this gene have been
reported to be hyperactive. WDR47 is also essential for brain development during the early stage of
embryogenesis[220]. It is possible that a modiﬁcation of the protein structure could have an impact on
the mature brain.
The second candidate SNP on chromosome 4, rs321660613, is located within the GPSM2 gene (G
protein signaling modulator 2). For the pig the reference allele is a cytosine (C) and the alternative
is a G. In other species the base is a G. The AA substitution is from glycine to alanine which is a
change from hydrophilic to hydrophobic. Depending on where the AA is located after the folding of
the protein, it could have an impact on its function. The region where the substitution is located is
relatively well conserved between the species. Most animals have an alanine at this location rather
than a glycine. The protein is a G-protein signalling modulator which regulates the activation of G-
proteins. Other than being involved in non syndromic deafness and Chudley-McCullough syndrome, a
neurologic disorder characterized by early-onset sensorineural deafness, there is not much know about
it's function. However, as discussed in the previous study done on gene expression [80], other G-proteins
have been linked to depression so this could be a good candidate.
Both of these candidate SNPs on chromosome 4 are in a peak region that was identiﬁed in the
Quilter et al study [2], supportive that this region is linked to the genetics of maternal infanticide.
These SNPs also display some of the largest changes in allele frequencies between between the control
and infanticide pools, between 42 to 52%. They are all from line C which is a Large White line. These
SNPs might be speciﬁc to the maternal infanticide trait in this line in particular.
The next variant, rs339509635, is located within an uncharacterised gene in the pig on chromosome
9. It has been selected for capture set 3 and category C, for line B. The reference allele is a C and the
alternative is a thymine (T), most species have a C at this location. The SNP has been classiﬁed as
deleterious with a change from arginine to cysteine which is a change from positively charged to neutral.
The region of the protein where the AA is located is highly conserved between species. The gene at
this location is unknown in the pig, but comparisons with the human and mouse return ABCB1 (
ATP binding cassette subfamily B member 1 also known as MDR1). The protein encoded by this gene
is a member of the superfamily of ATP-binding cassette (ABC) transporters. Its role is to transport
various molecules across extra and intra cellular membranes. It is expressed in the brain in human and
a GWAS has linked a SNP located in this gene to schizophrenia in a population of Ashkenazi Jews,
although it did not reach genome wide signiﬁcance [221]. Two others studies linked this gene to drug
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resistant epilepsy in Polish adult populations and in children [222, 223]. Finally a meta analysis has
linked this gene to Alzheimer's Disease [224]. The fact that this gene has been associated to some
brain pathologies makes this variant a good candidate.
On chromosome 10, four SNPs are classiﬁed as missense, covering two genes, PARP1 and ASPM.
For the two SNPs, rs319385750 and rs340769264, located in PARP1 (poly(ADP-ribose) polymerase
1), the substitution are both threonine to alanine, a change of polarity for the amino acid. The ﬁrst
location is in a highly conserved region of the protein. The second one is in a relatively conserved region
but substitution in the protein at this location is observed in other species. The change in polarity
could have an impact on the protein function, depending on how the protein structure is aﬀected.
Both SNPs were selected in capture set 2 category C and for line B. This is one of the dam lines, and
category C is for the pool with a family history of infanticide. The change in allele frequency is quite
high at 40%, and the infanticide pool has the alternative allele as the preferential allele in both cases.
Furthermore, this region was identiﬁed in the FBAT analysis and the SNP in it reached genome wide
signiﬁcance. As discussed before, PARP1 encodes an enzyme which is associated with the chromatin.
It is a transferase that modiﬁes nuclear proteins by poly(ADP-ribosyl)ation. It is involved in important
cellular processes (diﬀerentiation, proliferation, recovery from DNA damage). It is also expressed in
the human brain and has been linked to several brain pathologies such as Alzheimer's and Parkinson's
disease [193, 192]. In the mouse it has been linked to contextual fear memory [191]. These two SNPs
conﬁrm PARP1 as a strong candidate.
The next two SNPs on chromosome 10, rs328408424 and rs340828634, are both in the ASPM (ab-
normal spindle microtubule assembly) gene. The ﬁrst SNPs, rs328408424, will probably not have a
large impact on the protein, as the change it triggers does not change the polarity or charge at this
location. The change is from leucine to phenylalanine. The protein region it is located in is also very
variable in other species. The second SNP, rs340828634, is more interesting, it is classiﬁed as deleter-
ious by SIFT. It triggers a change from a polar, hydrophilic and neutral amino acid (asparagine) to
an hydrophobic and charged (lysine) amino acid. The protein alignment shows that the asparagine is
conserved in most species. The gene ASPM is an ortholog of the Drosophila melanogaster abnormal
spindle gene (asp). It is involved in mitotic spindle regulation which has a role in regulating neuro-
genesis. Microcephaly is triggered by mutations in this gene [225, 226], a GWAS study also linked
it to communication disorders [227], making it a potentially interesting target. It is the only SNPs
with deleterious consequence identiﬁed in line H, one of the sire lines, and both were identiﬁed in the
comparison involving the serial infanticide animals. The preferential allele in the infanticide animal is
the alternative allele: infanticide animals are more likely to have a charged hydrophobic lysine at this
protein location.
On chromosome 12, three SNP are closely located and are within two genes, TRPV2 (transient
receptor potential cation channel subfamily V member 2 ) and NCOR1 (nuclear receptor corepressor
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1). The ﬁrst SNP in this region, rs81438217, is in TRPV2. The variant has a reference allele G and
an alternative allele C In most species the DNA sequences have either a A or a G when compared by
phylogeny. The substitution of the AA triggers a change in the charge of the protein as it switches
from histidine (positively charged) to glutamine (neutral). The region is highly conserved and most
species have the neutral amino acid at this location instead of the histidine. Here the infanticide pool
has a higher frequency for the reference allele, therefore a charge will be present on the protein at
this location. The gene TRPV2 encodes an ion channel, activated at high temperature. It has been
linked to neural growth in developing neurons [228]. Not many functions of this gene are linked to
brain pathology so far. The next two SNPs are both located in the NCOR1 gene and have similar,
but reversed, impacts on the protein AA chain. The ﬁrst SNP, rs325360794, triggers a change from
glycine to serine while the second, rs81438358, a change from serine to glycine. Glycine is non-polar
and hydrophobic while serine is polar and hydrophilic. Interestingly, alignment of the protein sequence
against other species shows that most species have the modiﬁed AA at this position (so serine and
glycine respectively) in their proteins instead of the reference AA in the pig protein. Both SNPs comes
from capture set 1 category A (as well as B for the ﬁrst one) and were selected for line C. Capture
1 was designed based on Quilter et al [2] and NCOR1 was one of the gene identiﬁed in this study.
Unfortunately most of the known functions for this gene are linked to cancer, no studies have found
any linked between this gene and brain functions so far. However it is linked to our next target, the
gene ADORA2A, as a study [229] has found SNPs in both gene associated with gray matter volume
in the cuneus component. Thus there is a potential link between this two genes.
Only one candidate SNP is located on chromosome 14, it is located in the gene ADORA2A (adenosine
A2a receptor). The SNPs, rs328154476, triggers an AA change from glycine to glutamate which is non
polar, hydrophobic to polar, hydrophilic. The region where the AA change occurs is highly conserved.
The gene encodes for a member of the guanine nucleotide-binding protein (G-protein)-coupled receptor
(GPCR) superfamily. It interacts with the G(s) and G(olf) family of G proteins to increase intracellular
cAMP levels. It plays a role in many biological functions, including cerebral blood ﬂow control, pain
regulation and sleep. It is expressed in the brain and studies have linked it to anxiety disorder [230],
mild cognitive impairment and Alzheimer's Disease [231] and neurodegeneration [232]. As mentioned
previously, G proteins are of particular interest as their pathway was identiﬁed as a target in the gene
expression study of Quilter et al [80] and we already have a good candidate with the SNP located in
GPSM2. This particular SNP could also be a good candidate, it was selected in capture set 2 category
B in line C.
The last candidate SNP in this priority category, rs694857226, is located on chromosome 17, within
the AVP gene. The gene, arginine vasopressin encodes a protein of the vasopressin and oxytocin family.
It is secreted in the hypothalamus and goes into the blood stream. Polymorphisms in this gene have
been linked to social behaviours and psychiatric traits [233], notably depression [234] and aggression
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in children [235]. It also plays a role in social memory in rat [236]. Oxytocin was a protein of interest
identiﬁed by the gene expression study of Quilter et al [80]. The change in amino acid, however, is
valine to alanine which are both non polar and hydrophobic. The alignment of the protein show that
it is relatively conserved, but most species have an alanine at this location. The allele frequency in
the infanticide pool shows that only the reference allele is present, while it is less predominant in the
control pools. This variant was selected in capture set 2 category B for line C. It could be an interesting
candidate but it will be necessary to conﬁrm any impact it could have on the protein function.
4.3.5.2 Potential candidate SNPs and genes
As discussed in the previous section, four SNPs of interest are present on chromosome 4, two of which
are priority candidate. Another SNP in the gene CLCC1 (chloride channel CLIC like 1), rs332510157,
could be a potential candidate. It was found for line C in category B of capture set 1. In the pig the
reference allele is a T and the alternate allele is a G. For other species the base at this location is a G.
The AA substitution is leucine to arginine which changes the AA from neutral to positively charged.
This could have an impact on the protein structure, but the alignment suggests that the structure is
not well conserved for this region of the protein. Very little is known about this gene, other than it
is potentially coding for a chloride channel. The only interesting fact about it is that the loss of the
protein is linked to neurodegeneration [237]. As discussed in the previous section 4.3.5.1, it is in one
of the peak region of the GWAS study by Quilter et al [2].
The next two SNPs are located on chromosome 5, both within the same gene: MCAT (malonyl-
CoA-acyl carrier protein transacylase). They have been selected for capture set 2 for category A and
B and from line D and B. The ﬁrst SNP, rs342779307, might not be a very good candidate, the AA
substitution is from alanine to valine and both are non polar, hydrophobic. Furthermore, the results
of the blastp revealed that this location is variable, with either alanine or valine present in diﬀerent
species. Unfortunately the results are similar for the second SNP, rs330946522. The AA substitution
is proline to leucine which are both non polar, hydrophobic. There is no good alignment when blasting
the AA sequence and very little is known about the function of the MCAT gene. However some
interesting facts are linking this gene to other candidates. The protein encoded by this gene is found
exclusively in the mitochondria. It is a transacylase, which is involved in the metabolism of fatty acids.
This could be an interesting target as some of or other target genes are linked to the mitochondria.
The fact that two SNP are located closely together in this gene is important, this SNP and other could
deﬁne haplotypes.
The next two SNPs, rs340611738 and rs333510524, are located on chromosome 6 and both are within
the PMFBP1 (polyamine modulated factor 1 binding protein 1) gene, just two nucleotides apart. The
SNPs have an A and a T as reference and both have a G as their alternative allele. Both SNPs aﬀect
the same amino acid, the ﬁrst one trigger a change from serine to arginine which changes the charge
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from neutral to positive. The second is a change to glycine, from polar to non polar, so hydrophilic
to hydrophobic. If both SNPs have the alternative allele, the substitution is also serine to arginine.
The region where the nucleotides and amino acids are located is highly variable. The gene itself is
expressed in the brain in human at a low level but nothing is known about the function of the protein
it produces. As this region came up in the section looking at region with a high number of variants
above our threshold 4.3.6, it is a region that should be investigated in more detail.
The SNP on chromosome 12, rs334711032, is within the ZZEF1 (zinc ﬁnger ZZ-type and EF-hand
domain containing 1) gene. The same SNP was selected on capture set 3, category A for line B,
and category C for line C. Both lines are the dam lines and capture set 3 is based on the PO study.
This might be a good candidate for dam to daughter preferential transmission. The allele frequency
diﬀerence between control and infanticide for line C is quite high at 40%. The SNP alleles trigger a
change from alanine to serine which is a change from non polar, hydrophobic to polar, hydrophilic.
The region where the substitution is located in the protein is highly conserved: the alanine is present in
most species. Not a lot is known about the gene function but it is highly expressed in the hippocampus
and has been linked to impaired memory in the mouse [238], making it a candidate.
Another potential candidate SNP, rs692365780, is located on chromosome 12, within the gene TTC19
(tetratricopeptide repeat domain 19). This gene is an interesting target because its function has
been linked to ataxia [239], a neurological disease characterised by a lack of coordination in muscle
movements. More importantly it is related to mitochondrial complex III deﬁciency and neurological
impairment [240]. As we saw in the previous studies (section 1.4.2), mitochondrial dysfunction has
been associated with bipolar disorder and schizophrenia [66, 67]. While the gene is a good candidate,
unfortunately the SNP is not. The substitution it triggers switch an isoleucine for a valine, which are
both neutral and non polar. Furthermore the protein region is not very conserved . Despite of this, it
might be interesting to investigate the gene in more details, as other variants might be more impactful.
On chromosome 13, one of the potential candidate, rs337655527, is located within the gene IGSF5
(immunoglobulin superfamily, member 5). The SNP has been selected for capture set 2 and category
B (serial infanticide) on line C. This gene has been linked by GWAS with suicide attempts in mood
disorder patients [241]. The protein region is highly conserved but the change is valine to alanine: both
are polar, hydrophobic. The alignment returns a prevalent alanine in that location so the valine could
have an impact even if the polarity is similar. However this is diﬃcult to assess.
The last SNP in our list of potential candidates, rs324827243, is located within the KIAA1755 gene.
Not a lot is know about the gene but it is expressed in the brain. The change in AA is from alanine
to threonine which is change of polarity, from polar, hydrophilic to non polar, hydrophobic. The AA
is located in a highly conserved region and alanine is present at this location in all of the protein
alignments. It could be a good candidate due to diﬀerence in allele frequencies. It is found in capture
set 3, category B and in line C. The aggressive pool has only the reference nucleotide C while the
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control have a allele frequency for the reference allele of 56% for both. It is one of the largest change
in allele frequencies in the table. The function of the gene needs to be investigated to validate this
candidate.
4.3.5.3 Unlikely candidates.
The ﬁrst group of SNPs, located on chromosome 1, are within two diﬀerent genes, TSPYL4 (testis-
speciﬁc Y-encoded-like protein 4 ) and TSPYL1 (testis-speciﬁc Y-encoded-like protein 1). There are
three SNPs with missense consequence in TSPYL4, rs337246460, rs321068974 and rs80970369. One
in TSPYL1, rs327767403. There several changes in the amino acid chain of the protein coded by
the gene TYSPL4. The three SNPs are causing a change of polarity at that location, with changes
from isoleucine to threonine (non polar to polar), threonin to alanine (polar to non polar) and ﬁnally
from glutamine to proline (polar to non polar). The blastp of the protein sequences around the AA
subsitution shows that the protein is not very conserved between species at these locations. As the
region is not very conserved it is hard to predict if a change of polarity will aﬀect the protein function.
Furthermore there is very little known about this gene. The change of polarity also happens for
TSPYL1, a change from proline to serine. For this protein the region is conserved and most species
have conserved the proline. This substitution could have an impact on the protein function but very
little is known about it. The TSPYL family is related to genes located on the Y chromosome and
involved in male fertility. However one member is known to linked to brain function TSPYL2. These
variants were found in line C, one of the dam lines, and were picked up by the capture set 3, category
B (serial infanticide), suggesting a potential dam to daughter transmission. In all cases the alternative
allele was more frequent in the infanticide pool than in the control pool. Therefore the substitution of
polarity in the protein happens more often in infanticide animals.
Of the candidates found on chromosome 4, two SNPs are less likely to be good candidate due to the
unknown nature of the gene they are in, they are rs325683130 and rs339852659. They were found for
capture set 3 category C (family history of infanticide) and one of them is classiﬁed as deleterious by
SIFT. The gene at this location (109.6MB) is unknown in the pig but comparisons with the human
returns CYMP (chymosin pseudogene) as a potential match for this gene. The pig gene is classiﬁed as
a pseudo gene and has to potential to produce a protein. The protein might have divergent functions to
CYMP. The ﬁrst AA substitution is a like for like substitution as it is change from serine to asparagine,
both are neutral and polar. The second is deemed deleterious by the SIFT prediction however the
change is between two neutral and non polar AAs, leucine to proline. The blastp alignments gave little
information as there were no matches for the part of the protein where the AA substitution happens.
Unfortunately, there is very little known about the gene other than it is a peptidase, it is not well
characterised and the only indication of function is a GWAS study on depression [242] that identiﬁed
one SNP, located in this gene. It almost reached genome wide signiﬁcance (5.10−7).
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The next variants in this category are located on chromosome 9. They cover an uncharacterised gene
and TNN (tenascin N). The ﬁrst SNP, rs333013901, is classiﬁed as deleterious by the SIFT prediction.
The diﬀerence in allele frequencies is modest, the infanticide pools being at 50% and 41.7% and the
controls at 22% and 14%, the average diﬀerence is 28% between the two categories of pools. This
SNP was also only identiﬁed for capture set 3, category A in line C. It is probably below the ﬁltering
threshold for category B and C. However the change in the AA chain is interesting, it is a change from
threonine to arginine which modiﬁes the charge of the amino acid, from neutral to positively charged.
The position is also well conserved between species. However the gene in the pig is very short and not
characterised. Comparing it to the human and mouse genome suggest that it might be PCNP (PEST
proteolytic signal containing nuclear protein). Unfortunately the gene PCNP is poorly characterised
and not much is known about its function other than being involved in the cell cycle [243].
The other variant on chromosome 9, rs332900783, is in the gene TNN (tenascin N ). It has an A
as its reference allele and a G as its alternative allele. Other close species (cow, horse) have also a A
at this position but other have a G. The change in amino acids is isoleucine to valine which are both
neutrally charged and non polar. TNN itself is uncharacterised and has low expression in the mouse
and human brain, however tenascin proteins are involved in axon generation and the protein encoded
by this gene has been found in the hippocampus [244].
The SNP located in the gene NLE1 (notchless homolog 1) on chromosome 12, rs321307993, might
not be an interesting candidate. Nothing is known about this gene's function but it is expressed in
the brain. The change in AA triggered by the SNPs is likely to have little impact as the substitution
has the same polarity, polar and the same charge, positive. The position is however highly conserved
unfortunately, as little is known about this gene and its protein in other species, it makes it hard to
evaluate this SNPs.
One SNP located on chromosome 13, rs346399941, is located within the CLIC6 (chloride intracellular
channel 6) gene. The AA substitution triggers a change in charge in the protein, from serine to arginine,
from neutral to positively charged. Unfortunately the AA chain is not very conserved at this location
and nothing relevant to a role in the brain is known about this gene.
Another variant in this category, rs81209170, is located on chromosome 16 and within the FAM114A2
(family with sequence similarity 114 member A2) gene. Unfortunately despite begin found in two
diﬀerent capture sets (two and three, both for category A), it is not a high priority candidate. The
change is from lysine to arginine, both are hydrophilic and positively charged. The region is relatively
conserved, but both lysine and arginine are presents at that location in other species. Furthermore
little is known about the function of this gene product.
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Most of our candidate SNPs were found in line B and C, the two dam lines. This suggests that the
genetic component of maternal infanticide is more prevalent in the line B and C, which is interesting
as these two lines are the pure breed lines. One hypothesis could be that pure breed lines are more
susceptible to the inﬂuence of the genome compared to cross breed lines.
4.3.6 Regions of interest
Reminder of the categories used: for category A all the infanticide pools were compared against the
controls. For category B the infanticide pool containing serial infanticide animals were compared to the
controls and for capture C the pools with animals with a family history of infanticide were compared
to the controls.
In order to identify more regions of interest, the repartition of the SNPs passing the ﬁlter threshold
were investigated using genomic plots. By visually inspecting the genomic plots generated for variants
passing the threshold and overlapping with target regions, it became clear that some regions are
covered by a large number of variants.Other regions only have a few variants covering them. Regions
with a large number of SNPs passing the threshold or with genes of interest were selected in order to
investigate the genes present in that region.
The category investigated are category B and C as A tend to select the regions in common between
the two, usually with a lower diﬀerence in allele frequencies, resulting in lower amount of SNPs selected.
One of the aim of this work is to try to ﬁnd genes or region that are more likely linked to animals
classiﬁed as serial infanticide or relating more to animals with a family history of infanticide. Therefore
the region was ﬁrst investigated for category B and C before looking at its presence or not in category
A.
4.3.6.1 Capture set 1
The ﬁrst region of interest is on chromosome 3 at 27MB, it is covering the gene XYLT1 (xylosyltrans-
ferase 1) for category A and B mainly and to a lesser extend on category C. In category B, 70 variants
cover this region, 52 are found in category A, but only 2 for category C. This region was one of the
target region in the GWAS study by Quilter et al [2]. The SNP observed were from line C mainly.
Unfortunately there are no known functions linking XYLT1 to our phenotype of interest so far, but it
is expressed in the brain.
The second region of interest is more interesting and is located on chromosome 3. It covers the gene
RBFOX1 (RNA binding fox-1 homolog 1) and its upstream region. It is found for all three category,
but mainly for line C again. For category A, SNPs in lines B and D are also found. The number of
variant passing threshold in this region is large, 321 for category B, and 310 for category C and only
70 for category A. This region was one of the major peaks identiﬁed in the Quilter et al study [2]. It
is of particular interest because it is syntenic with an human locus on chromosome 16 that has been
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linked to puerperal psychosis [108] and bipolar disorders [109]. The gene is also almost exclusively and
highly expressed in the human brain. The region surrounding it has been recently linked to depression
by GWAS [245, 246]. It has also been implicated in other psychiatric and brain disorders such as
attention-deﬁcit hyperactivity disorder (ADHD) [113, 115, 114], autism [247, 112], generalised anxiety
disorder [248], and copy number variations in this region are linked to developmental coordination
disorder [249]. The protein produced by the gene is one of a Fox-1 family of RNA-binding proteins
that is evolutionary conserved. It is also linked to GRIN1 (glutamate ionotropic receptor NMDA type
subunit 1), a target of interest from previous studies. RBFOX1 modulates the expression of alternate
splice variants for neuronally expressed genes, including GRIN1 [250]. This region is a very strong
candidate due to the fact that it is found in all three categories. It is most strongly correlated to line
C (Large White), but the fact that some other lines were found in diﬀerent categories is encouraging.
As no missense SNPs were found in this gene, the variants are probably located in introns or in the
5' region of the genes. This suggest that any inﬂuence they have on the gene would come from splice
variants or regulatory features of the genes, thus regulating its expression rather than changing its
protein. A more detailed study of this region could be lead to some interesting results.
One of the region with a very large number of SNPs covers three of the candidate genes identiﬁed
in the previous section, on chromosome 4 at 111MB, WDR47, CLCC1 and GPSM2. Once more most
of these SNPs are selected for line C, mainly category A and B, with only a small fraction found for
category C. For category B 309 variants are selected, 114 for category A but only 6 for category C.
Line C is the large white pure breed. As the SNPs are found in majority for the category B, it suggests
an inﬂuence on the fact that the animals will be those with serial infanticide trait. As discussed before,
all three genes in the interval are interesting candidates.
The next region is on chromosome 12 and is another region that conﬁrms some of our previous
results. It covers three of the genes identiﬁed as potential candidates before, NCOR1, TRPV2 and
TTC19. This time, some SNPs above the threshold are found in line B, but in the majority are in
line C. The region is well covered with SNPs passing the threshold for categories A and B but has less
coverage for category C. The number of variants passing the threshold for category A is 249, 124 were
selected for category B and only 23 for category C. It does conﬁrm this region as a candidate region
for further investigation.
A region on chromosome 14 with a large number of SNPs above the thresholds. For category A
248 selected variants are present from line B and C. For category B only 70 are present, all from
line C. Finally, for category C 154 variants are selected from both line B and C. The intervals covers
four genes, POLE, GALNT9, P2RX2 and FBRSL1. Of these four, one of them is a more interesting
candidate, P2RX2. This gene is linked to the regulation of the release of vasopressin and oxytocin [251]
. One of the gene of interest selected by the missense SNPs analysis in the previous section was AVP,
which encodes for polypeptides of the vasopressin and oxytocin family. Low levels of oxytocin have
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been linked to aggressive behaviour [83] and, as described in the previous section, other psychiatric
disorders are linked to both vasopressin and oxytocin. The later hormone was also a protein of interest
in Quilter et al gene expression study [80], making this key target. The other genes in this region have
no function linked speciﬁcally to the brain or behavioural phenotypes but they are all expressed in the
brain. This region was also one of the top haplotype region found in Quilter et al [2].
The last region of interest for capture set 1 is located on chromosome 15 and cover the gene PAX3
(paired box 3). This region was selected for all three categories, but once more only found in line
C. The number of variants passing the threshold for category A is 99, 43 for category B and 49 for
category C. The 3' region of this gene and the gene itself are one of the regions that reached genome
wide signiﬁcance in the GWAS carried out by Quilter et al [2]. The gene is critical in foetal development
and more speciﬁcally neurological development. In mice mutations of this gene cause spina biﬁda and
exencephaly [123]. In humans, mutations in this gene are linked to major developmental syndromes,
such as the Waardenburg syndrome [252] and the craniofacial-deafness-hand syndrome [124].
4.3.6.2 Capture set 2
For category B (serial infanticide) of capture set 2, several regions conﬁrm some of the results found
using the missense SNPs table. A large number of SNPs are found to cover the region of the MCAT
gene, on chromosome 5 at 5.5MB, for line B. For category A only 8 variant were selected, 71 were
present for category B and 3 for category C.
Another region covered by a high proportion of SNPs, from line H, covers the ASPM gene region, on
chromosome 10 at 20MB. Only 2 and 4variants were selected for category A and C respectively in line
B and D. For category B, 47 variants passed threshold for line H. Another interval is on chromosome
14 and covers the ADORA2A gene. Here the SNPs are all selected for line C. No variants were selected
for category A and B, 9 are selected for category B but the target interval is really small. Despite
the low number of variant this region should be investigated further. For category C animals (family
history of infanticide), a large number of SNPs (47) cover the gene PARP1, which was also one of our
targets from the missense SNPs, this time all the SNPs were selected from line B.
Other regions not found in the previous analysis but covered by a large number of SNPs are described
below. On chromosome 3 there is a region covering the gene TGFA (transforming growth factor alpha),
selected for category B and in line C, with 113 variants selected. Unfortunately there are no know
function for this gene linking the gene to our phenotype of interest to date. The next region of
interest found for category B with 132 selected variants covering the gene ARPP21 (cAMP regulated
phosphoprotein 21), on chromosome 13 at 21 MB. Most of the SNPs selected are found in line C.
The same region is also selected for category C with a larger proportion of SNPs above threshold,
almost all found in line B, but two in line C. This gene is a very promising candidate as it encodes
for cAMP-regulated phosphoprotein. It is highly expressed in the brain and enriched in the caudate
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nucleus. It is an area of the brain involved in memory, sleep and the reward system, which is linked
to dopomine secretion. In the mouse a similar protein regulates the eﬀects of dopamine in the basal
ganglia. As discussed before, dopamine plays a important role in the prevention of depression and is
a target for several of the genes identiﬁed in this study and previous ones. It is also a regulator of
calmodulin signalling and when a mouse knockout was generated, it resulted in anxiety like behaviours
[253]. Deletion of this gene could be a potential pathogenic factor for intellectual disability [254]. This
makes this region a priority candidate in line C.
The ﬁnal region of interest for capture set 2 is located on chromosome 11 and covers the gene LRCH1
(leucine rich repeats and calponin homology domain containing 1), it was selected on line B for category
C with 626 variants present. This gene was found in a RNA sequencing experiment performed in our
lab and part of another thesis [176]. The gene is expressed in the brain but so far no interesting
function related to our phenotype has been found. However it is classiﬁed as a negative regulator of
GTPase activity, which links it to G-proteins.
4.3.6.3 Capture set 3
The ﬁrst region of interest for capture set 3 is found on chromosome 1 for categories A and B (serial
infanticide) in line C, and covers the genes TYSPL4 and TYSPL1. As discussed previously ( section
4.3.5.3) this region had several missense SNPs in it and could be a candidate for further investigation,
however the genes function is currently not well characterised. The number of selected variants for this
region for category A is 50, for category B it is 78 and for category C, there are only 3 variants.
The next region of interest is located on chromosome 2 at 84.5MB and covers two genes, COL4A3BP
(collagen type IV alpha 3 binding protein) and POLK (DNA polymerase kappa). It was selected for
category C (history of infanticide) and found in line B, 116 variants passing threshold are present.
Both genes are expressed in the brain and mutations in COL4A3BP have been linked to developmental
disorders in a large scale study [255]. It is also involved in the Goodpasture syndrome, an auto-immune
disorder. POLK functions are largely linked to cancer. This region could be interesting but there is
no clear link to our phenotype of interest.
Another region with a tight cluster of SNPs is located on chromosome 3 and was selected for category
C, on line B. A total of 180 selected variants are found in this region. Two genes are close to this
location, RNF144A (ring ﬁnger protein 144A) and RSAD2 (radical S-adenosyl methionine domain
containing 2). Both are expressed in the brain but no functions are described that would overlap our
phenotype of interest.
The next region is on chromosome 4 and was selected for the three categories, A, B and C. Inter-
estingly both categories were selected on diﬀerent lines. For category A , 115 SNPs were found from
line C. For category B, 100 SNPs were selected and came for line C. For category C, 65 SNPs were
and they were selected for line B. The gene this region covers is ASAP1 (ArfGAP with SH3 domain,
185
4 Discussion
ankyrin repeat and PH domain 1). It is expressed in the brain and a human GWAS study has linked
it schizophrenia in the Ashkenazi Jews [221]. This could be interesting as the Ashkenazi Jews are a
population which had very little genetic mixing. Commercial breeds tend to also have poorer genetic
mixing, due to the selection for particular trait. This lack of genetic mixing will elevate the frequencies
of certain alleles in the population, some of which could have deleterious eﬀects.
There are three other regions of interest on chromosome 4. The ﬁrst two were selected for category
B for line C, the ﬁrst one with 242 variants and covering NKAIN3 and the second with 116 selected
variants and covering KCNA2, KCNA10 and PROK1. The second region was also found for category
A, with 66 SNPs selected originating from line B and D. The last region was selected for category
C and line B, covering EXT1 with 124 variants. The ﬁrst candidate NKAIN3 (sodium/potassium
transporting ATPase interacting 3) is highly expressed in the brain but little is known about its
function apart from one GWAS on Alzheimer's disease which found a genome wide signiﬁcant SNPs in
this gene [256]. For the second region, found in categories A and B, only KCNA2 (potassium voltage-
gated channel subfamily A member 2) might be an interesting candidate. It is expressed in the brain
and mutations in this gene have been linked to episodic ataxia and hereditary ataxia [257, 258]. Ataxia
is a neurological disorder that aﬀects coordination, balance and speech in humans. The other genes in
this region (KCNA10 and PROK1 ) have no functions linked to the brain or any psychiatric disorders.
The ﬁnal gene of interest on chromosome 4, EXT1 (exostosin glycosyltransferase 1) is expressed in the
brain. So far, most of its functions are linked to bone growth and related diseases. The allele frequency
diﬀerences in this region of EXT1 are very high. If this gene was to be linked to any psychological
disorder or brain functions, it could be a good candidate.
One of the gene identiﬁed in the missense SNPs table and conﬁrmed in the region study is PMFBP1.
It is located on chromosome 6 and is covered by a cluster of SNPs with a relatively large allele diﬀerence
between control and infanticide pools (40 to 60%). A total of 100 SNPs were found in line B and were
selected for category C (family history of infanticide). A second region of interest on chromosome 6 is
just downstream of the gene CDH11 (cadherin 11). The SNPs, at total of a 172, are also from line B,
and were selected for category C. One GWAS found genome wide signiﬁcant association of this gene
with schizophrenia [210].
The next genomic interval is located on chromosome 9. It covers the region upstream and the gene
EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) itself. This region was selected for
categories A (35 SNPs), B (serial infanticide, 32 SNPs) and C (family history of infanticide, 213 SNPs),
but on diﬀerent lines: on line H for category B, line B for category C and line B and C for category
A. This gene has been linked to ataxia [259] and schizophrenia [260]. It is the only region which has
been selected for line H, one of the two lines with the highest incidence of maternal infanticide.
Two regions have been selected on chromosome 10. One is upstream and covering partially the
gene FRMD4A (FERM domain containing 4A), and the second one is within the GPR158 (G protein-
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coupled receptor 158) gene. For the gene FRMD4A, the region has a large cluster of SNPs for category
A (128 SNPs), B (44 SNPs) and C (255 SNPs) but for diﬀerent lines, in line C for category B and line
B for categories A and C. The gene itself has been associated to Alzheimer's disease by GWAS, and
the variant associated reached genome wide signiﬁcance [261]. The second gene, GPR158, also has a
large cluster of SNPs for both category B (84 SNPs) and C (353 SNPs), but again for diﬀerent lines,
C and B respectively. This gene is almost exclusively expressed in the brain and the protein it encodes
is a G protein-coupled receptor. One study found that it regulates stress induced depression in the
mouse and increased expression of this gene has been observed in the pre-frontal cortex in depressive
animals [262]. Once again, it is a gene linked to G-protein signalling, linking it with several of our
other target regions.
One interesting observation from this set of data is that line B and C are still the predominant lines
for which regions surpass our threshold. More speciﬁcally, the lines are segregating between category
B (line C) and category C (line B). This suggests that line B, a Landrace line, might have a more
strong genetic linkage for the pathology in category C, which is for the pools with a family history of
infanticide. For line C, a large white line, the predominant category is B, linked to the serial aggressor
individuals. It suggests that the genetic component for this line might be diﬀerent, and the breeds as
a more systematic occurrence of infanticide in individuals. Disappointingly there are very few results
for either line D or H. This is true for all capture sets. Diﬀerent genes might be involved for these
lines, or the regions we selected to study are not the best candidate regions for these two lines.
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This work provides a good example of how the genetic tools currently available can be used to invest-
igate the genetic components of a pathology. The staged screening process used in this work could be
applied to other diseases and other species. Using a combined approach of genotyping and sequencing
opens new possibilities to identify the genes and loci in the genome linked to maternal infanticide.
The results presented here suggest that the genetic component of this pathology is not restricted to
a single location of the genome, but that several loci are contributing to an increased risk of infant-
icide. Each of these regions will contribute modestly to the overall phenotype, but taken together,
they can increase the risk of incidence of infanticide events. Regions identiﬁed might be shared by
diﬀerent lines, others are more speciﬁc to a single line, suggesting variability of the genetic component
in diﬀerent lines and breed. It is possible that pressure of selection due to commercial breeding has
the unwanted consequence of selecting diﬀerent susceptibility loci in diﬀerent lines and breeds. This
could be caused by the LD structure present in the genome. The desirable traits selected for breeding
might be linked by LD to less desirable trait. Thus these traits will hitch-hike with the selected trait
and become more prevalent in a population selected for breeding. It was also noted that some lines
had more candidates in one of our three categories. Line C, the Large White, has more candidates
found in the category including the serial infanticide sows. Line B, the Landrace, on the other hand,
has more candidates for the category involving the animals selected because of their family history
of infanticide. Line D and H returned very few regions of interest. It is diﬃcult to understand why,
one hypothesis could be that because they are cross breeds, their genomes are more heterogeneous
and therefore the penetrance of causal loci is lower than the pure bred lines. There are some common
trends between some of the genes that were identiﬁed as targets by previous studies and this work.
Genes involved with G-protein pathway, the regulation of dopamine, vasopresine and oxytocin levels
were found in diﬀerent parts of this work. Another interesting trend the are genes involved with the
mitochondria and energy production, suggesting that alteration of the genome impacting on the way
the cells produce energy could have an behavioural impact.
While looking at individual gene function can lead to identifying interesting targets, genes tend to
work together in pathways and networks to regulate a biological functions or processes. Therefore,
the list of target genes obtained can be investigated as group of genes using tools such as DAVID
[179]. It uses an approach called gene set enrichment, comparing a list of genes of interest against
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the background of all the genes in the genome to identify functions that may be over-represented in
the candidate genes compared to all the genes. This analysis was performed using human genes as
they are better annotated. Unfortunately no signiﬁcant enriched clusters were found, only a few genes
grouped with related functions, such as ADORA2A and AVP involved in glutamate secretion and
NAV2, NRN1, PAX3 and RBFOX1 which are involved in the development of the nervous system.
Both type of functions are linked to the nervous system which is encouraging. However the lack of any
other interesting function linking our candidate genes together is disappointing. This could be due to
poor characterisation of a lot of our candidate genes, more work is needed to expand the knowledge of
the functions linked to these genes.
In order to conﬁrm some of this work and the region and genes identiﬁed, restriction fragment length
polymorphism (RFLP) work has started. This will conﬁrm if the diﬀerence in allele frequencies found
a certain loci in the pools is valid for single individuals. Using this approach, genotype on individual
animals can be determined and used to determine the type of model they contribute to the trait, such
additive, dominant, etc... It can be done for a lot of animals at a low cost. This work will be carried
out on selected loci for which primers can be designed. Another possibility to validate some of our
variants is to investigate which allele is present in lines from the same breed where no or lower incidence
of maternal infanticide was reported.
If the RFLP approach validates some of the candidates found here, more experimental work will
be needed. Most of the variants selected are in non coding regions, to investigate their impact on
the function of genes, cell models or animal models will need to be designed. Without validation, the
ﬁndings of this thesis will remain theoretical.
The approach used in this study returns some interesting results but is not without ﬂaws. For
example the array used has low coverage compared to other arrays available now. Furthermore, not
all the SNPs covered are of interest for all breeds. While the design used ﬁve diﬀerent breed to select
SNPs, the state of the reference was poor at the time of its conception and a lot of SNPs were of
poor quality. Given the improvement both in array technology and in the reference genome, it would
be possible to design a much better array. These advances can help increase the number of probes
on the array, to similar density used in human for example. Furthermore, with more sequencing data
becoming available every day, probes speciﬁc to breeds could be integrated to broaden the range of
lines and breeds that can be investigated using it. For this study, the array design used was based on
version 10.2 of the genome, redesigning it for version 11 of the genome might reﬁne some of the regions.
This could lead to better typing of all the LD blocks present in the pig and get a better understanding
of their impact on this phenotype. Some studies have used this approach to look at heritability of
traits in families, by typing LD blocks using arrays in human [263].
This is also true for the sequence capture design; some of the probes are also targeting small areas
and this could result in missing some interesting target loci. Some genes might have been left out of
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the capture probe design because of the quality of the genome build 10.2. Now that a better genome
build is available, it would be worth checking if more genes could be included. Another approach to
resolve this issue is to design PCR primer targetting the genes of interest and produce amplicons for
sequencing. This is a low cost solution, allowing the sequencing of the target regions in a large number
of animals.
Pooling animals was a sensible approach because of the cost related to sequencing at the time, but
unfortunately most of the infanticide pools had a low number of animals in them, raising the question
of how representative they might be as a sample of the infanticide population. Obtaining good samples
is also diﬃcult, especially for some of the categories, such a serial infanticide. Breeders tend to kill
sows for economic reasons, as losing a litter is a signiﬁcant ﬁnancial loss. If good samples can be
provided, the approach described here could be revisited using single animals instead of pools. This
is provided that sequencing becomes aﬀordable enough, and a suﬃcient number of samples can be
collected. This would allow the use of more rigorous statistical methods to compare the infanticide
animals against the controls. Another approach that could follow from this work is to sequence all the
members of several families in order to conduct a linkage study based on variants called via sequencing.
Using single individuals instead of pools would also enable the calling of structural variants (or copy
number variant), which was not possible due to the algorithm used to call variants on the pools. These
approaches could be done on the whole genome if enough funding is available, or using sequence capture
to lower the costs. An hybrid approach could also be to sequence a few animals at genome wide level
to identify new regions of interest before designing a capture panel to interrogate these in more detail.
If a new array can be constructed, or if enough sequencing can be ﬁnanced, combining family
and population analysis can be a powerful tool that has been used with success [264]. Furthermore,
combining a new array and a sequencing approach could prove to be a powerfull, especially for diﬃcult
diseases [265].
Finally, another avenue of investigation would be to look at the epigenetic change between control
and infanticide animals, for example comparing methylation levels of the DNA between the two groups.
Ideally the methylation change should be investigated in the brain, it might help to shade light on
some of our candidates for which no functions related to the brain or its pathologies were found. This
could be combined with a gene expression study to assess the impact of the methylation of the genome
on the expression of the genes.
While no deﬁnitive targets were found using our approach, several interesting regions have been
identiﬁed for further work. With the advances in technology and reﬁnement of the pig genome, it will
be soon possible to conﬁrm and potentially ﬁnd additional targets with greater certainty and at a lower
cost. The approach used here is not restricted to the pig and maternal infanticide, it could be applied
to other pathologies and animals.
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Contribution to work related to this thesis
An association and haplotype analysis of porcine maternal infanticide: A model for human
puerperal psychosis?
Quilter, C. , Sargent, C. , Bauer, J. , Bagga, M. R., Reiter, C. P., Hutchinson, E. L., Southwood, O.
I., Evans, G. , Mileham, A. , Griﬃn, D. and Aﬀara, N. (2012),
Am. J. Med. Genet., 159B: 908-927. doi:10.1002/ajmg.b.32097
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